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Historical perspective 
The curative application of digitalis-like compounds (DLCs) dates back to 1550 BC 
when squill plant was known as diuretic, heart tonic and rat poison (Luderitz, 2005). 
Plant extracts containing DLCs were also recommended for headache, spasm, epilepsy, 
and skin diseases in the 13th century (Somberg et al., 1986; Silverman, 1989). In Chinese 
medicine, the skin powder of the Bufo gargarizans toad was used as a medication that 
apparently contained bufalin (Somberg et al., 1986). Furthermore, the plant and toad-
derived DLCs were used as an arrow poison in African tribes and foxglove extracts were 
used as a strong poison by ancient Romans (Cassels, 1985).
In the 18th century the British medical doctor and botanist, William Withering, 
discovered that digitalis was the prominent part of an herbal remedy that was introduced 
to him by a rural woman called “Mother Hutton” in Shropshire (England) for treatment 
of edema. In December 1775, a fi fty year old man, who was suffering from accumulation 
of fl uid and diffi culties with breathing (called dropsy in that time), was the fi rst patient 
prescribed digitalis by William Withering. Since then, Withering began his study and 
experiments on foxglove extract containing digitalis and published the book “An account 
of the Foxglove, and some of its medical uses: with practical remarks on dropsy, and 
other diseases” in 1785 (Rahimtoola, 1975; Krikler, 1985; Rossner, 2006).
After treatment of 163 documented patients, Withering described medication 
preparation from purple foxglove (Digitalis purpurea), different sensitivity of patients 
to the medication, dose-response characteristics and some adverse effects of foxglove 
extract such as vomiting, observation of yellow and green objects, increased urine 
secretion, slow heart rhythm and death (Fisch & Knoebel, 1985; Breckenridge, 2006). 
Although he considered this medication as a diuretic agent at fi rst, he also mentioned 
the effect on cardiac pulses (Fulton, 1953; Kinne-Saffran & Kinne, 2002). In addition, 
he combined the treatment with opium to diminish vomiting and nausea effects of the 
drug (Bessen, 1986; Somberg et al., 1986). 
After Withering’s death in 1799, disregarding his warnings about digitalis toxicity and 
dosing, digitalis therapy was extended all over Britain to treat all forms of edema and 
neurological disorders, which caused the death of many patients (Somberg et al., 1986). 
Due to its toxicity, digitalis therapy was less accepted in France and Germany during the 
19th century. In the US, purple foxglove was grown by Hall Jackson who received seeds 
of the plant from Withering after studying his book and it was used for therapeutic 
purposes. The fi rst extracted DLC was strophanthinic acid isolated by Richard Fraser in 
1885 from Strophanthus plant, which was used as arrow poison by some African tribes. 
The production of injectable strophanthinic acid by Albert Fraenkel opened the way to 
the therapeutic use of DLCs in cardiology (Luderitz, 2005). 
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Structure 
DLCs consist of two moieties: a genin or aglycone moiety and a sugar moiety. 
The genin core is composed of steroid rings (A-D rings) with a cis conformation 
between A/B and C/D rings and a trans combination of B/C (Figure 1). However, in 
some plants (Asclepiadaceae) the A/B ring has a trans combination (e.g. uscharin and 
calactin) (Thomas et al., 1974; Mijatovic et al., 2007). The genin moiety has methyl 
groups at position C10 and C13 and 2-6 hydroxyl groups at different positions. The 
aglycone moiety of DLCs can bind to 1-4 sugar molecules such as digitoxose, rhamnose 
and mannose to form glycosides (Hussain et al., 2006). Moreover, the lactone ring 
at position 17β discriminates cardenolides with a butyrolactone ring (5-membered 
unsaturated γ-butyrolactone) from bufadienolides with a pyrone ring (6-membered 
double unsaturated δ-valerolactone) (Figure 1). Cardenolides such as digoxin, digitoxin, 
and oleandrin are derived from foxglove and Oleander, whereas bufadienolides such as 
bufalin originate from toads (Vaklavas et al., 2011) (Table 1). The aglycone core of the 
cardiac glycoside conserves the cardiotonic activity and the sugar moiety plays a role in 
its pharmacokinetic properties and water solubility (Thomas et al., 1974; Smith et al., 
1984).
Interaction with Na,K-ATPase
DLCs inhibit Na,K-ATPase, which was fi rst characterized by Schatzmann in 1965 
(Schatzmann, 1953; Schatzmann & Rass, 1965). Na,K-ATPase, also known as sodium 
pump, is an antiporter enzyme in the plasma membrane, which regulates the resting 
potential and volume of the cells. It pumps three Na+ ions out of the cell and takes up 
two K+ ions by direct hydrolysis of ATP to drive transport. Na,K-ATPase consists of 
two subunits: the α-subunit is the catalytic subunit of the enzyme, whereas the β-subunit 
plays a role in post-translational maturation and plasma membrane localization (Shull 
et al., 1985; Sverdlov et al., 1987; Katz et al., 2010). The α- and β-subunits have several 
different isoforms (α1-4 and β1-3), which are distributed tissue-specifi cally. The α1 
and β1 subunits are ubiquitously expressed, whereas α2 and β2 are present in muscle 
(skeletal, smooth and heart) and α3 is expressed in nervous tissue (Lavoie et al., 1997; 
Katz et al., 2010). Moreover, α4 is specifi cally expressed in testis (Blaustein et al., 2009; 
Katz et al., 2010) and β3 is present in testis, retina, liver, and lung (Malik et al., 1996; 
Arystarkhova & Sweadner, 1997).
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Figure 1. Chemical structure of digitalis-like compounds (DLCs). (A) Steroid core structure of 
DLCs illustrating four rings (A, B, C and D), carbon numbers, γ-butyrolactone and δ-valerolactone 
at position C17 of cardenolides and bufadienolides, respectively and a sugar moiety (R) at C3. 
(B) Five DLCs, digoxigenin (aglycone), digoxin, digitoxigenin (aglycone), digitoxin, and ouabain 
(glycoside) have been presented.  
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Digitalis-like compounds (DLCs) bind to the α subunit of the enzyme, and various 
studies have been performed to determine the selectivity for Na,K-ATPase isoforms 
(Lingrel & Kuntzweiler, 1994; Malik et al., 1996; Kaplan, 2002). In rat, the α1 isoform 
is the most resistant one to ouabain (affi nity of ouabain: α3 > α2 > α1) (O’Brien et al., 
1994; McDonough et al., 2002). However, all nine combinations of human α-subunits 
with β-subunits have a similar high affinity for ouabain (Crambert et al., 2000; Wang et 
al., 2001; McDonough et al., 2002). Comparing the structural moieties of DLCs and their 
inhibitory potency, different DLCs have different affi nities for α subunits and it seems 
that the sugar moieties play a role in the pharmacodynamic profi le of DLCs (Hauck et 
al., 2009; Katz et al., 2010). Recently, Weigand et al. showed that amino acids Met119 
and Ser124, located in the fi rst extracellular loop of the Na,K-ATPase, are responsible 
for the low affi nity of dihydro-DLCs (DLCs with a hydrogenated lactone ring) for α2 
isoform (Weigand et al., 2014). There are fi ve structural criteria for interaction of DLCs 
with Na,K-ATPase: (1) a cis conformation of the C/D rings, (2) an unsaturated lactone 
ring, (3) a β attachment of the lactone ring to C17, (4) a β attachment of the hydroxyl 
group at positions C3 and C14, and (5) a β attachment of C3 with the sugar moiety 
(Chen & Henderson, 1954; Brown et al., 1962; Thomas et al., 1974; Sevillano et al., 
2002).
Table 1. Number of DLCs derived from different plant or animal species
Digitalis-like compounds Source species Reference
Cardenolides    
Convallatoxin Convallaria majalis (Lily of the valley) (Choi et al., 2006)
Cymarin Apocynum cannabinum (Dogbane) (Kupchan et al., 1964)
Digitoxigenin, Digitoxin, Digoxin Digitalis purpurea, Digitalis lanata (foxglove) (Mijatovic et al., 2007)
Digoxigenin, Gitoxigenin    
Ouabain, Ouabagenin Strophanthus gratus (Mijatovic et al., 2007)
Strophanthidin, Strophanthidol Strophanthus Kombe (Grosa et al., 2005)
Peruvoside Thevetia peruvians (Yellow Oleander) (Arora et al., 1967)
Bufadienolides    
Bufalin Bufo vulgaris (Brubacher et al., 1999)
Proscillaridin A Drimia maritima (Squill) (Gould et al., 1971)
Na,K-ATPase exists in two main conformational states: E1 and E2 and ouabain 
has the highest affi nity for the phosphorylated form of E2 (Matsui & Schwartz, 1968). 
It has been shown that ouabain binds to the extracellular side of Na,K-ATPase. Based 
on site-directed mutagenesis studies, the important amino acids for binding of ouabain 
to Na,K-ATPase have been identifi ed. Two polar residues, Gln111 and Asn122 located 
at the extracellular border of transmembrane segments (M1 and M2) are responsible 
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for the sensitivity of this pump to ouabain in non-rodents (Price et al., 1989). As H,K-
ATPase is a closely-related enzyme to Na,K-ATPase, a chimera of these two enzymes 
was used to determine the ouabain-binding residues of Na,K-ATPase in a number of 
studies. In conclusion, Glu312, Val314, Ile315, and Gly319 located in M4, Pro778 and 
Phe783 located in M5 and Leu795, The797, Cys802, and Asp804 located in M6 have 
been reported as key amino acids of Na,K-ATPase leading to high affi nity ouabain-
binding chimera (Koenderink et al., 2000; Qiu et al., 2003; Qiu et al., 2005; Qiu et al., 
2006).
Effects on heart failure 
In the 1980’s and 1990’s, a number of well-designed trials were performed, showing 
that digoxin therapy increased the cardiac output by the left ventricle and thereby 
increased exercise time and decreased the symptoms of heart failure (GAXS, 1988; 
JAMA, 1988; DiBianco et al., 1989; Gosselink et al., 1997). Three extensive studies, 
Prospective Randomized Study of Ventricular Function and Effi cacy of Digoxin 
(PROVED), Randomized Assessment of Digoxin on Inhibitors of the Angiotensin 
Converting Enzyme (RADIANCE), and Digitalis Investigators Group (DIG), played 
an important role in approving digoxin for the treatment of heart failure in 1998 by the 
Food and Drug Administration (Gheorghiade et al., 2006). In the 12 week PROVED 
study, digoxin was randomly withdrawn from 113 patients with mild to moderate heart 
failure. These patients showed worsened exercise time and an increased incidence of 
treatment failure as compared to patients who continued to receive digoxin (Uretsky et 
al., 1993). In 1993, Packer et al. conducted the RADIANCE study in which 178 patients 
with heart failure receiving digoxin, diuretics and angiotensin-converting-enzyme-
inhibitors participated. Random withdrawal of digoxin worsened heart failure by 6 
folds, deteriorated ejection fraction and exercise capacity while increasing heart rate and 
body weight (Packer et al., 1993).
The Digitalis Investigation Group (DIG) performed in 1997 a double-blind clinical 
trial on 3397 patients with a 37 month follow-up. They showed that prescription of 
digoxin reduced hospitalization, whereas it did not infl uence mortality (DIG, 1997). 
Additionally, digoxin was shown effective in controlling the heart rate in atrial 
fi brillation (Fuster et al., 2006). The effect of digoxin can be categorized in three groups: 
electrophysiological, hemodynamic and neurohormonal (Gheorghiade et al., 2006).
The electrophysiological effect of digoxin can be divided into three effects: ionotropic, 
chronotropic, and dromotropic. The positive ionotropic effect is a consequence of the 
inhibitory effect on Na,K-ATPase, which increases the intracellular Na+ concentration 
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leading to a rise in the intracellular Ca2+ concentration via the Na+/Ca2+ exchanger and 
subsequent stimulation of heart muscle contraction (Hauptman & Kelly, 1999; Currie 
et al., 2011).
The heart contains two nodes: the sinoatrial node (SA node) in the right atrium and 
the atrioventricular node (AV node) between the atria and ventricles of the heart. The 
impulses of the heart are generated in the SA node, spread through the atria where they 
activate the AV node, which in turn transfers the impulses from the atria to the ventricles. 
At therapeutic dosages, digoxin has a negative chronotropic effect, which is originated 
from its sympathoinhibitory effect. It decreases the ability of the heart to begin impulses 
due to external stimuli through the SA node; however, a supratherapeutic dose exerts a 
positive chronotropic effect and increases sinus rates and ultimately sinus arrest at very 
high dosages. In addition, a therapeutic dose of digoxin has a negative dromotropic 
effect and slows the conduction through the atrioventricular node, whereas it increases 
the conduction via this node in toxic dosages (Antman & Smith, 1985; Ferguson et al., 
1989; Hauptman & Kelly, 1999; Eichhorn & Gheorghiade, 2002). In general, automatic 
impulses are initiated after toxic dosages of digoxin, which are independent of the 
autonomic system of the heart.
Although digoxin was thought to be effective in heart failure treatment because of 
its inhibitory effect on Na,K-ATPase, it also has therapeutic hemodynamic and 
neurohormonal effects.
Digoxin increases heart contractility in both heart failure patients and healthy 
subjects. Baroreceptors adjust the blood pressure by infl uencing cardiac output and 
vascular smooth muscle tone via the central nervous system. In healthy subjects, 
baroreceptors function to increase systemic vascular resistance after digoxin-induced 
heart contractility, therefore, the cardiac output is not changed. As atrial baroreceptors 
are less sensitive to blood pressure changes in heart failure patients, increased contractility 
by digoxin results in a higher cardiac output (Gheorghiade & Ferguson, 1991; Eichhorn 
& Gheorghiade, 2002; Gheorghiade et al., 2004). However, this is not observed in a 
healthy subject, because digoxin also increases the systemic vascular resistance (Ross et 
al., 1960; Mason & Braunwald, 1964; Lee & Klaus, 1971; DeMots et al., 1978; Vivo et 
al., 2008). As no signifi cant difference was observed between the expression of Na,K-
ATPase in the heart of normal subjects and long term digoxin-administered patients 
(Braunwald, 1985; Schmidt et al., 1991; Schmidt et al., 1993; Eichhorn & Gheorghiade, 
2002), the hemodynamic effect of digoxin seems to play a more important role than its 
electrophysiological effect to increase heart output.
Heart failure induces neurohormonal abnormalities via the renin-angiotensin system, 
adrenergic nervous system, cytokines, and vasopressin, which are all modulated in presence 
of digoxin. Therapeutic doses of digoxin restore the sensitivity of baroreceptors leading 
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1
to a reduction in sympathetic nervous system activity and therefore, decreased release 
of norepinephrine and renin in plasma (Gheorghiade & Ferguson, 1991; Eichhorn & 
Gheorghiade, 2002). In addition, digoxin-induced reduction of renin results in reduced 
aldosterone levels (Covit et al., 1983; van Veldhuisen et al., 1993; Gheorghiade et al., 
2004). Digoxin also has a vagomimetic effect due to its inhibitory effect on SA and AV 
conductions as described above (Ferguson et al., 1989; Krum et al., 1995).
Therapeutic dosing 
Digoxin is preferably administered orally (tablet or elixir) or intravenously and not 
intramuscularly because it is painful (Smith et al., 1984; Hanratty et al., 2000). Doehrty 
et al. investigated the pharmacokinetic profi le of digoxin administered via these three 
different routes. The increase of digoxin in serum was categorized as follows: intravenous 
> intramuscular > oral (elixir) > oral (tablet) (Doherty et al., 1978; Smith et al., 1984).
A benefi cial effect of digoxin was observed among patients treated with less than 1 
ng/ml compared with those treated with higher dosages (Packer et al., 1993; Uretsky et 
al., 1993; Slatton et al., 1997). Moreover, patients with plasma digoxin levels between 
0.5-0.9 ng/ml experienced reduced mortalities and hospitalization than those that 
used higher dosages (Ahmed et al., 2006). Factors such as renal function, sex, age and 
other drugs that infl uence digoxin concentration in serum should be considered in 
administration of digoxin dosage. Generally, an oral dose of 0.125-0.250 mg digoxin per 
day is prescribed for a patient with heart failure to achieve a serum concentration of 0.5-
1.0 ng/ml. In the case of atrial fi brillation, an intravenous loading dose of 0.25 mg every 
two hours is prescribed for rapid response and for maintenance therapy, an oral dose of 
0.5 mg per day is prescribed (Packer et al., 1993; Uretsky et al., 1993; Adams et al., 2002; 
Gheorghiade et al., 2006; Vivo et al., 2008).
Beside digoxin, digitoxin is prescribed in countries such as Germany, France, and 
Norway. The hydrophobicity of digitoxin enhances its gastrointestinal absorption. In 
addition, metabolism and excretion of digitoxin is different from digoxin (Roever et 
al., 2000). Therapeutic concentrations of digitoxin in plasma should be between 10-30 
ng/ml and a daily oral dose of 0.05-0.07 mg is recommended to achieve steady state 
within three days (Belz et al., 2001). Ouabain, the hydrophilic DLC, has a short onset 
of action. Although ouabain is excreted mostly unchanged into urine, gastrointestinal 
excretion also occurs (Doherty et al., 1978). Moreover, ouabain is not suitable for oral 
administration because of its poor gastrointestinal absorption (Joubert, 1990).
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Toxicity
In 1785, Withering already described serious toxic effects of digitalis and different 
sensitivities of patients towards digitalis (Finch et al., 1984). In 1969, a huge intoxication 
of digitoxin occurred in Juliana Hospital, Veenendaal, the Netherlands due to a 
production error in digoxin tablets. The tablets contained 0.2 mg digitoxin and 0.05 mg 
digoxin instead of 0.25 mg digoxin (Lely & van Enter, 1970). Beller et al. showed that of 
patients treated with digoxin, 20% had possible and defi nite digoxin toxicity, however, in 
1997 the DIG group observed a lower toxicity incidence (Beller et al., 1971; DIG, 1997). 
In a large heart failure study in 2006, it was reported that although the use of digoxin 
was declined from 31% in 2001 to 24% in 2004, the number of toxic exposures was not 
changed (Hussain et al., 2006).
Generally, a plasma concentration of more than 2 ng/ml digoxin is considered toxic. 
DLCs toxicity symptoms vary from gastrointestinal indications to nervous system 
manifestations. Nausea, anorexia and fatigue are the most frequently observed and other 
symptoms include abdominal pain, diarrhea, dizziness, headache, muscular weakness, 
visual complaints such as fl ashing lights, halos and impairment in green-yellow perception 
(xanthopsia), psychic complaints and vomiting (Lely & van Enter, 1970; Rawlins, 1974; 
Eichhorn & Gheorghiade, 2002; Vivo et al., 2008). The severity of toxicity depends on 
different factors. It has been reported that hyperthyroidism, hyperkalemia, childhood, 
and atrial fi brillation decrease digitalis toxicity, whereas hypokalemia, hypomagnesemia, 
hypercalcemia, hypoxia, ischemic heart disease, hypothyroidism and advanced age all 
aggravate toxicity (Vivo et al., 2008). Most of the above-mentioned factors interfere with 
digitalis absorption, metabolism, and excretion, whose relation with digitalis toxicity is 
discussed in detail below. 
Drug-drug interactions 
The interactions of drugs with DLCs include pharmacodynamic as well as 
pharmacokinetic interactions at absorption, metabolism, and excretion levels (Table 2).
 
Absorption. In rat, guinea pig and human, DLCs are absorbed via passive diffusion 
into intestine (Greenberger et al., 1969; Haass et al., 1972; Smith et al., 1984). Therefore, 
lipid-solubility of DLCs plays an important role in their absorption (Greenberger et al., 
1969; Shaw et al., 1972; Lindenbaum, 1973). Gastrointestinal absorption of DLCs is 
infl uenced by food and the digestive system. The presence of food or fasting situation 
infl uences the concentration of digoxin when it is administered orally (White et al., 
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1971). In addition, mucosal situation, intestinal mobility, malabsorption syndromes, gut 
microbial fl ora, and acidity of gastric fl uid play a role in DLCs absorption. In an acidic 
condition, digoxin is easily hydrolyzed to digoxigenin and other metabolites with less 
toxicity (Gault et al., 1980). In addition, drugs that alter digestive system-related factors 
can interact with DLC absorption. For example, drugs that increase intestinal mobility 
such as cathartics and drugs that bind to DLCs such as cholestyramine decrease DLCs’ 
gastrointestinal absorption (Heizer et al., 1971; Lindenbaum et al., 1976; Kuhlmann 
et al., 1981). Additionally, antacids (aluminum hydroxide, magnesium hydroxide and 
magnesium trisilicate) and cytostatic drugs (cyclophosphamide and bleomycin) decrease 
digoxin absorption by induction of diarrhea and intestinal damage, respectively 
(Kuhlmann et al., 1981; Rodin & Johnson, 1988; Ehle et al., 2011). Since digitoxin 
undergoes enterohepatic circulation, its absorption might also be infl uenced by drugs at 
this level, even when administered intravenously. For example, ion-exchange resins such 
as cholestyramine and colestipol hydrochloride decrease enterohepatic circulation of 
digitoxin and consequently its absorption (Bazzano & Bazzano, 1972; Smith et al., 1984). 
In Table 2, drugs that are interacting with DLCs at different levels are summarized. In 
addition to passive diffusion, intestinal effl ux transporters such as P-glycoprotein have 
an important role in limiting the bioavailability of digoxin. This will be discussed further 
in Excretion section.
Metabolism. Factors that can infl uence DLCs metabolism vary based on the type 
of DLCs and its metabolic route. Less than 1% of administered digoxin is metabolized 
to digoxigenin, digoxigenin mono-digitoxose and digoxigenin bis-digitoxose (Doherty, 
1968). However, in 10% of digoxin-using patients, digoxin is metabolized by Eggerthella 
lenta (classifi ed as Eubacterium lentum) in gut and metabolites such as dihydrodigoxin 
and dihydrodigoxigenin were observed in the urine (Lindenbaum et al., 1981; Saha et al., 
1983; Smith et al., 1984; Robertson et al., 1986; Moffett et al., 2013).
Recently, Haiser et al. has shown that two gene operons in E. lenta DSM2243 are 
highly up-regulated upon exposure to digoxin. The protein products of these operons 
are responsible for reduction of α,β-unsaturated butyrolactone ring of cardenolides 
such as digoxin. Interestingly, arginine suppresses these operons and therefore, high 
protein diet decreased digoxin reduction and increased digoxin levels in serum and urine 
of mice. This highlights the role of gut bacterium and patients diet on pharmacokinetics 
of DLCs (Haiser et al., 2013; Haiser et al., 2014).
In addition, the concentrations of bacterium-produced metabolites were reduced after 
co-administration of antibiotics such as erythromycin, clarithromycin, roxithromycin, 
and tetracycline (Luchi & Gruber, 1968; Peters et al., 1978; Lindenbaum et al., 1981; 
Bizjak & Mauro, 1997; Nawarskas et al., 1997). However, a number of these antibiotics 
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infl uence digoxin excretion and thereby plasma levels, which is further discussed below. 
In rat, digoxin is metabolized by cytochrome P450 and excreted into bile as didigitoxide, 
monodigitoxide, and digoxigenin (Salphati & Benet, 1999).
Unlike digoxin, digitoxin is extensively metabolized in the liver and there are many 
drugs that infl uence its metabolism. During digitoxin metabolism, fi rst, the three sugar 
groups are removed leading to bisdigitoxide, monodigitoxide, and fi nally digitoxigenin. 
Digitoxigenin and digoxigenin can be deactivated after epimerization from 3β-OH to 3α-
OH, which can be further metabolized to glucuronide or sulfate derivatives (Herrmann 
& Repke, 1964; Abshagen & Rietbrock, 1973). For the β to α epimerization, fi rst the 
hydroxyl group of digitoxigenin and digoxigenin is converted to a ketone group by 
human liver alcohol dehydrogenase (Frey & Vallee, 1980).
Digitoxin and digitoxigenin are further metabolized by the addition of a hydroxyl 
group at position 12 that converts digitoxin and digitoxigenin to digoxin and 
digoxigenin, respectively (Solomon & Abrams, 1972). Moreover, in vitro studies have 
shown that C5 and C6 hydroxylation of digitoxigenin leads to more polar digitoxigenin 
metabolites, which are renally excreted (Bulger & Stohs, 1973; Bulger et al., 1974). 
The same procedures of epimerization can occur for digoxigenin. Drugs such as 
diphenylhydantoin, phenylbutazone, phenobarbital, rifampicin and spironolactone 
decrease plasma digitoxin levels, due to induction of its hepatic metabolism (Peters et 
al., 1974; Vohringer et al., 1975; Wirth et al., 1976; Boman et al., 1980; Poor et al., 1983) 
(Table 2).
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Furthermore, the metabolic routes of other DLCs, which are not often applied in 
the clinic, have been clarifi ed. Ouabain is weakly absorbed after oral administration 
(1.4% of dose), and it is mainly excreted via the kidney, 80% of which in the unchanged 
form and 20% as ouabain metabolites (Strobach et al., 1986). Cymarin is metabolized 
via different steps in the liver: cleavage of its sugar (cymarose) to K-strophanthidin, 
reduction of the aldehyde group at position C19 and subsequent conversion of cymarin 
to cymarol and K-strophanthidin to K-strophanthidol, and formation of conjugated 
metabolites at C3 position (glucuronide and sulphate) (Moerman, 1965; Strobach et 
al., 1986). In addition, the cleavage of K-strophanthoside sugar moiety by intestinal 
fl ora can lead to cymarin production, which is metabolized further according to the 
above-mentioned steps. Sometimes the metabolism of DLCs depends on their route of 
administration. K-strophanthoside is metabolized mainly to glucuronates and sulphates 
when it is administered orally; on the other hand, it is excreted unchanged in the case of 
intravenous administration (Strobach et al., 1986). Furthermore, proscillaridin A and 
its synthetic form, methyl-proscillaridin are metabolized in the liver. The aglycone of 
these two DLCs, 3β-scillarenin, its epimer 3α-scillarenin, and 12β-OH-episcillarenin are 
the metabolites of these DLCs found in human urine and plasma (Belz et al., 1974; 
Rietbrock & Staud, 1975).
Excretion. Cardiac glycosides and their metabolites can be eliminated via feces by 
intestinal and biliary excretion and via urine by renal excretion. The elimination half-
life of digoxin is 30-40 hours. After one week of continuous administration, a steady-
state concentration in plasma is achieved (Hanratty et al., 2000). About 60-80% of 
bioavailable digoxin is excreted unchanged into urine, by glomerular fi ltration and 
active tubular secretion (Sumner & Russell, 1976; Hanratty et al., 2000). A small amount 
is metabolized in the liver and the rest is secreted via the intestine. Drugs that affect 
glomerular fi ltration can infl uence renal DLC excretion. For example, antihypertensive 
agents such as guanethidine, bethanidine, and debrisoquine delay digoxin excretion 
due to reduction of glomerular fi ltration rate (Smith et al., 1984). Besides glomerular 
fi ltration, tubular secretion plays a role in digoxin excretion and can be infl uenced by 
drugs such as spironolactone and triamterene that reduce digoxin renal elimination by 
inhibition of P-gp whose role in digoxin excretion is discussed below (Steiness, 1974; 
Waldorff et al., 1983; Nakamura et al., 2001; Varma et al., 2003).
Many studies have demonstrated that co-administration of digoxin with drugs such 
as quinidine and verapamil reduces digoxin clearance and distribution (Ejvinsson, 1978; 
Doering, 1979; Reiffel et al., 1979; Klein et al., 1980; Pedersen et al., 1981; Schwartz et 
al., 1982). In 1992, digoxin was reported to be a P-glycoprotein (P-gp) substrate by De 
Lannoy et al. (de Lannoy & Silverman, 1992).
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P-gp belongs to the ATP-binding cassette transporter (ABC) family and is mainly 
expressed in kidney, intestine, liver, and brain (Sakaeda et al., 2002; Choudhuri & 
Klaassen, 2006). An in vivo study using mdr1a (-/-) knockout mice showed that the 
absence of P-gp increased digoxin accumulation in the brain 20-50 times compared to 
wild type mice and decreased the digoxin elimination rate (Schinkel et al., 1995). P-gp 
is prominently expressed in the brush border of renal proximal tubules, the canalicular 
membrane of hepatocytes, luminal membrane of capillary endothelial cells of brain and 
testis, the apical membrane of enterocytes, and in placental trophoblasts and adrenal 
gland (Thiebaut et al., 1987; Sugawara et al., 1988; Cordon-Cardo et al., 1989). This 
tissue distribution of P-gp guarantees the excretion of potential toxic compounds like 
digoxin from the body into bile and urine and prevents its accumulation in brain and 
testis. Furthermore, P-gp transports digoxigenin, as digoxin metabolite, acetyl-digoxin, 
methyl-digoxin, and digitoxin (Pauli-Magnus et al., 2001a) (Table 3). 
Discovery of P-gp as digoxin transporter elucidated the mechanism of many 
digoxin-drug interactions. The concomitant administration of quinidine and digoxin 
increases the digoxin plasma concentration due to inhibition of P-gp by quinidine (Ito 
et al., 1993a; Fromm et al., 1999). In addition, quinidine decreases biliary excretion of 
digoxin by 40% (Angelin et al., 1987). Generally, drugs that are a substrate or inhibitor 
of P-gp can infl uence active renal, biliary, and intestinal excretion of digoxin and 
induce its toxicity. Additionally, P-gp plays an important role in intestinal absorption of 
digoxin and its bioavailability. The intestinal expression of P-gp is associated negatively 
with the plasma concentration of orally administered digoxin but not intravenously 
administered digoxin (Greiner et al., 1999). For example, rifampicin has been shown 
to induce the expression of intestinal P-gp. Co-administration of rifampicin leads to 
reduction of orally-administered digoxin absorption with no signifi cant effect on renal 
digoxin excretion (Greiner et al., 1999; Finch et al., 2002). P-gp expression is induced by 
rifampicin via the nuclear pregnane X receptor (PXR) (Drescher et al., 2003; Larsen et 
al., 2007). The presence of PXR in the intestine but not in the kidney could explain the 
lack of rifampicin-induced P-gp expression in the kidney (Lehmann et al., 1998; Kullak-
Ublick & Becker, 2003). On the other hand, rifampicin is an acute inhibitor of P-gp and 
it seems that the overall rifampicin effect is a combination of inhibition and induction 
of P-gp (Reitman et al., 2011). 
As is listed in Table 2, different groups of drugs such as antiarrhythmic agents 
(verapamil, amiodarone, propafenone and mexiletine) (De Cesaris et al., 1983a; b; 
Sphakianaki et al., 1992; Ito et al., 1993b; Woodland et al., 1997; Laer et al., 1998; 
Verschraagen et al., 1999), antibiotics (clarithromycin, roxithromycin, ciprofl oxacin, 
rifampin and telithromycin) (Nenciu et al., 2006; Hughes & Crowe, 2010; Reitman 
et al., 2011; Moffett et al., 2013), antifungal agents (ketoconazole, tryptanthrin, 
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itraconazole) (Partanen et al., 1996; Fan & Rodriguez-Proteau, 2008; Zhu et al., 2011), 
anti-malarial medicines (lumefantrine, amodiaquine, and artesunate) (Oga et al., 2012) 
and proton pump inhibitors (omeprazole, pantoprazole and lansoprazole) (Pauli-
Magnus et al., 2001b; Li et al., 2013) decrease digoxin and digitoxin excretion due to 
P-gp inhibition and increase their oral absorption. Interestingly, not only drugs that 
are P-gp inhibitors can modulate the digoxin concentration and lead to DDIs, but also 
metabolites of administered drugs. Kotah et al. showed that azelastine and amiodarone 
and their metabolites are P-gp inhibitors and thus infl uence digoxin kinetics (Katoh et 
al., 2001). Propafenone and its two metabolites, 5-hydroxy propafenone and N-desalkyl 
propafenone, are inhibitors of P-gp-mediated digoxin transport (Bachmakov et al., 
2005). Drugs that inhibit P-gp and thereby decrease excretion of digoxigenin, digoxin, 
methyl-digoxin, and digitoxin have been listed in Table 2.
Daily food ingredients contain compounds that modulate P-gp activity or expression 
and they could lead to variability in digoxin concentration. Capsaicin, the ingredient 
of chili peppers, can reduce digoxin plasma levels by increasing expression of P-gp. In 
addition, major ingredients of turmeric powder, ginger and black pepper, curcumin, 
6-gingerol and piperine, respectively, inhibit P-gp-mediated digoxin transport (Han et 
al., 2006; Han et al., 2008; Zhang & Lim, 2008; Yue et al., 2012). Further, fl avonoids, 
present in citrus fruit, have been shown to inhibit P-gp and modulate digoxin transport 
(Yoo et al., 2007).
Besides DDIs, other factors can change expression and function of P-gp such as 
mutations or polymorphisms might infl uence digoxin excretion and toxicity. Hoffmeyer 
et al. showed that individuals who are homozygous for a polymorphism in exon 26 of 
P-gp (C3435T) have lower expression and function of P-gp and consequently higher 
digoxin plasma levels due to increased absorption and reduced excretion (Hoffmeyer et 
al., 2000), however, there are also populations in which the digoxin concentration was 
not infl uenced by this polymorphism (Sakaeda et al., 2001; Gerloff et al., 2002; Morita 
et al., 2003).
OATP4C1, an organic anion transporting polypeptide (OATP) family member that 
is expressed in the kidney, was found to be a digoxin and ouabain uptake transporter. 
OATP4C1 located in the basolateral membrane of proximal tubular cells plays a role 
in the uptake of digoxin and ouabain from blood (Mikkaichi et al., 2004). Recently, 
bupropion, an antidepressant drug, has been found to stimulate human OATP4C1-
mediated digoxin transport in vitro (He et al., 2014). Human Multiple drug resistance 
3 protein (MDR3), a phosphatidylcholine translocase, is expressed in the liver and has 
been reported as digoxin transporter in vitro; however, no DDIs for MDR3 are known 
(Smith et al., 2000).
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DDIs can occur at the level of active uptake of drugs into the liver followed by 
biliary excretion. The hepatic solute carrier (SLC) transporters play an important role in 
the absorption of drugs from the blood. The uptake of ouabain by rat liver was found 
to be transporter-dependent and was inhibited by digitoxin, whose uptake is by simple 
diffusion (Schwenk, 1980; Schwenk et al., 1981). In rat, Oatp2, expressed in brain, liver 
and kidney, is responsible for digoxin and ouabain uptake (Noe et al., 1997; Reichel 
et al., 1999). Ouabain is also found to be transported by Oatp1 in mouse (Hagenbuch 
et al., 2000). Therefore drugs, that inhibit active uptake of digoxin or ouabain in rat 
liver, cause DDI at uptake level. Rifampicin and amiodarone inhibit Oatp2-mediated 
uptake of digoxin in rat and consequently increases digoxin plasma levels (Lau et al., 
2004; Funakoshi et al., 2005). Kullak-Ublik et al. reported OATP1B3 (OATP8) and 
OATP1A2 (OATP-A) as human transporters of digoxin and ouabain, respectively. Their 
involvement in DDIs is not yet clear and need to be studied in more details (Kullak-
Ublick et al., 2001). The uptake and effl ux transporters of DLCs have been listed in 
Table 3.
Since digoxin and digitoxin are most often applied in therapy, DDIs for other 
DLCs have not been studied; however, their route of excretion has been determined. 
Ouabain, cymarin, k-strophanthoside and their metabolites cymarol, strophanthidin, 
strophanthidol, helveticoside and helveticosol are mainly excreted by the kidney 
(Strobach et al., 1986). Furthermore, peruvoside is eliminated by renal and hepatic 
excretion; therefore, renal excretion is signifi cantly increased in patients with cirrhosis 
to compensate for impaired biliary excretion (Lahrtz & van Zwieten, 1968). Elimination 
of proscillaridin A is by extrarenal processes. The conjugates of proscillaridin A are 
eliminated via the bile or reabsorbed by enterohepatic recycling after deconjugation 
(Andersson et al., 1977b; Andersson et al., 1977c). Although the excretion routes of many 
DLCs have been determined, information about their possible excretory transporters 
that could be involved in DDIs is lacking. 
Pharmacodynamic interactions 
Binding to cardiac Na,K-ATPase can be another site for the interaction of drugs with 
DLCs. DLCs have a higher affi nity for myocardial than skeletal muscle Na,K-ATPase. 
As DLCs and potassium compete for binding to Na,K-ATPase and DLCs bind without 
potassium ion (Palasis et al., 1996), hypokalemia increases DLCs binding to cardiac 
Na,K-ATPase and its toxicity (Hall et al., 1977; Steiness, 1978). Consequently, higher 
and more variable plasma concentrations of DLCs are observed during hypokalemia and 
hypomagnesemia (Dutta et al., 1968; Vivo et al., 2008) (Table 2). Therefore, hyperkalemia 
and hypokalemia induced by diuretics, potassium-depleting diet, corticosteroid therapy, 
and insulin therapy can predispose digoxin-administered patients in toxicity (Smith et 
al., 1984). 
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As mentioned above, digoxin has a negative dromotropic effect and it reduces the 
conduction through the atrioventricular node. Therefore, concomitant administration 
of digoxin with catecholamine-depleting drugs like β-adrenergic blockers leads to 
bradycardia and atrioventricular block (Lown et al., 1961; Smith et al., 1984; Vincent et 
al., 1984; Hanratty et al., 2000; Vivo et al., 2008).
Predisposing factors in toxicity
Although DDIs play a key role in digoxin toxicity, the altered physiological conditions 
and diseases could also predispose digoxin treated patients to a higher risk of toxicity. 
As aging can coexist with renal insuffi ciency and kidney diseases, it may indirectly affect 
digoxin excretion and increases the risk of toxicity in elderly patients (Vivo et al., 2008). 
Aging and its consequences can infl uence absorption, metabolism, and excretion of 
digoxin which is associated with a higher possibility of digoxin toxicity. Elderly people 
have a slower rate of digoxin absorption (Cusack et al., 1979; Hammerlein et al., 1998) 
which can be caused by a relatively high gastric pH and low gastrointestinal motility. As 
digoxin binds to skeletal muscle rather than other tissues, aging that is associated with 
less body mass, can infl uence the volume of digoxin distribution and increase the risk of 
toxicity (Cusack et al., 1979; Haas & Young, 1999).
As DLCs are absorbed by the gastrointestinal tract, malabsorption syndromes and 
diseases that associate with high gastrointestinal pH, low motility and changed intestinal 
microfl ora, small bowel transit and short intestine length alter digoxin absorption 
(Ehrenpreis et al., 1994; Hanratty et al., 2000; Severijnen et al., 2004; Ward, 2010). 
Digoxin has a large volume of distribution (4-7 L/Kg) and its body distribution can be 
affected by body mass and adipose tissue. In the condition of decreased lean body mass 
and increased adipose tissue, which occurs often during aging, the volume of distribution 
for hydrophilic drugs is reduced and for lipophilic drugs increased. Thus, the body mass 
and obesity of the patients should be considered in DLCs administration (Cusack et al., 
1979; Abernethy et al., 1981; Hanratty et al., 2000). 
Diseases such as hyperthyroidism, hypoglycemia, diabetes mellitus, and respiratory 
diseases infl uence DLCs excretion indirectly as well. For example, hypoglycemia has 
shown to down-regulate P-gp expression and impair digoxin excretion. Whereas, 
hyperthyroidism enhances P-gp expression and decreases the plasma digoxin 
concentration signifi cantly (Nishio et al., 2008; Vivo et al., 2008; Yeh et al., 2012).
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Table 3. Infl ux and effl ux transporters of DLCs
Transporters Substrate Species Organs References
Oatp1 ouabain mouse liver, kidney (Hagenbuch et al., 2000)
Oatp1a4 digoxin, ouabain rat brain, liver, kidney (Hagenbuch et al., 2000)
(Noe et al., 1997)
(Reichel et al., 1999)
Oatp4c1 digoxin rat kidney (Mikkaichi et al., 2004)
OATP1B3 digoxin human liver (Kullak-Ublick et al., 2001)
OAP1A2 ouabain   liver (Kullak-Ublick et al., 2001)
OATP4C1 digoxin, ouabain   kidney (Mikkaichi et al., 2004)
P-glycoprotein digoxin human, 
mouse
brain, liver, kidney (de Lannoy & Silverman, 
1992)
(Schinkel et al., 1995)
P-glycoprotein digitoxin human intestine, placenta (Pauli-Magnus et al., 2001a)
P-glycoprotein methyl-digoxin     (Pauli-Magnus et al., 2001a)
P-glycoprotein acetyl-digoxin     (Pauli-Magnus et al., 2001a)
P-glycoprotein digoxigenin     (Hughes & Crowe, 2010)
MDR3 P-gp digoxin     (Smith et al., 2000)
       
Therefore, in hyperthyroid condition, increased digoxin and digitoxin doses are 
needed for therapeutic purposes (Frye & Braunwald, 1961; Croxson & Ibbertson, 1975; 
Curfman et al., 1977). The necessary concentration of digoxin to control the ventricular 
rate in patients with hypoxia (resulting from pulmonary disease) is higher (2.5-6 ng/ml) 
than the therapeutic dosage (Goldman et al., 1975). It was shown that P-gp expression is 
induced by ambient hypoxia in vitro, which might explain the requirement for the higher 
digoxin dose in patients with hypoxia (Comerford et al., 2002).
Toxicity treatment
In the case of DLCs toxicity, oxygen supplementation is applied to control hypoxia. 
In addition, atropine and lidocaine are used for symptomatic bradycardia and ventricular 
tachycardia, respectively (Vivo et al., 2008). Atropine suppresses the inhibitory effect of 
digoxin on heart SA and AV nodes and lidocaine enhances ventricular automaticity. 
Inductions of vomiting and gastric lavage are not recommended because they both 
increase vagal tone and may worsen arrhythmias (Dugdale, 2013; Vinod & James, 2014). 
Hydration with IV fl uids such as saline and sometimes correction of electrolyte imbalance 
could be performed as supportive care and it should also be considered that correction 
of electrolyte imbalances may cause dysrhythmias. Toxicity-induced hyperkalemia could 
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be controlled using sodium bicarbonate to correct metabolic acidosis (Vinod & James, 
2014). Insulin plus glucose improves potassium uptake by cells and magnesium, as the 
regulating cofactor of Na,K-ATPase, could be used to control hyperkalemia (Reisdorff 
et al., 1986; Ahee & Crowe, 2000). Magnesium reverses digitalis-induced inhibition of 
Na,K-ATPase, blocks cellular Ca2+ infl ux, reduces plasma potassium levels and stabilizes 
myocardial conductivity; however, extra caution should be considered for treatment 
of digitalis toxicity in patients with impaired renal function who might already have 
hypermagnesemia (Beller et al., 1974; Rajapakse, 2009). Additionally, charcoal and 
cholestyramine (discussed in DDIs section) can be used to interrupt DLCs absorption 
and enterohepatic circulation (Lalonde et al., 1985; Park et al., 1985; Rawashdeh et al., 
1993).
Digibind and Digifab are available forms of digoxin IgG antibody developed in sheep 
to treat life threatening digoxin toxicity. Due to the high affi nity of these antibodies 
digoxin redistributes from tissues and digoxin-antibody complex will be excreted via the 
kidneys (Bauman et al., 2006; Vivo et al., 2008). Antibody treatment is recommended in 
the case of massive ingestion of digitalis, at digoxin concentrations higher than 10 ng/ml 
and hyperkalemia (serum potassium higher than 5 mEq/L) (Yang et al., 2012).
Endogenous digitalis-like compounds
The conserved site in Na,K-ATPase for binding of DLCs and existence of 
bufadienolide in some amphibians led to the speculation that DLCs might be produced 
in the human body too. In 1991, an ouabain-like compound (10 μg) was isolated from 
85 liters human plasma (Hamlyn et al., 1991). Later on, ouabain-like factors were also 
measured in dog plasma, bovine hypothalamus and adrenal glands of rat and human 
(Haupert & Sancho, 1979; Tymiak et al., 1993; Schneider et al., 1998; Kawamura 
et al., 1999). Beside ouabain-like factors, other DLCs such as digoxin, bufalin, 
marinobufagenin, proscillaridin A and 19-norbufalin have been found in human plasma, 
bile, urine, cataractous lens, placenta and hypothalamus (Diamandis et al., 1985; Kieval 
et al., 1988; Goto et al., 1991; Lichtstein et al., 1993; Hilton et al., 1996). It was shown 
that the ouabain concentration is elevated in conditions such as sodium imbalance, 
chronic renal failure, hyperaldosteronism, congestive heart failure, and preeclampsia 
(Kelly et al., 1986; Masugi et al., 1986; Masugi et al., 1987; Gottlieb et al., 1992; Averina 
et al., 2006). Moreover, the concentration of endogenous ouabain was associated with 
high blood pressure, vasoconstriction, and thickness of the left ventricular heart wall 
in human. Interestingly, these effects have not been observed with other DLCs such as 
digoxin and digitoxin (Manunta et al., 2000; Pierdomenico et al., 2001). Two mechanisms 
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have been postulated by which ouabain is involved in hypertension: 1) Inhibition of 
vascular α2 Na,K-ATPase and increased peripheral vascular resistance 2) Increased re-
absorption of renal Na+ and volume expansion due to inhibition of α1 Na,K-ATPase 
in renal caveolae (Bagrov et al., 2009). Beside all studies trying to measure endogenous 
DLCs, there were also reports on failure to detect endogenous ouabain in human plasma 
using ultra-sensitive methods (Doris et al., 1994; Lewis et al., 1994; Nicholls et al., 2009; 
Baecher et al., 2014).
The detection and isolation of  bufadienolides in mammalian tissues arouse 
controversy about the biosynthesis of these compounds. As DLCs have steroid rings 
in their structure, the fi rst precursor which was suggested to be cholesterol. Applying 
radiolabeled cholesterol and acetate, the biosynthesis of digoxin and marinobufagenin 
in murine adrenal cells was demonstrated in vitro (Siperstein et al., 1957; Dmitrieva et al., 
2000; Qazzaz et al., 2004). If  endogenous DLCs originated from steroids, enzymes for its 
synthesis have to be present. Enzymes for the conversion of the cholesterol side chain to 
the DLC lactone ring have not been described. Moreover, the structure of steroid rings 
in mammals is in trans-trans-trans form, however, DLCs have cis-trans-cis steroid rings 
(Qazzaz et al., 2004).
Signal transduction by digitalis-like compounds 
Interestingly, very low DLC concentrations that do not inhibit Na,K-ATPase 
transduce signaling pathways which contribute to cell growth and apoptosis (Prassas 
& Diamandis, 2008). Localization of Na,K-ATPase in caveolae, which are enriched in 
several signaling molecules, suggests a signal transduction pathway due to DLC binding 
to Na,K-ATPase. One of these signaling molecules associated with caveolae is Src, which 
binds to the cytosolic part of Na,K-ATPase. The binding of DLCs such as ouabain to 
the α-subunit induces Src activation and release (Tian et al., 2006; Riganti et al., 2011). 
Next, activated Src induces various signaling cascades. It may trans-activate epidermal 
growth factor receptor (EGFR) which leads to the Src/Ras/Raf/ERKs pathway (Wang 
et al., 2004). In addition, Src increases the hydrolysis of phosphatidylinositol-4,5-
bisphosphate due to phosphorylation and activation of phospholipase-γ, which opens 
the inositol 1, 4, 5-triphosphate (IP3) receptor/Ca2+ channel and increases the cytosolic 
Ca2+ concentration due to release of calcium from its intracellular storage. This increased 
Ca2+ concentration does not depend on Na+ /Ca2+ exchanger activity (Yuan et al., 2005). 
The resulting Ca2+ oscillations induce cell proliferation by activating transcription factors 
such as AP1 (activating protein 1) and NF-κB (nuclear factor-κB) (Miyakawa-Naito et 
al., 2003). The activation of ERK1/2 and c-Jun NH2-terminal kinase (JNK) followed by 
Src activation results in increased cell cycle inhibitors and reduction of cell proliferation.
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The pro-apoptotic effect of DLCs due to their infl uence on molecules such as Bad, 
Bcl-2, p21cip1 and Bax has been reported in different cell types such as human breast 
cancer cells, human prostate cancer cells and human lung cancer cells (Riganti et al., 
2011). Kometiani et al. demonstrated that non-inhibiting concentrations of ouabain and 
therapeutic concentrations of digoxin and digitoxin inhibit human breast cancer cell 
proliferation due to activation of Src, EGFR1/ 2, p21cip1 and JNK (Kometiani et al., 
2005). The effect of DLCs such as digoxin and ouabain on down-regulation of P53 via 
MAP/ERK were reported by Wang et al. (Wang et al., 2009). The signaling cascades 
induced by DLCs may result in cell migration, apoptosis, impaired cell metabolism and 
altered gene expression, thus, it seems that DLCs have pleiotropic effects due to signal 
transduction.
Conclusion
Over more than 200 years DLCs have been applied for different purposes ranging from 
arrow poison to treatment of heart failure. Although the toxicity of cardiac glycoside 
has been considered since 1785, they are still applied in therapy due to their benefi cial 
effects. Optimization of digoxin and digitoxin dosage based on pharmacological studies, 
development of assays to measure these compounds in plasma, and development 
of antibodies to treat digitalis toxicity have reduced the incidence of DLCs toxicity. 
However, they are still ranked in the top ten drugs leading to hospitalization caused 
by adverse drug effects. Currently, the development of new drugs and ingredients in 
pharmacy and food industry increase the chance of DDIs for patients that are treated 
with digoxin and digitoxin. 
Different DLCs exist in nature and they all have the same backbone structure 
and mechanism of action (inhibition of Na,K-ATPase), however, they vary in their 
pharmacokinetic profi le. Different sugar moieties and chemical substitutions at the 
steroid rings contribute to the different pharmacokinetic characteristics of these 
compounds. Currently, digoxin and digitoxin are the most prescribed DLCs for heart 
failure and some types of arrhythmias. In this chapter, the factors that infl uence DDIs 
with DLCs have been described. Different factors such as uptake transporters, effl ux 
transporters, interacting drugs, and interfering physiological conditions infl uence the 
levels of DLCs and consequently their toxicity. In addition, we discussed the diversity 
in DLCs absorption, metabolism, excretion and the role of drug transporters at these 
levels. We think that knowledge about DLCs transporters will identify DLCs with less 
DDIs potential and better pharmacokinetic profi les. 
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1
Aim and outline of this thesis
In this thesis, research was focused on the identifi cation and characterization of infl ux 
and effl ux transporters that could play a role in the disposition of DLCs in intestine, 
kidney, and liver. To identify the interaction with effl ux transporters, we studied a series 
of structurally-related DLCs for their interactions with BCRP, BSEP, and MRP1-4 in 
chapter 2 and with P-gp in chapter 3. Furthermore, in chapter 3 we aimed to elucidate 
the P-gp amino acid residues that play an important role in the interaction with DLCs.
To identify whether DLCs are substrates for ABC transporters, ATP-dependent 
uptake was studied in membrane vesicles overexpressing effl ux transporters using an 
ouabain-Na,K-ATPase replacement assay and LC-MS detection methods in chapters 2 
and 4, respectively. Next, an in vivo study was performed to confi rm the in vitro results of 
a newly-identifi ed P-gp substrate, convallatoxin. Moreover, the key amino acid residues 
of P-gp that play a role in convallatoxin transport were determined. The results of these 
studies are described in chapter 4. 
In chapter 5, new P-gp substrates were identifi ed using an accumulation assay in cells 
overexpressing P-gp. Additionally, two different P-gp transport assays and the criteria 
for the selection of a suitable transport assay to study DLCs are discussed in this chapter.
In chapter 6, the interaction of DLCs with the hepatic infl ux transporters, Na+-
taurocholate cotransporting polypeptide (NTCP), OATP1B1, and OATP1B3 was 
investigated. In addition, the transport of DLCs by these transporters and new substrates 
of OATP1B3 were determined. Finally, the results and conclusions emanating from this 
thesis and their implications are discussed in chapter 7. 

Chapter 2
Cardenolides Modulate Transport Activities 
of BSEP, BCRP and MRP1-4
Elnaz Gozalpour, Jeroen J. M. W. van den Heuvel, Amar Devit, 
Frans G. M. Russel, and Jan B. Koenderink
Department of Pharmacology and Toxicology, 
Radboud University Nijmegen Medical Center, 
Radboud Institute for Molecular Life Sciences
Manuscript in preparation
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Abstract
Digitalis-like compounds (DLCs) such as digoxin and digitoxin have been applied 
to treat heart failure for more than 200 years. Toxicity as a consequence of drug-drug 
interactions at the transport level, ranked DLCs in the top ten drugs with adverse effect 
leading to hospitalization. Here, we investigated the interaction of cardenolide DLCs 
with effl ux transporters; breast cancer resistance proteins (BCRP), bile salt export pump 
(BSEP), and multidrug resistance-associated proteins (MRPs). 
The effect of 13 cardenolides on ATP-dependent uptake of [3H]estrone sulphate 
(E1S), [
3H]taurocholic acid (TCA) and [3H ]β-estradiol 17β-D-glucuronide (E217βG) into 
BCRP, BSEP and MRP1-4 overexpressing inside-out membrane vesicles, respectively, 
was determined. In addition, the transport of the most potent inhibitors was determined 
using a Na,K-ATPase-[3H]ouabain replacement assay. 
BCRP transport activity was inhibited completely by 1 m M digitoxin, digoxin, and 
peruvoside. This concentration of digitoxin also completely inhibited BSEP transport, 
whereas peruvoside and strophanthidol inhibited BSEP transport by approximately 
50%. In this study strophanthidol was the strongest MRP1 and MRP3 inhibitor 
and digitoxigenin was the most potent MRP2 and MRP4 stimulator and inhibitor, 
respectively. Additionally, the present study showed that substitutions at C1, C3, C11, 
C12, C16 and C19 positions of the DLCs infl uence the interaction with BCRP, BSEP, 
and MRPs. Although many cardenolides interact with BCRP, BSEP, and MRP1, 2, 3, 
and 4 transport activities, signifying their potential role in drug-drug interactions, none 
of the tested compounds was a substrate for these effl ux transporters in the vesicular 
transport assay.
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Introduction
Digitalis-like compounds (DLCs), or cardiac glycosides, are classifi ed as cardenolides 
with a 5-membered lactone ring (γ-lactone) or bufadienolides with a 6-membered lactone 
ring (δ-lactone) (Figure 1) (Barrueto et al., 2006). The best-known cardenolide, digoxin, 
was approved by FDA for heart failure treatment in 1998 (Packer et al., 1993; Uretsky et 
al., 1993; DIG, 1997). DLCs bind and inhibit Na,K-ATPase and the resulting increased 
intracellular Ca2+ concentration stimulates heart muscle contraction (Hamlyn et al., 
1991; Pervaiz et al., 2006). They are eliminated via renal clearance, intestinal secretion 
and biliary excretion (Pauli-Magnus et al., 2001a). Drug-drug interactions (DDIs) 
of digoxin at the excretion level could occur due to the co-administration of digoxin 
with verapamil and quinidine leading to toxic symptoms such as headache, dizziness, 
fatigue, visual disturbance and nausea (Hooymans & Merkus, 1985; Belz et al., 2001). 
Digoxin-interacting medications are substrates or inhibitors of the digoxin transporter 
P-glycoprotein (P-gp) (de Lannoy & Silverman, 1992). Although transport of digoxin, 
digitoxin, and ouabain by P-gp has been well studied (Cavet et al., 1996; Brouillard et al., 
2001; Pauli-Magnus et al., 2001a; Gozalpour et al., 2014a), other major ATP-dependent 
effl ux transporters like breast cancer resistance protein (BCRP), bile salt export pump 
(BSEP), and multidrug resistance associated-proteins (MRPs) could also play a role in 
the excretion of DLCs. 
BCRP/ABCG2 is a half  transporter that requires dimerization to function as an 
effl ux transporter. It is categorized as a xenobiotic transporter that has a broad range 
of substrates and is expressed in placenta, prostate, small intestine, brain, colon, liver, 
mammary gland, and kidney (Maliepaard et al., 2001; Doyle & Ross, 2003; Bart et al., 
2004; Fetsch et al., 2006; Huls et al., 2008). BSEP/ABCB11 is the major bile acid effl ux 
transporter expressed in the canalicular membrane of hepatocytes (Strautnieks et al., 
1998; Byrne et al., 2002; Noe et al., 2002). Members of the MRP/ABCC family have 
broad substrate specifi city from organic anions to some organic cations. Being expressed 
in the excretory organs such as intestine, kidney and liver, MRPs limit the accumulation 
of drugs in these organs (Keppler, 2011). MRP1 is highly expressed in lung, testis, 
kidney, skeletal and cardiac muscles, placenta, and macrophages (Flens et al., 1996). 
Although MRP1 is located basolaterally in most tissues, it is expressed apically in 
endothelial cells of brain capillary (Nies et al., 2004). MRP2 is apically expressed in liver, 
kidney, intestine, colon, bronchi, and placenta (Kruh et al., 2007; Keppler, 2011). MRP3 
expressing tissues include liver, gallbladder, pancreas, kidney, spleen, and adrenal cortex 
where it is localized basolaterally (Scheffer et al., 2002). Finally, MRP4 is localized 
in prostate, liver, pancreas, and choroid plexus basolaterally and in kidney and brain 
capillary endothelial cells apically (Russel et al., 2008; Keppler, 2011).
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Figure 1. Structural features of cardenolides. (A) Steroid core structure of cardenolides presenting 
carbon numbers, γ-lactone ring at C17. (B) Thirteen cardenolides, with different chemical 
substitutions on their core structure are presented.
Interaction of cardenolides with these effl ux transporters has impact on the 
pharmacokinetics of these compounds and it might cause possible drug-drug 
interactions. In the present study, we have investigated the interaction of thirteen 
cardenolides (Figure 1) with human BCRP, BSEP, and MRP1, 2, 3, and 4 using a 
vesicular transport assays. Estrone sulfate (E1S), taurocholic acid (TCA) and β-estradiol 
17β-D-glucuronide (E217βG) were used as prototypic substrates of BCRP, BSEP, and 
MRPs, respectively. Moreover, to study the possible transport of cardenolides by these 
transporters, we have developed an assay using the potency of DLCs to replace Na,K-
ATPase bound [3H] ouabain (Flier et al., 1979; Gruber et al., 1980; De Pover, 1984; Kelly 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Cardenolides Modulate Transport Activities of BSEP, BCRP and MRP1-4
37
2
et al., 1985; Halperin, 1989). Using this replacement assay, we were able to determine the 
uptake of cardenolides by membrane vesicles.
Materials and Methods
Materials. [6, 7-3H(N)]Estradiol 17-β-D-glucuronide (34.3 Ci/mmol), [6, 7-3H(N)]
estrone sulfate (45 Ci/mmol), [ 3H(G)]ouabain (25.2 Ci/mmol) and [3H(G)]taurocholic 
acid (5 Ci/mmol) were purchased from PerkinElmer Life and Analytical Sciences 
(Groningen, The Netherlands). Bac-to-Bac and Gateway systems, Dulbecco’s modifi ed 
Eagle’s medium + GlutaMAX-I culture medium, and fetal calf  serum were purchased 
from Invitrogen (Breda, The Netherlands). Triple fl asks (500 cm2) were purchased from 
Sanbio BV Biological Products (Uden, The Netherlands). Estradiol 17-β-D-glucuronide 
(E217βG), estrone 3-sulfate potassium salt (E1S), adenosine 5’-triphosphate magnesium 
salt (from bacterial source), adenosine 5’-monophosphate monohydrate (from yeast) 
and DLCs (convallatoxin, cymarin, digitoxigenin, digitoxin, digoxigenin, digoxin, 
dihydroouabain, gitoxigenin, ouabagenin, ouabain, peruvoside, strophanthidin, 
strophanthidol) were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). 
Protein concentrations were determined using a Bio-Rad protein assay kit from Bio-Rad 
Laboratories (Veenendaal, The Netherlands). Purifi ed swine Na,K-ATPase was kindly 
provided by Dr. N. U. Fedosova (Department of Biomedicine, Aarhus University, 
Denmark).
Generation of human BCRP, BSEP, MRP1, 2, 3, and 4 baculovirus. Full-length human 
BCRP, BSEP, MRP1, MRP2, MRP3, MRP4, and enhanced yellow fl orescent protein 
(eYFP) as a negative control were cloned previously (Mutsaers et al., 2011; Wittgen et 
al., 2011; Dankers et al., 2012; van Beusekom et al., 2013). Briefl y, full length human 
BCRP, BSEP, MRP1, 2, 3, and 4 and eYFP cDNA, were cloned into the gateway entry 
vector. The gateway system was used to clone the constructs into a VSV-G-improved 
pFastBacDual vector with mammalian promotor (El-Sheikh et al., 2008). The Bac-
to-Bac system was used to produce the human BCRP, BSEP, MRP1, MRP2, MRP3, 
MRP4, and eYFP baculoviruses as described in the manual (Invitrogen). 
Cell culture and transduction. Human embryonic kidney (HEK293) cells were 
grown in 10% fetal calf  serum-supplemented Dulbecco’s modifi ed Eagle’s medium-
GlutaMAX-I at 37°C under 5% CO2-humidifi ed air. HEK293 cells were cultured in 500 
cm2 triple fl asks. After 24 hours, culture medium was removed and 25 ml of medium 
and 10 ml of baculovirus (BCRP, BSEP, MRP1, MRP2, MRP3, MRP4, or eYFP) were 
added. Cells were incubated for 15 minutes at room temperature, after which a further 
40 ml of medium and 5 mM sodium butyrate were added. Three days after transduction, 
cells were harvested at 3500×g for 20 minutes.
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Isolation of membrane vesicles and protein analysis. Membranes were isolated 
according to a previously described method (El-Sheikh et al., 2008). In brief, cell 
pellets were resuspended in ice-cold homogenizing buffer supplemented with protease 
inhibitors. The lysed cells were centrifuged at 100,000×g at 4°C for 30 minutes. The pellet 
was homogenized in ice-cold TS buffer (10 mM Tris-HEPES and 250 mM sucrose, pH 
7.4) supplemented with the protease inhibitors using a tight-fi tting Dounce homogenizer 
for 25 strokes. After centrifugation at 2000×g, 4°C for 20 min, the supernatant was 
centrifuged at 100,000×g at 4°C for 60 min. The membrane pellet was resuspended 
in ice-cold TS buffer and passed through a 27-gauge needle 25 times to form vesicles. 
Protein concentration was measured using the Bio-Rad protein assay kit (Bio-Rad). 
Crude membrane vesicles were frozen in liquid nitrogen and stored at −80°C until use.
Vesicular transport assay. A rapid fi ltration technique (Wittgen et al., 2012) was 
applied to measure [3H]E1S, [
3H]TCA and [3H]E217βG uptake into BCRP, BSEP and 
MRPs membrane vesicles, respectively. T he 30 μl of reaction mix containing 7.5 μg 
prewarmed vesicles preparations, TS buffer, 10 mM MgCl2, 4 mM ATP, and 0.05 μM 
[3H]E1S (BCRP), 0.67 μM [
3H]TCA (BSEP), 0.16 μM (MRP1), 0.1 μM (MRP2), 0.08 μM 
(MRP3) and 0.1 μM (MRP4) [3H]E217βG was used. The reaction mix was supplemented 
with 20 μM unlabeled E217βG for MRP2 and 0.2 μM unlabeled E1S for BCRP. After 1 
minute (BCRP) or 5 minutes (BSEP and MRPs) incubation at 37°C, the reaction was 
stopped using 150 μl of ice-cold TS buffer. A MultiscreenHTS vacuum manifold fi ltration 
device (Millipore, Etten-Leur, The Netherlands) was applied to fi lter the diluted samples 
through MultiscreenHTS-HV, 0.45-μm pore, polyvinylidene difl uoride (BSEP and MRPs) 
and MultiscreenHTS-HV, 0.65-μm pore, FB glass fi ber (BCRP) 96-well fi lter plates 
(Millipore) that had been prewashed with TS buffer. After aspiration of the samples, the 
fi lters were washed with TS buffer twice and separated from the plate. Subsequently, 2 
ml scintillation fl uid was added to each sample followed by liquid scintillation counting. 
The uptake of [3H]E1S, [
3H]TCA and [3H]E217βG into the membrane vesicles was 
determined by measuring radioactivity associated with the fi lters. In all experiments, 
ATP-dependent transport was calculated by subtracting values measured in presence of 
AMP from those measured in presence of ATP. 
Vesicular inhibition assays. Cardenolides that inhibited the effl ux transporters more 
than 60% were selected to evaluate their concentration-dependent effect on transporter 
activity. For BCRP-mediated E1S transport, previously described assay was performed 
in the presence of convallatoxin, digitoxigenin, digitoxin, digoxin, and peruvoside 
concentrations ranging from 1 to 1000 μM. The transport of TCA by BSEP was 
measured in the presence of increasing concentrations of digitoxin. MRP1- and MRP3-
mediated E217βG transport was also measured in the presence of strophanthidol.
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Preparation of extracted membrane vesicles for Na,K-ATPase-[3H]ouabain 
replacement assay. To determine the transport of cardenolides into membrane vesicles 
expressing BCRP, BSEP or MRPs, the affi nity of DLCs for Na,K-ATPase was applied 
to develop a quantitative assay. Cardenolides (1 mM) with an inhibitory potency of 
more than 30% of the control were incubated with BCRP, BSEP, MRP1, MRP3, and 
MRP4 expressing membrane vesicles for 5 minutes at 37°C. All inhibitory cardenolides 
were also incubated with eYFP membrane vesicles as negative control. After aspiration 
of the samples, the fi lters were separated from the plates and transferred to Eppendorf 
tubes. Further, the fi lters were dissolved in 250 μl 98% acetonitrile + 0.1% formic acid 
for 45 minutes at room temperature and the fi lter-associated proteins were precipitated 
for 30 minutes at -20°C. The samples were centrifuged at 16000×g for 5 minutes and 
the supernatant was evaporated under N2 gas at 37°C to reconstitute the samples. The 
pellets were dissolved in 50 μl distilled water containing 5% dimethyl sulfoxide (DMSO) 
to determine the DLC concentration in the Na,K-ATPase-[3H]ouabain replacement 
assay (Figure 5). The above mentioned procedure was developed for P-gp expressing 
membrane vesicles that had been incubated for 5 minutes at 37°C with 1 mM of the P-gp 
substrate convallatoxin as a positive control (Gozalpour et al., 2014a).
Na,K-ATPase-[3H]ouabain replacement assay. To quantify the amount of 
cardenolides taken up into the extracted membrane vesicles, the Na,K-ATPase-[3H]
ouabain replacement assay was developed (De Pont et al., 2009). Purifi ed Na,K-ATPase 
(0.069 μg) from swine kidney (Klodos et al., 2002), in sucrose buffer (250 mM sucrose, 
20 mM histidine, 0.9 mM EDTA (II) pH 7.0) was added to distilled water containing 20 
mM Histidine, 10 mM MgCl2, 5 mM H3PO4, and 25 nM [
3H]ouabain at a fi nal volume of 
50 μl. After 2 hour incubation at room temperature, the reaction was stopped using 100 
μl of ice-cold distilled water. A MultiscreenHTS vacuum manifold fi ltration device was 
applied to fi lter the diluted samples through MultiscreenHTS-HV, 0.65-μm pore, FB glass 
fi ber 96-well fi lter plate that had been prewashed with distilled water. After aspiration 
of the samples, the fi lters were washed with distilled water twice and separated from 
the plate. Next, 4 ml scintillation fl uid was added to each sample followed by liquid 
scintillation counting. The binding of [3H]ouabain to Na,K-ATPase was determined by 
measuring the radioactivity associated with the fi lters.
Inhibition of ouabain binding to Na,K-ATPase by cardenolides and extracted 
membrane vesicles. The Na,K-ATPase-[3H]ouabain replacement assay was performed 
in the presence of convallatoxin concentrations ranging from 0 to1000 nM, cymarin, 
digitoxigenin, digoxigenin, digoxin, peruvoside, strophanthidin, and strophanthidol 
concentrations ranging from 0 to 3000 nM and of digitoxin concentrations ranging 
from 2000 to 3000 nM in 5% DMSO. The extracted membrane vesicles obtained from 
vesicular transport of cardenolides were applied in this assay to determine the amount 
taken up into the vesicles. 
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Kinetic analysis. Data analysis was done by nonlinear regression analysis using 
GraphPad Prism software version 5 (GraphPad Software Inc., San Diego, CA). 
Concentration-dependent inhibition curves were fi tted to the data using the following 
equation: y = bottom + (top – bottom) / (1+10 (logIC50−x). Hill slope), in which, x and y indicate 
the log inhibitor concentration and uptake versus control (percentage), respectively. In 
all experiments, the mean value ± S.E.M of three experiments were shown. Statistical 
differences were tested by one-way ANOVA followed by Dunnett’s post hoc multiple 
comparison and unpaired Student’s t-test. A p < 0.05 was considered signifi cant.
Calculation of physicochemical property of cardenolides. The octanol: water partition 
coeffi cient (shown in Table 2) was calculated using clogP add-ins in the program 
ChemBio3D Ultra version 12.0 (Cambridge Software). 
Results 
Effect of cardenolides on BCRP, BSEP, MRP1, MRP2, MRP3, and MRP4 transport 
activity. To study the interaction of cardenolides with BCRP and BSEP, 0.25 μM [3H]
E1S and 0.67 μM [
3H]TCA were used, respectively. These concentrations were below the 
reported Km value as determined in previous studies (Dankers et al., 2012; van Beusekom 
et al., 2013). Based on the kinetic study described previously (Wittgen et al., 2011), 
different [3H]E217βG concentrations, 0.16 μM for MRP1, 20 μM for MRP2, 0.08 μM for 
MRP3 and 0.10 μM for MRP4, were used to study the cardenolides-MRPs interactions. 
Figures 2 and 3 show the effect of 100 and 1000 μM cardenolides on transport activity 
of BCRP, BSEP, MRP1, MRP2, MRP3, and MRP4. Convallatoxin, digitoxigenin, 
digitoxin, digoxin, peruvoside, strophanthidin, and strophanthidol inhibited BCRP-
mediated E1S transport by 50-100% at 1000 μM. Digitoxin, the most potent inhibitor of 
BCRP, inhibited E1S transport by 78% at 100 μM. In addition, the BCRP-mediated E1S 
transport was inhibited by 45% by the highest concentration of cymarin. Digoxigenin, 
dihydroouabain, and ouabagenin had stimulatory effects on E1S transport by BCRP. 
Digitoxin was the single potent inhibitor of BSEP-mediated TCA transport at 1000 μM 
(90% inhibition). Moreover, transport activity of BSEP was inhibited by digitoxigenin, 
digoxigenin, and strophanthidol moderately (35-45%). BSEP-mediated TCA transport 
was stimulated and inhibited by 100 and 1000 μM peruvoside, respectively. In addition, 
convallatoxin, cymarin, and ouabagenin stimulated BSEP transport activity by 25-36%. 
The highest concentration of digitoxin, peruvoside, and strophanthidol inhibited MRP1 
by 56%, 57%, and 73%, respectively. MRP1-mediated E217βG transport was stimulated 
by digitoxigenin, digoxigenin, gitoxigenin, and strophanthidin at 100 μM, whereas 
digoxigenin was the most potent stimulator of this transporter (43-124%). There were 
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no inhibitors for MRP2-mediated E217βG transport among the tested cardenolides, but 
cymarin, digitoxigenin, digitoxin, gitoxigenin, peruvoside and strophanthidin stimulated 
MRP2 transport activity more than 50%. Digitoxigenin, the most potent MRP2 
stimulator, increased E217βG transport by MRP2 by 260% at 1000 μM. MRP3-mediated 
E217βG transport was inhibited by strophanthidin and strophanthidol at 1000 μM for 
58% and 80%, respectively. Digitoxin, digoxin, and peruvoside inhibited MRP3 by 20-
30% and digoxigenin was the only cardenolide that stimulated MRP3 transport (20%). 
Finally, MRP4-mediated E217βG transport was inhibited by 1000 μM digitoxigenin for 
56%, whereas the inhibitory effect of convallatoxin, cymarin, digoxigenin, digitoxin, 
ouabagenin, peruvoside, and strophanthidol was less than 50%. Transport activities of 
BCRP, BSEP, MRP1, and MRP3 were completely inhibited in the presence of their 
substrates (E1S, TCA, and E217βG), whereas MRP4 was not completely inhibited by 100 
μM E217βG (74%) and MRP2 was stimulated by E217βG (55%).
Concentration-dependent inhibition of BCRP, BSEP, MRP1, and MRP3 by 
cardenolides. Transport activity of BCRP, BSEP, and MRPs was determined in the 
presence of increasing concentrations of the cardenolides that were selected as potent 
inhibitors (>60%) from the foregoing experiments (Figure 4). 
The ATP-dependent E1S transport activity of BCRP in the absence of cardenolides 
(50 ± 3 pmol/mg protein/min) was set at 100% (Figure 4) and BCRP-mediated transport 
in the presence of increasing concentrations of convallatoxin, digitoxigenin, digitoxin, 
digoxin, and peruvoside was plotted. The IC50 values of the most potent BCRP inhibitors, 
digitoxin, and digoxin were 11 and 103 μM, respectively (Figure 4). The highest 
concentration of digitoxigenin did not completely inhibit BCRP and convallatoxin 
showed the highest IC50 among the tested cardenolides (570 μM). Digitoxin appeared 
to be the only potent BSEP inhibitor. BSEP-mediated TCA transport (37 ± 4 pmol/mg 
protein/min) was set at 100% and was plotted against increasing digitoxin concentrations 
(Figure 4). Digitoxin inhibited BSEP with an IC50 value of 104 μM.
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Figure 2. Inhibitory effect of thirteen cardenolides on ATP-dependent transport activity of BCRP, 
BSEP, and MRP1 overexpressing membrane vesicles. The transports of E1S (for BCRP), TCA (for 
BSEP) and E217βG (for MRP1) were measured in the presence of 100 and 1000 μM cardenolides. 
ATP-dependent transport in the absence of cardenolides were 48 ± 3 for BCRP, 41 ± 8 for BSEP 
and 3.14 ± 0.04 for MRP1, (pmol/mg protein/min) that were set at 100% for each transporter 
(Ctrl) and it was also measured in the presence of 100 μM E1S and TCA separately. Mean ± 
S.E.M. values of three independent experiments are shown. Each mean value was compared with 
Ctrl using one-way ANOVA test post-hoc Dunnett’s multiple comparison, * p < 0.05, ** p < 0.01, 
*** p < 0.001.
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Figure 3. Inhibitory effect of thirteen cardenolides on ATP-dependent transport activity of MRP2, 
MRP3, and MRP4 overexpressing membrane vesicles. The transport of E217βG by MRP2, MRP3, 
and MRP4 were measured in the presence of 100 and 1000 μM cardenolides. ATP-dependent 
transport in the absence of cardenolides were 265 ± 9 for MRP2, 9.77 ± 1.35 for MRP3 and 1.737 
± 0.035 for MRP4 (pmol/mg protein/min) that were set at 100% for each transporter (Ctrl) and it 
was also measured in the presence of 100 μM E217βG for each transporter. Mean ± S.E.M. values 
of three independent experiments are shown. Each mean value was compared with Ctrl using one-
way ANOVA test post-hoc Dunnett’s multiple comparison, * p < 0.05, ** p < 0.01, *** p < 0.001.
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ATP-dependent E217βG transport in the absence of cardenolides was 3.5 ± 0.2 pmol/
mg protein/min for MRP1 and 9.4 ± 0.6 pmol/mg protein/min for MRP3. These values 
were set at 100% and the MRP1 and MRP3 transport activities were plotted against 
strophanthidol concentrations. Strophanthidol inhibited MRP1 and MRP3 with IC50 
values of 550 and 280 μM, respectively (Figure 4). 
Figure 4. Concentration-dependent inhibition of BCRP, BSEP, and MRPs by cardenolides. ATP-
dependent transports of E1S by BCRP, TCA by BSEP and E217βG by MRP1 and MRP3 in the 
presence of increasing cardenolide concentrations were measured. Different concentrations (0.5 to 
1000 μM) of convallatoxin, digitoxigenin, digitoxin, digoxin, and peruvoside were incubated with 
BCRP membrane vesicles in presence of 0.25 μM E1S for 1 minute. ATP-dependent transport of 
0.67 μM TCA by BSEP membrane vesicles in presence of digitoxin concentrations ranging from 
1 to 1000 μM for 5 minutes was measured. MRP1 and MRP3 membrane vesicles were incubated 
with increasing strophanthidol concentrations from 1 to 1000 μM in presence of 0.1 μM E217βG 
for 5 minutes.
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Cardenolide transport and Na,K-ATPase inhibition. Cardenolides that could inhibit 
BCRP, BSEP, MRP1, MRP3, and MRP4 by more than 30% were used to determine 
whether they were also substrates of these transporters. Therefore, the transporter-
expressing membrane vesicles were incubated with 1000 μM cymarin (BCRP), 
convallatoxin (BCRP, MRP1 and 4), digitoxigenin (BCRP, BSEP, MRP4), digitoxin 
(BCRP, BSEP, MRP1 and 4), digoxigenin (BSEP), digoxin (BCRP), peruvoside 
(BCRP, BSEP, MRP1, 3, and 4), strophanthidin (BCRP, MRP3), and strophanthidol 
(BCRP, BSEP, MRP1, 3, and 4) in the presence of AMP or ATP at 37 °C for 5 minutes. 
Uptake into the membrane vesicles was quantified by the Na,K-ATPase-[3H]ouabain 
replacement assay, based on the potency of the transported DLCs to replace ouabain 
(Figure 5). 
Figure 5. Extracted membrane vesicles used in the Na,K-ATPase-[3H]ouabain replacement assay. 
Cardenolides (marked with D) were incubated with membrane vesicles expressing BCRP, BSEP, 
MRP1, MRP3, and MRP4 and fi ltered through PVDF (BSEP and MRPs) or glass fi ber (BCRP) 
fi lters to remove the buffers and nonspecifi cally bound compound (A). The fi lter-associated 
proteins were precipitated (B) and the supernatant was analyzed in the Na,K-ATPase-[3H]ouabain 
replacement assay (C).
As previously reported, convallatoxin is transported by P-glycoprotein membrane 
vesicles ATP-dependently (Gozalpour et al., 2014a). The extracted membrane vesicles 
of P-gp and mock (eYFP) that had been incubated with 1000 μM convallatoxin or its 
solvent (DMSO) in the presence of AMP or ATP, were tested in the Na,K-ATPase-
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[3H]ouabain replacement assay (Figure 6). Ouabain binding to Na,K-ATPase in the 
presence of mock and extracted P-gp membrane vesicles that have been incubated with 
DMSO, ranged between 390-430 pmol/mg protein, which is hardly different from the 
binding of [3H]ouabain to Na,K-ATPase in the absence of extracted membrane vesicles 
(Ctrl) (412 ± 9 pmol/mg protein). Na,K-ATPase ouabain binding was inhibited in the 
presence of mock (eYFP) and extracted P-gp membrane vesicles that were incubated 
with convallatoxin. Binding in the presence of extracted AMP or ATP mock-membrane 
vesicles was not signifi cantly different (230 ± 20 pmol/mg protein in the presence of 
AMP, 210 ± 20 pmol/mg protein in the presence of ATP). The extracted P-gp-membrane 
vesicles that had been incubated with convallatoxin, however, showed a signifi cant 
difference between the presence of ATP or AMP (41 ± 1 pmol/mg protein in the presence 
of ATP, 197 ± 8 pmol/mg protein in the presence of AMP) (Figure 6). We demonstrated 
that ATP-dependent uptake of DLCs into the membrane vesicles can be measured with 
the Na,K-ATPase-[3H]ouabain replacement assay.
Figure 6. The effect of convallatoxin present in extracted P-gp-membrane vesicles on Na,K-
ATPase-[3H]ouabain replacement assay. Mock (eYFP)- and P-gp-membrane vesicles were 
incubated with DMSO or convallatoxin in the presence of AMP or ATP. Purifi ed swine Na,K-
ATPase (0.069 μg protein) was incubated with 25 nM [3H]ouabain in the presence of extracted 
Mock (eYFP)- or P-gp- membrane vesicles, distilled water containing 5% DMSO (Ctrl) and 1 
mM ouabain in room temperature for 2 hours. The extracted membrane vesicles that had been 
incubated with AMP and ATP are shown by blank and full bars, respectively.
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The cardenolides, convallatoxin, cymarin, digitoxigenin, digitoxin, digoxigenin, 
digoxin, peruvoside, strophanthidin, and strophanthidol were studied for their transport 
into BCRP, BSEP and/or MRPs (except MRP2) membrane vesicles using the Na,K-
ATPase-[3H]ouabain replacement assay. First, the inhibitory potency of these DLCs on 
25 nM ouabain binding to Na,K-ATPase was quantifi ed. The affi nity for Na,K-ATPase 
could be ranked as follows: strophanthidin > cymarin = convallatoxin = digitoxigenin 
> digoxigenin > peruvoside > digoxin > digitoxin (Table 1, Supplementary Figure 1).
Table 1. The IC50 values of nine cardenolides for Na,K-ATPase
  Na,K-ATPase
  IC50 (nM)
Convallatoxin 56 ± 9 a
Cymarin 54 ± 5
Digitoxigenin 58 ± 11
Digitoxin 2430 ± 20
Digoxigenin 80 ± 3
Digoxin 610 ± 30
Peruvoside 110 ± 20
Strophanthidin 47.3 ± 0.4
Strophanthidol 79.0 ± 0.6
a The IC50 values (Mean ± S.E.M) were obtained from three different experiments.
Binding of ouabain to Na,K-ATPase in the absence of extracted membrane vesicles 
was 507 ± 14 pmol/mg protein that was set at 100% (Ctrl) (Figure 7A). The extracted 
eYFP-membrane vesicles that had been incubated with convallatoxin, cymarin, 
peruvoside, strophanthidin, and strophanthidol infl uenced binding of ouabain to 
Na,K-ATPase hardly. Digitoxigenin, digitoxin, and digoxin inhibited ouabain binding 
to Na,K-ATPase by 95%, 85%, and 97%, respectively. Inhibition of ouabain binding 
by digitoxigenin, digitoxin, and digoxin suggested passive uptake into eYFP-membrane 
vesicles, because transport was the same in the presence of AMP or ATP (Figure 7A).
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Figure 7. Inhibition of ouabain binding to Na,K-ATPase by extracted membrane vesicles. The 
binding of ouabain to Na,K-ATPase was measured after 2 hour incubation at room temperature 
in the presence of extracted Mock- (A) and BCRP-expressing membrane vesicles (B). These 
extracted membrane vesicles had been incubated with 1000 μM of different cardenolides in 
presence of AMP or ATP for 5 minutes at 37°C before performing the Na,K-ATPase-[3H]ouabain 
replacement assay.
For BCRP the binding of ouabain to Na,K-ATPase in the absence of extracted 
membrane vesicles was 523 ± 11 pmol/mg protein and was set at 100% (Ctrl) (Figure 
7B). The extracted membrane vesicles, which had been incubated with convallatoxin 
and cymarin inhibited the binding of ouabain to Na,K-ATPase, whereas the binding of 
ouabain was not signifi cantly different between AMP and ATP conditions (convallatoxin: 
46 ± 3% for AMP vs. 40 ± 6% for ATP, cymarin: 66 ± 5% for AMP vs. 62 ± 7% for 
ATP). The extracted membrane vesicles that had been incubated with digitoxigenin, 
digitoxin and digoxin, inhibite d the [3H]ouabain binding completely, however, those 
of peruvoside, strophanthidin and strophanthidol inhibited binding 12% to 40%. The 
extracted membrane vesicles of BSEP, MRP1, MRP3, and MRP4, which had been 
incubated with their inhibitory cardenolides, did not inhibit Na,K-ATPase ouabain 
binding signifi cantly (data not shown). 
Discussion
In this study, we investigated the interaction of cardenolide DLCs with the effl ux 
transporters BCRP, BSEP, MRP1, MRP2, MRP3, and MRP4. Convallatoxin, 
digitoxigenin, digitoxin, digoxin, peruvoside strophanthidin, and strophanthidol 
inhibited BCRP-mediated E1S transport (Figure 2). It seems that the sugar moiety at 
the C3 position of cardenolides improves their inhibitory effect. Digitoxin and digoxin 
inhibited BCRP more potently than digitoxigenin and digoxigenin, which are lacking 
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a sugar moiety at the C3 position (Figure 1). Additionally, convallatoxin, which 
has a sugar moiety at the C3 position, had a larger inhibitory effect on BCRP than 
strophanthidin, which contains a hydroxyl group at this position. Convallatoxin and 
cymarin only differ in the sugar at the C3 position. Convallatoxin seems a more potent 
BCRP inhibitor than cymarin. The presence of hydroxyl groups at the C12 (digoxin 
vs. digitoxin and digoxigenin vs. digitoxigenin) and C16 position (gitoxigenin vs. 
digitoxigenin) reduced the inhibitory effect of cardenolides for BCRP. The simultaneous 
presence of hydroxyl groups at positions C1 and C11 diminished the inhibitory effect 
(ouabagenin vs strophanthidol), whereas their presence at C5 and C19 (strophanthidol 
vs. gitoxigenin) favored BCRP inhibition. As strophanthidin and strophanthidol have 
the same inhibitory effect on BCRP, a carbonyl or a hydroxyl group substitution at the 
C19 position apparently does not infl uence the inhibitory effect.
Among the tested cardenolides, digitoxin, peruvoside, and strophanthidol are the 
most potent inhibitors of BSEP (Figure 2). By comparing the inhibition of BSEP in 
the presence of digitoxigenin and digitoxin, it might be concluded that the presence of 
sugar moiety at C3 increases the inhibitory potency of the tested cardenolides for BSEP. 
However, in some cases, the presence of a sugar group at C3 diminished the inhibitory 
effect (digoxin vs. digoxigenin) or improved the stimulatory effect on BSEP (convallatoxin 
vs. strophanthidin). The hydroxyl groups at C12 (digoxigenin vs. digitoxigenin and 
digoxin vs. digitoxin) and C16 (gitoxigenin vs. digitoxigenin) diminished the inhibitory 
effect of the cardenolides for BSEP. The hydroxyl groups at both C1 and C11 reduced 
the inhibitory effect (ouabagenin vs. strophanthidol), whereas the hydroxyl group at C19 
position (strophanthidol vs. strophanthidin) improved it (Figure 1).
The inhibitory potency of cardenolides against MRP1 could be ranked as follows: 
convallatoxin < digitoxin = peruvoside < strophanthidol (Figure 2). The cardenolides 
with a hydroxyl group at C3 are more potent stimulators of MRP1 than those with a sugar 
moiety at this position (digitoxigenin vs. digitoxin and strophanthidin vs. convallatoxin). 
Digitoxigenin and digoxigenin with a hydroxyl group at the C3 position seemed to have a 
larger stimulatory potency for MRP1 compared to digoxigenin and digoxin that contain 
a sugar moiety at this position. Digitoxin is a stronger MRP1 inhibitor than digoxin, 
illustrating that the hydroxyl group at C12 does not favor MRP1 inhibition. Apparently, 
the hydroxyl group at the C19 position of strophanthidol improved the inhibitory 
effect better than the carbonyl group of strophanthidin. In addition, the combination 
of a hydroxyl group at C1 and C11 diminished the inhibitory effect (ouabagenin vs. 
strophanthidol), but when they are located at the C5 and C19 position, the inhibitory 
effect was increased (strophanthidol vs. gitoxigenin) (Figure 1).
There were no inhibitors of MRP2 among the cardenolides tested, however, cymarin, 
digitoxigenin, peruvoside, and strophanthidin stimulated E217βG transport by MRP2 
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(Figure 3). Digitoxigenin with a hydroxyl group at the C3 position stimulated MRP2 
transport activity more potently than digitoxin, which contains a sugar moiety at this 
position. However, cymarin, digoxin, and ouabain, containing sugars at the C3 position, 
did not stimulate MRP2 more potently than non-sugar containing cardenolides, such 
as strophanthidin, digoxigenin, and ouabagenin. Therefore, the addition of a sugar or 
hydroxyl group at C3 does not result in an increased stimulatory capacity. The presence 
of a hydroxyl group at the C12 (digoxigenin and digoxin vs. digitoxigenin and digitoxin) 
and C16 position (gitoxigenin vs. digitoxigenin) reduced the stimulatory effect on MRP2. 
Unlike ouabain, the lactone ring at C17 in dihydroouabain is saturated, which improved 
the stimulatory potency of dihydroouabain for MRP2. Furthermore, the presence of a 
carbonyl group at C19 stimulated MRP2 more than a hydroxyl group (strophanthidin 
vs. strophanthidol) at the same position (Figure 1).
MRP3 is inhibited by strophanthidol, containing a hydroxyl group at the C19 
position, more potently than strophanthidin with a carbonyl group at that position. 
In addition to the hydroxyl group at C19, the lack of hydroxyl groups at C1 and C11 
improved the inhibitory effect of the tested cardenolides for MRP3 (ouabagenin vs. 
strophanthidol) (Figure1 and 3).
The inhibitory potency of the cardenolides on MRP4 could be ranked as follows: 
convallatoxin < peruvoside = strophanthidol < digitoxin < digitoxigenin (Figure 
3). Based on the presence of a hydroxyl group at the C3 position in digitoxigenin 
and ouabagenin, which inhibited MRP4 more potently than digitoxin and ouabain, 
respectively, it seems that the presence of a hydroxyl group at C3 is in favor of MRP4 
inhibition. However, convallatoxin with a sugar moiety at the C3 position is a more 
potent inhibitor as compared to strophanthidin with a hydroxyl group at this position. 
The hydroxyl groups at the C12 (digoxigenin and digoxin vs. digitoxigenin and digitoxin) 
and C16 positions (gitoxigenin vs. digitoxigenin) reduced the inhibitory effect on MRP4. 
Strophanthidol with a hydroxyl group at C19 position is a potent inhibitor compared 
with strophanthidin with a carbonyl group in this position (Figure 1).  
Based on our study and comparison of the structural features of cardenolides, it can 
be concluded that the substitutions at the C3 position play a key role in the interactions 
of cardenolides with BCRP and MRP1. Interestingly, based on our observations, the 
simultaneous absence of hydroxyl group at C1 and C11 positions improved the inhibitory 
potency of cardenolides for BCRP, BSEP, MRP1, and MRP3. In addition, cardenolides 
lacking a hydroxyl group at position C12 were more potent inhibitors of BCRP, BSEP, 
MRP1, and MRP4 and more potent stimulators of MRP2. The presence of a hydroxyl 
group at the C19 position favored BSEP, MRP1, MRP3, and MRP4 inhibition, whereas 
a carbonyl group at this position was in favor of MRP2 stimulation.
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Previously, we showed that the presence of a sugar moiety and hydroxyl group at 
the C3 and C19 positions is associated with a higher inhibitory potency against P-gp 
(Gozalpour et al., 2013). Here, we show that substitutions of cardenolides at positions 
C1, C3, C11, C12, C16, and C19 play a key role in their inhibitory or stimulatory potency 
on BSEP, BCRP, MRP1, MRP2, MRP3, and MRP4. 
In this study, we showed that digoxin inhibited BCRP transport activity, which is 
in line with the study of Pavek et al. who reported digoxin as an inhibitor of BCRP-
mediated mitoxantrone transport in MDCKII-BCRP cell lines (Pavek et al., 2005). 
Moreover, Huang et al. showed that the biliary and urinary excretion of digoxin is not 
altered in BCRP knock-out rats and digoxin is not transported by BCRP in MDCK cell 
line (Huang et al., 2012).
It has been shown that ouabain decreases MRP1 expression reversibly in an 
embryonic kidney cell line and a concentration higher than 100 nM reduces MRP1-
mediated carboxyfl uorescein diacetate transport activity (Valente et al., 2007). However, 
no inhibitory effect of ouabain on MRP1-mediated E217βG transport activity was 
observed in the present study. 
To determine whether cardenolides are transport substrates of BCRP, BSEP, and 
the MRPs, an indirect method based on the affi nity of DLCs for Na,K-ATPase was 
developed. Using this assay, we were able to determine the uptake of cardenolides into 
membrane vesicles. Convallatoxin, cymarin, digoxigenin, peruvoside, strophanthidin, 
and strophanthidol did not enter the membrane vesicles in the absence or presence 
of ATP for all tested transporters. Interestingly, digitoxigenin, digitoxin, and digoxin 
accumulated into control membrane vesicles. The clogP values, that represent the 
lipophilicity of the compounds, were calculated for the tested cardenolides (Table 2). 
Digitoxigenin, digitoxin, and digoxin have the highest clogP values (2.85, 2.48, and 1.42) 
among tested cardenolides, which explains their passive diffusion into the membrane 
vesicles. 
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Table 2. Calculated logP values of cardenolides
Compounds clogP a
Convallatoxin -0.67
Cymarin 0.22
Digitoxigenin 2.48
Digitoxin 2.85
Digoxigenin 1.05
Digoxin 1.42
Dihydroouabain -1.80
Gitoxigenin 0.32
Ouabain -1.66
Ouabagenin -1.32
Peruvoside 0.32
Strophanthidin -0.30
Strophanthidol -0.28
Proscillaridin A 2.55
a Calculated octanol: water partition coeffi cient.
In conclusion, our results show that substitutions at the C3 position infl uence the 
inhibitory potency of cardenolides for BCRP and MRP1. The hydroxyl groups at the 
C12 and C16 positions reduced the inhibitory potency for BCRP, BSEP, and MRP4 
and the stimulatory potency for MRP2. The simultaneous presence of hydroxyl groups 
at C1 and C11 positions diminished the inhibitory potency for BCRP, BSEP, MRP1, 
and MRP3. Interestingly, the presence of a hydroxyl group at the C19 position favored 
BCRP, BSEP, MRP1, MRP3, and MRP4 inhibition, whereas the presence of a carbonyl 
group at this position favored MRP2 stimulation. In addition, the saturation of the 
cardenolide lactone ring seems to improve the stimulation of MRP2. Although we have 
shown that several DLCs interact with BCRP, BSEP, MRP1, MRP2, MRP3, and MRP4, 
in the vesicular assay, none of them are substrates of these transporters. The interaction 
of DLCs with effl ux transporters can infl uence the distribution of other medications 
and might give rise to drug-drug interactions. Knowledge on DLC structure-function 
relationship can help to select those DLCs that have little or no interaction with effl ux 
pumps and thereby decrease the risk of drug-drug interactions.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Cardenolides Modulate Transport Activities of BSEP, BCRP and MRP1-4
53
2
Supplementary Figure 1. Concentration-dependent inhibition of ouabain binding to Na,K-
ATPase by cardenolides. The binding of [3H]ouabain to Na,K-ATPase in the presence of 
increasing concentrations of convallatoxin (A) from 0 to 1000 nM, of cymarin (B), digitoxigenin 
(C), digoxigenin (E), digoxin (F), peruvoside (G), strophanthidin (H) and strophanthidol (I) from 
0 to 3000 nM and of digitoxin (D) from 2000 to 3000 nM was plotted. The binding of [3H]ouabain 
to Na, K-ATPase in the absence of DLCs were 469 ± 54 (A), 574 ± 34 (B), 452 ± 24.2 (C), 497± 
45.7 (D), 643 ± 16 (E), 628 ± 8.6 (F), 603 ± 36.6 (G), 453 ± 17.8 (H), 581 ± 42.5 (I) pmol/mg 
protein (Mean ± S.E.M). These values were set at 100% and the mean value of three independent 
experiments was shown.
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Abstract
Digitalis-like compounds (DLCs), or cardiac glycosides, are produced and 
sequestered by certain plants and animals as a protective mechanism against herbivores 
or predators. Currently, the DLCs digoxin and digitoxin are used in the treatment 
of cardiac congestion and some types of cardiac arrhythmia, despite a very narrow 
therapeutic index. P-glycoprotein (P-gp; ABCB1) is the only known ATP-dependent 
effl ux transporter that handles digoxin as a substrate. 
Ten alanine mutants of human P-gp drug-binding amino acids Leu65, Ile306, Phe336, 
Ile340, Phe343, Phe728, Phe942, Thr945, Leu975, and Val982 were generated and expressed in 
HEK293 cells with a mammalian baculovirus system. The uptake of [3H]-N-methyl-
quinidine (NMQ), the P-gp substrate in vesicular transport assays, was determined. 
The mutations I306A, F343A, F728A, T945A, and L975A abolished NMQ transport 
activity of P-gp. For the other mutants, the apparent affi nities for six DLCs (cymarin, 
digitoxin, digoxin, peruvoside, proscillaridin A, and strophanthidol) were determined. 
The affi nities of digoxin, proscillaridin A, peruvoside and cymarin for mutants F336A 
and I340A were decreased two to four fold compared with wild type, whereas that of 
digitoxin and strophanthidol did not change. In addition, the presence of a hydroxyl 
group at position 12β seems to reduce the apparent affi nity when the side chain of 
Phe336 and Phe942 is absent.
Our results showed that a δ-lactone ring and a sugar moiety at 3β of  the steroid 
body are favorable for DLC binding to P-gp. Moreover, DLC inhibition is increased 
by hydroxyl groups at positions 5β and 19, whereas inhibition is decreased by those 
at positions 1β, 11α, 12β, and 16β. The understanding of the P-gp-DLC interaction 
improves our insight into DLCs toxicity and might enhance the replacement of digoxin 
with other DLCs that have less adverse drug effects.
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Introduction
Digitalis-like compounds (DLCs), or cardiac glycosides, are made by certain plants 
(e.g., Apocynaceae family) and animals (e.g., Bufonidae family) (Lopez-Lazaro, 2007; 
Hallbook et al., 2011). These toxic metabolites are produced and sequestered as a 
protective mechanism against herbivores or predators, and plant extracts were used as 
arrow poison by humans. DLCs have been employed therapeutically for the treatment 
of congestive heart failure for many years. Digoxin is the most prescribed DLC, and 
its use is characterized by a narrow therapeutic plasma concentration range (0.8–2 
μg/L). Above 3 μg/L symptoms of toxicity occur, such as fatigue, nausea, vomiting, 
anorexia, visual disturbances, ventricular fi brillation, and ultimately death (Vivo et al., 
2008). Digoxin toxicity has been ranked as the second cause of drug-related hospital 
admissions in the United States (Abad-Santos et al., 2000; Haynes et al., 2009). The 
drug is excreted via renal clearance and intestinal secretion. Comedication with drugs 
such as verapamil, nifedipine, nitrendipine, propafenone, amiodarone, quinidine, 
cyclosporine, and itraconazole is known to increase digoxin in plasma up to toxic levels 
due to inhibition of transporters in the excretory organs (Belz et al., 1983; Woodland et 
al., 1998; Verschraagen et al., 1999; Pauli-Magnus et al., 2001a). 
As digoxin interaction with P-glycoprotein (P-gp; MDR1/ ABCB1) substrates is one 
of the key factors in its toxicity, transport via P-gp has been extensively studied (de 
Lannoy & Silverman, 1992) and there is ample evidence that inhibition of P-gp transport 
increases the digoxin plasma levels and thereby its toxicity (Boyd et al., 2000; Westphal et 
al., 2000; Lowes et al., 2003; Englund et al., 2004; Shoaf et al., 2011). Moreover, numerous 
studies have shown that P-gp polymorphisms infl uence digoxin plasma concentration. 
The synonymous polymorphisms, C3435T (Ile1145Ile) and G2677C (Ala893Pro), are 
the alleles that have been shown to increase orally administered digoxin levels in plasma 
in German population. On the other hand, there are also studies that reported that 
there is no association between these two polymorphisms and the digoxin plasma levels 
in Polish Caucasian and Japanese populations (Hoffmeyer et al., 2000; Sakaeda et al., 
2001; Johne et al., 2002; Kurzawski et al., 2007). It seems that P-gp polymorphisms 
might infl uence the digoxin plasma levels population dependently. P-gp is located mainly 
in tissues with a barrier function like intestine (brush border membrane of enterocytes), 
kidney (brush border membrane of proximal tubular cells), and lumenal side of brain 
capillary endothelial cells (Pauli-Magnus et al., 2001a; Jutabha et al., 2010).
P-gp is an ATP-dependent drug pump that mediates effl ux of a broad range of 
compounds. It is a 1280 amino acid long plasma membrane glycoprotein that consists of 
two halves, each of which begins with a transmembrane domain (TMD) containing six 
transmembrane helices (TM), followed by a nucleotide-binding domain (NBD) (Loo et 
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al., 2009). The intracellular NBDs exhibit ATPase activity that is necessary for substrate 
translocation, whereas the drug-binding pocket is located between the interface of two 
TMDs (Loo et al., 2007; 2008; 2009). Recently, the crystal structure of mouse P-gp 
(ABCB1), which has 87% sequence identity to human P-gp, has been determined in the 
presence of cyclic peptide inhibitors (Aller et al., 2009; Ravna et al., 2009). Several amino 
acids involved in binding of these inhibitors were previously identifi ed in mutagenesis 
studies as amino acids that play a role in substrate binding (Loo et al., 2006a; 2007). 
In addition to digoxin, a number of DLCs have been discovered that might also have 
therapeutic value in treatment of heart disease. These compounds all have the same 
mechanism of action as digoxin, but they have a different pharmacokinetic profi le, which 
could be more favorable for treatment. Because P-gp activity infl uences digoxin plasma 
levels, identifi cation of DLCs that have less interaction with P-gp could be valuable. 
Until now, only digoxin, digitoxin, and ouabain have been studied in P-gp transport 
assays, but knowledge about their P-gp-binding site is lacking (Sharom, 1995; Cavet et 
al., 1996; Pauli-Magnus et al., 2001a). 
In the present study, we have expanded the knowledge about DLC interaction with 
human P-gp by investigating the inhibitory effect of 15 different DLCs (Figure 1) on 
P-gp-mediated transport of N-methyl-quinidine (NMQ) into human P-gp-containing 
membrane vesicles. NMQ is actively transported by P-gp in a vesicular transport 
assay (Hooiveld et al., 2002). Our experiments showed that DLCs such as digitoxin, 
proscillaridin A, peruvoside, cymarin, and strophanthidol inhibited P-gp transport 
activity. To further understand the interaction of DLCs and NMQ with human P-gp, 
amino acids were mutated that could play a key role in the binding and translocation 
of drugs. Based on the description of drug-binding amino acids in crystallized mouse 
P-gp (Aller et al., 2009), we selected Leu65 in TM1, Ile306 in TM5, Phe336, Ile340, and 
Phe343 in TM6, Phe728 in TM7, Phe942 and Thr945 in TM11, and Leu975 and val982 
in TM12 of human P-gp for mutation to alanine, and thereby investigated the role of 
these amino acids in transport of NMQ in the presence and absence of different DLCs. 
Removal of the side chain resulted in loss of NMQ transport activity of fi ve human 
P-gp mutants: I306A, F343A, F728A, T945A, and L975A, which seem to have key role 
in the transport of NMQ. However, transport activity was preserved in L65A, I306A, 
I340A, F942A, and V982A. These mutants were further analyzed to elucidate their role 
in DLC binding.
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Figure 1. Structural characteristics of DLCs: cardenolides and bufadienolides. (A) DLCs have 
different substituents on the steroid ring, which is the core structure. (B) Steroid ring structure of 
DLCs illustrating carbon numbers, sugar moiety position on C-3 (R1), and lactone ring position 
on C-17 (R2). Based on the structure of DLCs, one of the illustrated sugars is located on C-3. 
The cardenolides and bufadienolides contain γ-butyrolactone (γ-lactone) and δ-valerolactone 
(δ-lactone) at the 17 position, respectively. γ-Lactone is saturated in dihydro forms of cardenolides 
such as dihydroouabain. The inhibition pattern of DLCs (1000 μM) on P-gp-mediated NMQ 
transport is shown as 25–50% (+), 50–75% (++), 75–90% (+++), and 90–100% (++++) inhibited 
transport by P-gp.
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Materials and Methods
Materials. Dulbecco’s Modifi ed Eagle’s Medium (DMEM) and Gluta-MAX-11 were 
purchased from Invitrogen (Breda, The Netherlands). [3H]-NMQ (specifi c activity, 76.7 
Ci/mmol) and unlabeled NMQ were purchased from Solvo Biotechnology (Szeged, 
Hungary). The Bac-to-Bac system, Cellfectin II reagent, and Grace’s insect cell medium 
were purchased from Invitrogen. The primers for the mutagenesis were produced by 
Biolegio (Nijmegen, The Netherlands). The plasmid purifi cation midiprep kit was from 
Genomed (Löhn, Germany). Protein concentration was measured with an assay kit from 
Bio-Rad Laboratories (Veenendaal, The Netherlands). DLCs (convallatoxin, cymarin, 
digitoxigenin, digitoxin, digoxigenin, digoxin, dihydroouabain, gitoxigenin, ouabagenin, 
ouabain, peruvoside, strophanthidin, strophanthidol, bufalin, and proscillaridin A) 
were purchased from Sigma (Zwijndrecht, The Netherlands). The mouse monoclonal 
antibody against P-gp, C219, and the secondary antibody, fl uorescent goat anti-mouse 
IgG antibody IRDye 800, were purchased from Abcam (Cambridge, United Kingdom) 
and Rockland immunochemicals for research (Heerhugowaard, The Netherlands), 
respectively.
Cell culture. HEK293 cells were grown in 182-cm2 fl asks using DMEM + GlutaMAX-1 
supplemented with 10% fetal calf  serum at 37°C under 5% CO2 humidifi ed air. The cells 
were recultured twice a week when they were 70–80% confl uent in a ratio of 1:4.
Generation of human P-gp baculovirus. Full-length human P-gp cDNA, according to 
Genbank accession number NM_000927, was cloned into the gateway entry clone. The 
gateway system was used to clone the constructs in to a VSV-G-improved pFastBacDual 
vector and transduce mammalian cells as described before (El-Sheikh et al., 2008). The 
Bac-to-Bac system was used to produce human P-gp baculovirus as described in manual 
(Invitrogen).
Site-directed mutagenesis. A site-directed PCR was performed using pENTR-P-gp 
vector as template and PfuUltra II fusion HS as DNA polymerase. Ten different P-gp 
mutants were produced: L65A, I306A, F336A, I340A, F343A, F728A, F942A, T945A, 
L975A, and V982A and all mutations were confi rmed by sequencing of full-length P-gp 
cDNA.
Transduction of HEK 293 cells with P-gp and mutant expression vectors. HEK293 
cells were cultured in 182-cm2 fl asks, 13 ml of which were seeded in 500-cm2 triple fl asks 
(Sanbio, Uden, The Netherlands) at 85–95% confl uency. After 24 h, the culture medium 
was removed and 25 ml of fresh medium and 10 ml of baculovirus preparations of 
enhanced yellow fl uorescent protein (eYFP), P-gp, or P-gp mutants were added. These 
cells were incubated at 37°C for 20 min and fi nally, 40 ml of medium was added to them. 
Sodium butyrate was added to the cells 6 h after transduction up to a fi nal concentration 
of 5 mM, and the cells were harvested 3 days later.
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Isolation of membrane vesicles and protein analysis. Transduced cells were harvested 
by centrifugation at 3500×g for 20 min. The isolation of membrane vesicles was 
performed according to previously described method (El-Sheikh et al., 2008). Briefl y, 
the pellets were resuspended in ice-cold hypotonic buffer supplemented with protease 
inhibitors. The lysed cells were centrifuged at 100,000×g at 4°C for 30 min. The pellet 
was homogenized in ice-cold TS buffer (10 mM Tris-HEPES and 250 mM sucrose, pH 
7.4) supplemented with the protease inhibitors using a tight-fi tting Dounce homogenizer 
for 25 strokes. After centrifugation at 4000×g, 4°C for 20 min, the supernatant was 
centrifuged at 100,000×g at 4°C for 60 min. The membrane pellet was resuspended 
in ice-cold TS buffer and passed through a 27-gauge needle 25 times to form vesicles. 
Protein concentration was measured by using the Bio-Rad protein assay kit (Bio-Rad). 
Crude membrane vesicles were frozen in liquid nitrogen and stored at -80°C until use.
Western blot analysis. The preparations of the membrane vesicle (18 μg) were 
solubilized in SDS-PAGE sample buffer and separated on SDS containing 7.5% 
acrylamide. The protein samples were blotted on nitrocellulose membrane using iBlot 
dry blotting system (Invitrogen). P-gp and mutant P-gp were detected by monoclonal 
anti-human P-gp mouse serum antibody. β-Actin was detected by monoclonal anti-
human β-actin mouse serum antibody as a loading control in eYFP and P-gp vesicle 
preparations. The fl uorescent goat anti-mouse IgG antibody IRDye 800 was used as a 
secondary antibody and Odyssey infrared imaging system (Li-Cor Biosciences, Lincoln, 
NE) was used to visualize signals.
Vesicular transport assay. A rapid fi ltration technique was applied to measure [3H]-
NMQ uptake into membrane vesicles as described by (Wittgen et al., 2011). In summary, 
the vesicles preparations (7.5 μg) were prewarmed at 37°C and added to TS buffer 
containing 10 mM MgCl2, 4 mM ATP, and 0.1 μM [
3H]-NMQ at a fi nal volume of 
30 μl. The samples were transferred to ice to stop the reaction using 150 μl of ice-cold 
TS buffer. A MultiscreenHTS Vacuum Manifold fi ltration device (Millipore, Etten-Leur, 
The Netherlands) was applied to fi lter the diluted mixture through 0.65-μm pore, 96-
well MultiscreenHTS FB (glass fi ber) fi lters (Millipore) that were preincubated with TS 
buffer. After aspiration of the samples, the fi lters were washed with TS buffer twice. 
Subsequently, 2 ml scintillation fl uid was added to each sample followed by liquid 
scintillation counting. In all experiments, net ATP-dependent transport was calculated 
by subtracting values measured in presence of adenosine monophosphate (AMP) from 
the values measured in presence of ATP. All experiments were performed in triplicates 
and were repeated with three different preparations of membrane vesicles.
Vesicular inhibition assays. To investigate the effect of different DLCs on P-gp-
mediated NMQ transport, the previously described assay was performed in the presence 
of different DLCs. All DLCs were dissolved in dimethyl sulfoxide (DMSO) and 
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were diluted to a fi nal concentration of 100 and 1000 μM in the incubation medium. 
Further, 1% DMSO (vehicle control) and 100 μM NMQ were used as the negative and 
positive control for inhibition, respectively. The inhibitory effect of digoxin, digitoxin, 
proscillaridin A, peruvoside, strophanthidol, cymarin, and bufalin on wild-type and 
mutant P-gp-mediated NMQ transport was investigated further by applying different 
concentrations of these compounds ranging from 1 to 1000 μM.
Kinetic analysis. To determine Km and Vmax values for P-gp-mediated NMQ transport, 
membrane vesicles (7.5 μg protein) were incubated with increasing concentration of 
NMQ in the presence of 20 nM [3H]-NMQ for 1 min. The specifi c [3H]-NMQ transport 
(pmol/mg protein/min) by P-gp and eYFP was determined by subtraction of AMP values 
from ATP values. The ATP-dependent data points were fi tted by nonlinear regression 
analysis to the Michaelis–Menten equation. Inhibition curves were analyzed according 
to a one-site binding model and IC50 values were obtained by fi tting the below equation 
to the data.
y = bottom + (top – bottom) / (1 + 10 (logIC50− x). Hill slope)
In this equation, x and y indicate log inhibitor concentration and uptake versus control, 
respectively. Curve fi tting was done by using GraphPad Prism software version 5 
(GraphPad Software Inc., San Diego, CA). Statistical differences were tested by one-way 
ANOVA followed by Dunnett’s post hoc multiple comparison. A p < 0.05 was considered 
signifi cant.
Results
Expression of P-gp. Immunoblot analysis performed on membrane vesicles from 
HEK293 cells overexpressing P-gp demonstrated successful expression of P-gp at 
approximately 170 kDa (Figure 2A). The negative control, consisting of membrane 
vesicles from eYFP overexpressing HEK293 cells, showed no expression of P-gp. 
Kinetics of P-gp-Mediated NMQ Transport. To determine the kinetic characteristics 
of P-gp in our vesicle assay, we determined the time and concentration dependency of 
P-gp-mediated NMQ transport. Time-dependent NMQ transport activity at 100 nM 
was linear up to 1 min (Figure 2B). Next, we measured concentration-dependent uptake 
of NMQ into membrane vesicles (Figure 2C). ATP-dependent NMQ transport reached 
a maximum activity (Vmax) of 901 ± 51.3 pmol/mg protein/min (mean ± SEM). The 
Km of NMQ transport via P-gp was 2.2 ± 0.48 μM, which is somewhat lower than that 
reported previously for P-gp expressed in Sf21 insect cells (15 μM) (Hooiveld et al., 
2002).
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Figure 2. Immunoblot analysis of P-gp expression (A), time-dependent uptake of NMQ (B), and 
concentration-dependent uptake of (NMQ) (C) by membrane vesicles isolated from HEK293 
cells overexpressing human P-gp (▪) and eYFP (•). Top (A) represents membrane vesicles (18 μg) 
prepared from HEK293 cells overexpressing human P-gp and eYFP as the control. β-Actin was 
used as loading control for each vesicle preparation. Top (B) shows NMQ uptake of membrane 
vesicles (7.5 μg protein) incubated with 100nM NMQ at the indicated time points. Bottom (C) 
represents ATP-dependent NMQ uptake in the presence of increasing concentration of NMQ. 
In (B) and (C), the mean values (pmol/mg protein/min) ± SEM of three vesicle preparations are 
shown.
E ffect of  DLCs on P-gp-Mediated NMQ Transport. Two concentrations (100 and 
1000 μM) of 15 DLCs were used to determine the P-gp-DLC interaction. NMQ (100 
nM) transport activity of P-gp (43.7 ± 3.8 pmol/mg protein/min) was set at 100% and 
100 μM unlabeled NMQ was used as a positive control (Figure 3). The large difference 
between the substrate concentration (100 nM) and the DLC concentration (100 and 
1000 μM) ascertain that most inhibitory effects will be observed. Cymarin, digitoxin, 
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digoxin, peruvoside, strophanthidol, bufalin, and proscillaridin A inhibited P-gp-
mediated transport of NMQ by 70–100% at 1000 μM. At 100 μM, the most potent 
P-gp inhibitors, digitoxin and proscillaridin A, inhibited NMQ transport by 91 and 
97%, respectively. The DLC inhibitor potency of P-gp-mediated NMQ transport 
could be categorized as follows: digitoxin = proscillaridin A > digoxin = peruvoside = 
strophanthidol = bufalin > convallatoxin = digitoxigenin = cymarin > strophanthidin. 
Digoxigenin, dihydroouabain, gitoxigenin, ouabagenin, and ouabain did not signifi cantly 
inhibit P-gp-mediated NMQ transport.
DLC Concentration-Dependent Inhibition of P-gp-Mediated NMQ Transport. The 
inhibitory potencies of cymarin, digitoxin, digoxin, peruvoside, proscillaridin A, and 
strophanthidol were quantifi ed at 100 nM NMQ (Figure 4). The net NMQ transport by 
P-gp in the presence of increasing concentrations of DLCs was plotted and analyzed by 
nonlinear regression. The IC50 values of the most potent P-gp inhibitors, digitoxin and 
proscillaridin A, were 9 and 25 μM, respectively, whereas, cymarin, digoxin, peruvoside, 
and strophanthidol had 10-fold higher IC50 values of 432, 188, 214, and 242 μM, 
respectively.
Functional Expression of P-gp Mutants. To elucidate the DLC-binding site of P-gp, 
10 mutants of human P-gp were constructed and expressed in HEK293 cells (Figure 
5). All the indicated amino acids were replaced by alanine to remove the side chain of 
the residue (L65A, I306A, F336A, I340A, F343A, F728A, F942A, T945A, L975A, and 
V982A). First, the expression levels of wild-type and mutant enzymes were investigated 
by Western blot analysis (Figure 5A). Although, some variation was observed between 
the different batches, the average expression of the mutants was similar to that of wild 
type P-gp. Next, we determined the NMQ transport activity of these P-gp mutants 
(Figure 5B). NMQ transport activity of mutants L65A, F336A, I340A, F942A, and 
V982A as compared with wild-type P-gp ranged from 60 to 150%, whereas NMQ 
transport activity of I306A, F343A, F728A, T945A, and L975A varied between 8 and 
30%.
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Figure 3. Inhibitory effect of different DLCs on NMQ (100 nM) transport by P-gp. Dimethyl 
sulfoxide (Ctrl) and cold NMQ (100 μM) were used as controls. Fifteen DLCs of 100 and 1000 
μM were used in this assay. The transport activity of P-gp for 100 nM NMQ (43.7 ± 3.8 pmol/mg 
protein/min) in the presence of DMSO was set at 100%. Each bar represents mean ± SEM value 
of three experiments. Each mean value was compared with Ctrl (DMSO) using one-way ANOVA, 
followed by a Dunnett’s post hoc test, *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 4. Inhibition of P-gp-mediated NMQ transport by DLCs. Membrane vesicles were incubated 
with 100 nM NMQ in the presence of cymarin (A), digitoxin (B), digoxin (C), peruvoside (D), 
proscillaridin A (E), and strophanthidol (F) at concentrations ranging from 0 to 1000 μM. The 
highest specifi c NMQ transport (pmol/mg protein/min) for each vesicle membrane preparation in 
the presence of increasing concentrations of cymarin, digitoxin, digoxin, peruvoside, proscillaridin 
A, and strophanthidol were 34.4 ± 3.3, 37.7 ± 3.5, 34.4 ± 3.5, 36.2 ± 6.8, 37.4 ± 7.7, and 39.2 ± 4.6 
(mean ± SEM), respectively. These values were set at 100% for each vesicle membrane preparation 
and the percentage of mean values ± SEM of three to fi ve preparations are shown.
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Figure 5. Western blot analysis (A) and NMQ transport activity of wild type and L65A, I306A, 
F336A, I340A, F343A, F728A, F942A, T945A, L975A and V982A mutant P-gp (B). Top (A) 
represents a Western blot analysis of membrane vesicles isolated from HEK293 cells overexpressing 
wild-type (WT) and mutant P-gp and eYFP as a negative control (Ctrl). In each lane, 18 μg protein 
was loaded. Bottom (B) represents transport activity after subtraction of AMP values from ATP 
values. The wild-type P-gp transport activity for NMQ (20.3 ± 4.86 pmol/mg protein/min) was set 
at 100%. Mean ± SEM of four different vesicle preparations are shown. The transport activity of 
each mutant was compared with wild-type P-gp using one-way ANOVA, followed by a Dunnett’s 
post hoc test, *p < 0.05, **p < 0.01.
Concentration-Dependent Inhibition of DLCs on NMQ Transport by P-gp Mutants. 
The inhibitory potency of DLCs on NMQ uptake by selected P-gp mutants was analyzed. 
For this purpose, the DLCs that were used to determine the concentration-dependent 
inhibitions of P-gp-mediated NMQ transport were selected (Figure 4). In addition, fi ve 
P-gp mutants (L65A, F336A, I340A, F942A, and V982A), for which NMQ transport 
activity was at least 50% of wild-type transport, were selected. NMQ transport of 
these mutants was plotted in the absence and presence of increasing concentrations of 
cymarin, digitoxin, digoxin, peruvoside, strophanthidol, and proscillaridin A (Figure 6). 
The IC50 value of each compound was determined for wild-type and P-gp mutants using 
nonlinear regression analysis (Table 1). Comparing the IC50 values of the mutants with 
those of the wild type (mutant IC50/wild-type IC50), L65A, and V982A showed similar 
values as wild type (0.6–2.2). Most remarkable, however, was the role of Phe336 and 
Ile340 in DLC interaction, because removal of their side chains yielded proteins that 
were 2.3–4.4 times less sensitive for cymarin (not signifi cant for Ile340), digoxin (not 
signifi cant), peruvoside, and proscillaridin A, whereas it hardly affected the affi nity for 
digitoxin (1.6–2.0) or strophanthidol (0.6–1.1) (Figure 6). F942A seems to affect the 
digoxin binding (3.0), although not signifi cantly.
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Figure 6. Concentration-dependent inhibition of wild-type and mutant P-gp-mediated [3H]-
NMQ transport by DLCs. Wild-type, F336A (A) and I340A (B) mutant P-gp membrane vesicles 
were incubated with 100 nM NMQ (containing 10 nM [3H]-NMQ) in the absence or presence 
of indicated concentrations of cymarin, digitoxin, digoxin, peruvoside, proscillaridin A, and 
strophanthidol. ATP-dependent transport was determined by subtraction of uptake in presence 
of AMP from the value in presence of ATP. The data points have been shown by (•) for wild-type, 
(■) for F336A mutant and (▲) for I340A mutant P-gp. Mean ± SEM of three different vesicle 
preparations are shown.
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Discussion
DLCs like digoxin are used for treatment of heart failure; however, its narrow 
therapeutic window limits a safe application in therapy. P-gp transport is known to be 
a determinant of the plasma level of digoxin, and therefore drug-drug interactions with 
substrates or inhibitors of P-gp further complicate digoxin therapy. In this study, we 
investigated which structural features are important for interaction of DLCs with P-gp, 
and explored whether other DLCs could also interact with P-gp.
We expressed human P-gp in HEK293 cells using the mammalian baculovirus 
expression system described previously (El-Sheikh et al., 2008; Shukla et al., 2012) and 
determined NMQ transport into vesicles. The transport of NMQ could be inhibited by 
digitoxin, proscillaridin A, digoxin, peruvoside, strophanthidol, and bufalin, whereas 
the other DLCs did hardly (convallatoxin, cymarin, digitoxigenin, and strophanthidin) 
or not (digoxigenin, dihydroouabain, gitoxigenin, ouabagenin, and ouabain) inhibit this 
transport. Comparison of the inhibitory capacity of the different DLCs could provide 
information about which DLC substituent is important for binding to P-gp.
The sugar group at position 3β apparently can improve binding of most DLCs to 
P-gp. Digitoxin and digoxin are stronger inhibitors than digitoxigenin and digoxigenin, 
illustrating that the tri-D-digitoxose sugar moiety improves inhibitory potency (Figure 
1). In addition, proscillaridin A, which has a L-rhamnose group at the 3β position, has 
a higher inhibitory potency than bufalin, which lacks a sugar group. However, addition 
of L-rhamnose group at 3β does not necessarily assign a good inhibitory capacity to 
the compound, because in the case of ouabain and ouabagenin, the sugar-containing 
ouabain had no inhibitory effect. From our study, it is not clear if  different sugar groups 
contribute to the observed variation in DLC inhibitory potencies. The only difference 
between convallatoxin and cymarin is the sugar group (L-rhamnose vs. D-cymarose, 
respectively) and this apparently did not result in a different inhibitory potency.
The tested DLCs contain hydroxyl groups at positions 1β, 5β, 11α, 12β, 14, 16β, and 
19. In this series, the hydroxyls at positions 1β and 11α and at positions 5β and 19 are 
always present together; therefore we cannot come to a conclusion on the individual 
contribution of hydroxyl groups at these positions (Figure 1). The presence of both 
hydroxyl groups at positions 1β and 11α diminishes the inhibitory potency (strophanthidol 
vs. ouabagenin), whereas when located at positions 5β and 19, inhibitory potency is 
increased (strophanthidol vs. gitoxigenin). In addition, the presence of the 12β hydroxyl 
group (digitoxigenin vs. digoxigenin and digitoxin vs. digoxin) and a hydroxyl group at 
16β position (gitoxigenin vs. digitoxigenin) lowers the inhibitory potency. Comparing 
strophanthidin with strophanthidol shows that a hydroxyl at position 19 is favorable for 
binding over a carbonyl at this position. Comparing convallatoxin with ouabain shows 
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that the absence of hydroxyl groups at 1β and 11α results in a stronger inhibition than 
the replacement of an oxygen group by a hydroxyl at position 19. It can be concluded 
that all hydroxyls discussed above, lower the inhibitory potency of DLCs, except for the 
combination at positions 5β and 19.
In this study, we cannot state that saturation of the lactone ring infl uences the binding 
affi nity signifi cantly (ouabain vs. dihydroouabain). On the other hand, a δ-lactone ring 
increases inhibitory potency over a γ-lactone ring (digitoxigenin vs. bufalin).
Overall, the structure-function relationships observed indicate that a DLC with a 
sugar moiety at 3β, only hydroxyls at 5β, 14, and 19, and a δ-lactone ring should have 
a very high inhibitory capacity for P-gp. However, such a relationship might be too 
simple considering the polyspecifi c binding properties of P-gp as shown in the crystal 
structures of P-gp in complex with two stereoisomers of cyclic hexapeptide inhibitors 
(Aller et al., 2009), whereas only one R stereoisomer (cyclictris-tris-(R)-valineselenazole 
[QZ59-RRR]) was bound, two S stereoisomers (cyclic-tris-(S)-valineselenazole [QZ59-
SSS]) were bound in the binding pocket. Moreover, the location of these binding sites 
was not comparable.
To obtain a better indication of the precise binding site of the DLCs, we removed 
the side chains (mutation to Ala) of 10 amino acids. We selected these mutants from the 
description of Mus musculus P-gp (Aller et al., 2009). Leu65, Ile306, Phe942, Thr945, 
and Leu975 are known to interact with the well-studied P-gp substrate verapamil. On 
the other hand, Phe336, Ile340, and Phe343 bind to the cyclic peptide inhibitor QZ59, 
whereas Phe728 and Val 982 interact with verapamil and QZ59. All the amino acids 
mutated in the present study are highly conserved between mouse and human. Leu65, 
Ile306, Phe336, Ile340, Phe343, Phe728, Phe942, Thr945, Leu975, and Val 982 in human 
correspond to Leu64, Ile302, Phe332, Ile336, Phe339, Phe724, Phe938, Thr941, Leu971, 
and Val 978 in M. musculus P-gp, respectively.
The function of these P-gp mutants was characterized by their NMQ transport 
activity. NMQ is a P-gp substrate that is very well transported in vesicular transport 
assays (Hooiveld et al., 2002). It was found that P-gp mutants could be divided in two 
groups. The fi rst group of mutants (I306A, F343A, F728A, T945A, and L975A) exhibited 
a signifi cantly lower NMQ transport activity (8–30% of wild-type P-gp). Other studies, 
using site-directed mutagenesis indicated that Ile306, Phe727, Thr945, and Leu975 are 
also important for verapamil binding (Aller et al., 2009). In addition, Phe343 was shown 
to play a role in binding of P-gp substrates such as vinblastine, cyclosporine A, and 
colchicine (Loo et al., 2009). In several studies, all these amino acids have been shown 
to play a key role in P-gp substrate transport (Loo & Clarke, 1996; 1999b; a; Tran et 
al., 2005; Loo et al., 2006b; 2007; Lee et al., 2010). The reduced transport activity we 
observed indicates that these residues are also involved in NMQ transport. In Figure 7, 
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we illustrated the position of the amino acids mutated in this study. From this fi gure, it 
appears that the amino acids that might interact with NMQ are far apart and therefore 
some interactions likely are indirect or in different conformations of the enzymatic cycle. 
NMQ transport activity of the second group mutants (L65A, F336A, I340A, F942A, 
and V982A) was not signifi cantly different from that of the wild-type P-gp (60–150%). 
Although Leu65, Phe942, and Val982 have been shown to play a role in verapamil 
transport (Loo et al., 2006a; Aller et al., 2009; Loo et al., 2009), mutation of these amino 
acids did not affect NMQ transport in our assay. Other studies showed that Phe336 
and Ile340, which did not infl uence NMQ transport signifi cantly, seem to have a more 
indirect role in transport of substrates (Loo & Clarke, 2002a; b; 2005; Loo et al., 2009; 
Ravna et al., 2009) and the peptide inhibitors QZ59-RRR and QZ59-SSS bind to these 
amino acids in the mouse P-gp crystal structure (Aller et al., 2009).
Figure 7. Position of the mutated residues in P-gp (PDB 3G5U). (A) The amino acids that are 
located in different P-gp TMDs have been mutated in this study. (B) The mutation of Ile306, 
Phe343, Phe728, Thr945, and Leu975 abolishes NMQ transport activity of P-gp that was 
conserved following the mutation in Leu65, Phe336, Ile340, Phe942 and Val982 (view: from 
cytosol to membrane).
We only investigated the effect of amino acid mutations on DLC interaction in 
mutants in which NMQ transport could be measured. Inhibition of NMQ transport 
by L65A, F942A and V982A with six DLCs showed that in only one case the mutation 
caused a signifi cant difference in the IC50 value (ratio of 2.2) of the DLCs compared with 
wild-type P-gp. More remarkable were the inhibitory affi nities of F336A and I340A, 
which were signifi cantly different in fi ve cases. Moreover, the IC50 ratio for cymarin, 
digoxin, peruvoside, and proscillaridin A was largely increased (IC50 ratio of 2.3–4.4), 
whereas that of digitoxin (IC50 ratio of 1.6–2.0) and strophanthidol (IC50 ratio of 0.6–
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1.1) was hardly affected. It seems that the presence of a hydroxyl group at position 12β 
(present in digoxin and not in digitoxin) reduces the apparent affi nity when the side 
chain of Phe336 and Phe942 is absent. Strophanthidol is the only DLC tested that has 
no sugar moiety (at 3β). Although the sugars (cymarose, tridigitoxose, methyl glucose, 
and rhamnose) have different structures, they all contain a pyranose ring and several 
hydroxyl groups that are suffi cient for interaction with phenylalanine or isoleucine.
In conclusion, our results showed that a δ-lactone ring and a sugar moiety at 3β of  
the steroid body are favorable for DLC binding to P-gp. In addition, hydroxyls at 5β and 
19 increase DLC inhibition, whereas those at positions 1β, 11α, 12β, and 16β decrease 
DLC inhibition. Although the toxicity of several DLCs is primarily due to inhibition of 
their therapeutic target Na,K-ATPase, interactions at the transporter level can infl uence 
their concentration at the target site. Inhibition of P-gp transport by other drugs has 
been shown to be an important determinant in digoxin-induced toxicity. Elucidation of 
the molecular mechanism of DLC translocation by P-gp will help in understanding and 
predicting potentially harmful drug-drug interactions and will aid in the development 
of DLCs that are less susceptible to pharmacokinetic interactions. We identifi ed DLC 
properties that are important for their interaction with P-gp and that should be omitted 
in the selection of new therapeutic DLCs.
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Abstract
Digitalis-like compounds (DLCs), such as digoxin and digitoxin that are derived from 
digitalis species, are currently used to treat heart failure and atrial fi brillation, but have 
a narrow therapeutic index. Drug-drug interactions at the transporter level are frequent 
causes of DLCs toxicity. P-glycoprotein (P-gp, ABCB1) is the primary transporter of 
digoxin and its inhibitors infl uence pharmacokinetics and disposition of digoxin in the 
human body; however, the involvement of P-gp in the disposition of other DLCs is 
currently unknown. 
In the  present study, the transport of fourteen DLCs by human P-gp was studied 
using membrane vesicles originating from human embryonic kidney (HEK293) cells 
overexpressing P-gp. DLCs were quantifi ed by liquid chromatography-mass spectrometry 
(LC-MS). 
The Lily of the Valley toxin, convallatoxin, was identifi ed as a P-gp substrate (Km: 
1.1 ± 0.2 mM) in the vesicular assay. Transport of convallatoxin by P-gp was confi rmed 
in rat in vivo, in which co-administration with the P-gp inhibitor elacridar, resulted 
in increased concentrations in brain and kidney cortex. To address the interaction of 
convallatoxin with P-gp on a molecular level, the effect of nine alanine mutations was 
compared with the substrate N-methyl quinidine (NMQ). Phe343 appeared to be more 
important for transport of NMQ than convallatoxin, while Val982 was particularly 
relevant for convallatoxin transport.
We identifi ed convallatoxin as a new P-gp substrate and recognized Val982 as an 
important amino acid involved in its transport. These results contribute to a better 
understanding of the interaction of DLCs with P-gp.
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Introduction
Digitalis-like compounds (DLCs) are used to treat cardiac failure and atrial 
fi brillation because of their positive inotropic and anti-arrhythmic effects. DLCs bind 
and inhibit Na,K-ATPase and induce the accumulation of intracellular Na+, which leads 
to reverse action of the Na+/Ca2+ exchanger and subsequent increased intracellular Ca2+. 
Subsequently, the contraction of the heart muscle is stimulated by the high concentration 
of Ca2+ inside the muscle cell (Schwinger et al., 2003; Philippe & Angenot, 2005).
The foxglove derived well-known and extensively-studied DLC digoxin, has a narrow 
therapeutic index and above a plasma concentration of 3.84 nM (3 μg/L) toxicity 
symptoms occur, such as arrhythmia, anorexia, nausea, vomiting, diarrhea, abdominal 
pain, visual disturbances, headache, weakness and dizziness (Eichhorn & Gheorghiade, 
2002; Vivo et al., 2008). Drug-drug interactions at the excretion level are one of the 
factors playing a role in digoxin toxicity. The concomitant administration of digoxin 
with drugs such as amiodarone, propafenone, verapamil, quinidine, and omeprazole 
reduce digoxin excretion, resulting in high digoxin concentrations in plasma (Pedersen 
et al., 1981; Belz et al., 1982; Nademanee et al., 1984; Marcus, 1985; Woodland et al., 
1997; Laer et al., 1998; Fromm et al., 1999; Pauli-Magnus et al., 2001a; Li et al., 2013). 
These drugs are inhibitors of the digoxin effl ux transporter P-glycoprotein (P-gp) (de 
Lannoy & Silverman, 1992; Tanigawara et al., 1992; Schinkel et al., 1995).
The ATP-binding cassette transporter (ABC) family member P-gp, is the product 
of the Multi Drug Resistance 1 (MDR1, ABCB1) gene that is expressed mainly in 
transporting epithelia of kidney (brush border membrane of proximal tubular cells), 
intestine (brush border membrane of enterocytes), liver (canalicular membrane of 
hepatocytes) and brain capillary endothelial cells (apical membrane) (Sakaeda et al., 
2002; Choudhuri & Klaassen, 2006).
Although structurally different DLCs (Figure 1) have the same mechanism of action, 
they have different pharmacokinetic profi les (Smith, 1985). DLCs such as digoxin, methyl-
digoxin, acetyl-digoxin, and digitoxin have been reported as substrates of P-gp (Pauli-
Magnus et al., 2001a), however, it is not known whether other DLCs are transported by 
P-gp as well. Identifi cation of DLCs as substrates could provide more information about 
the possible drug-drug interaction at the P-gp level and could be a fi rst step towards the 
development of DLC analogues that do not cause these interactions.
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Figure1. Structure of digitalis-like compounds. Fourteen DLCs, convallatoxin, cymarin, 
peruvoside, strophanthidin, and strophanthidol (A), digitoxigenin, digitoxin, digoxigenin, digoxin, 
and gitoxigenin (B), dihydroouabain, ouabain, and ouabagenin (C) and proscillaridin A (D) are 
presented, categorized in four groups (A-D). DLCs are of similar structures, yet with minor 
differences in substitutions to the steroid core. Also note that the sugar moiety at position 3 of 
DLCs can contain different sugars (E) and that the lactone ring at position 17 can be 5-membered 
(γ-lactone) or 6-memberd (δ-lactone).
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In the present study, we investigated the transport of fourteen plant derived DLCs 
in P-gp-overexpressing membrane vesicles using a liquid chromatography-mass 
spectrometry (LC-MS) method to measure DLCs directly. A rat in vivo study was used 
to confi rm the fi ndings of the vesicle transport assay. In addition, quinidine and its 
monoquaternary derivative, N-methyl quinidine (NMQ), were applied as the P-gp 
substrates to establish the functionality of our in vivo and in vitro assays, respectively. 
Finally, a mutagenesis study was performed to determine the important amino acids that 
play a role in P-gp substrate translocation. 
Materials and methods
Materials. DLCs, convallatoxin (>70% purity), cymarin (>96% purity), digitoxigenin 
(>98% purity), digitoxin (>96% purity), digoxigenin (>98% purity), digoxin (>95% 
purity), dihydroouabain (>95% purity), gitoxigenin (>95% purity), ouabagenin (>95% 
purity), ouabain (>95% purity), peruvoside (90% purity), strophanthidin (>90% purity), 
strophanthidol (>96% purity), proscillaridin A (>80% purity), elacridar (GF120918), 
sodium butyrate, adenosine 5′-triphosphate magnesium salt (bacterial source) and 
adenosine 5′-monophosphate monohydrate (from yeast) were purchased from Sigma 
(Zwijndrecht, The Netherlands). ([3H]-N-methyl quinidine ([3H]-NMQ) (specifi c activity, 
80 Ci/mmol) and unlabeled NMQ were purchased from Solvo Biotechnology (Szeged, 
Hungary). Dulbecco’s Modifi ed Eagle’s Medium (DMEM) and Gluta-MAX-11 were 
purchased from Invitrogen (Breda, The Netherlands). The Bac-to-Bac system, Cellfectin 
II reagent, and Grace’s insect cell medium were purchased from Invitrogen. The primers 
for the mutagenesis were produced by Biolegio (Nijmegen, The Netherlands). Protein 
concentration was measured with a kit from Bio-Rad Laboratories (Veenendaal, The 
Netherlands). The mouse monoclonal antibody against P-gp, F4, and the secondary 
antibody, fl uorescent goat anti-mouse IgG antibody IRDye 800, were purchased from 
Abcam (Cambridge, United Kingdom) and Rockland immunochemicals for research 
(Heerhugowaard, The Netherlands), respectively. Ammonium formate (>99.0 purity) 
and formic acid (>98% purity) were purchased from Fluka (Steinheim, Germany). 
DMSO (dimethyl sulfoxide) was obtained from Merck (Darmstadt, Germany) and 
water was purifi ed with a Millipore® Milli-Q system (Millipore, Bedford, MA, USA). 
Methanol HPLC grade was purchased from Lab Scan (Dublin, Ireland) and acetonitrile 
super gradient grade was obtained from VWR (Leuven, Belgium). 
Cell culture. DMEM + Gluta MAX-1 supplemented with 10% fetal calf  serum was 
used to grow HEK293 cells at 37 °C under 5% CO2-humidifi ed air.
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Generation of baculovirus. First, full-length human P-glycoprotein (MDR1) cDNA 
(Genbank accession no. NM_000927) was cloned into the gateway entry clone. The 
P-gp construct and enhanced yellow fl uorescent protein (eYFP) were cloned in to VSV-
G-improved pFastBacDual vector for transduction of mammalian cells using gateway 
system as it was described (El-Sheikh et al., 2008) previously. To produce human P-gp 
baculovirus, the Bac-to-Bac system was used based on manual (Invitrogen) description.
Site-directed mutagenesis. A pENTR-P-gp vector as template and PfuUltra II fusion 
HS as DNA polymerase were used for site-directed PCR. Nine different P-gp mutants, 
I306A, F336A, I340A, F343A, F728A, F942A, T945A, L975A, and V982A, were 
produced and sequencing of full-length P-gp cDNA was used to confi rm all mutations 
(Gozalpour et al., 2013).
Transduction of HEK293 with wild-type and mutant P-gp. HEK293 cells were cultured 
in 500-cm2 triple fl asks. After 24 h at 40% confl uency of HEK cells, the culture medium 
was removed and 25 ml of fresh medium and 10 ml of baculovirus preparations of 
eYFP, P-gp, or P-gp mutants were added. After the incubation of these cells at 37 °C for 
20 min, 40 ml of medium was added to them. 5 mM sodium butyrate was added to the 
cells 6 hours after transduction to stimulate protein expression by inhibition of histone 
deacetylase (Davie, 2003). Three days later, the cells were harvested using centrifugation 
at 3500×g for 10 min.
Membrane vesicle isolation and protein analysis. Membrane vesicles were isolated as 
described previously (El-Sheikh et al., 2008). To lyse the cells the ice-cold hypotonic 
buffer supplemented with protease inhibitors was used to resuspend the cell pellets. 
After centrifugation of the lysed cells at 100,000×g at 4 °C for 30 min, the pellets were 
homogenized in ice-cold TS buffer (10 mM Tris-HEPES and 250 mM sucrose, pH 7.4) 
supplemented with the protease inhibitors using a tight-fi tting Dounce homogenizer 
for 25 strokes. Next, the samples were centrifuged at 4000×g, 4 °C for 20 min and the 
consequent supernatant was centrifuged at 100,000×g at 4°C for 60 min. The ice-cold TS 
buffer was used to resuspend the membrane pellets and pass them through a 27-gauge 
needle 25 times to form vesicles. A Bio-Rad protein assay kit (Bio-Rad) was used to 
determine the protein concentration. After freezing in liquid nitrogen, crude membrane 
vesicles were stored at -80 °C until use.
Western blot analysis. Membrane vesicles (18 μg protein) were solubilized in SDS-
PAGE sample buffer and separated on SDS containing 7.5% acrylamide. IBlot dry 
blotting system (Invitrogen) was applied to blot the protein samples on nitrocellulose 
membrane. Monoclonal anti-human P-gp mouse serum antibody (F4, 1: 500) followed 
by incubation with fl uorescent goat anti-mouse IgG antibody IRDye 800 was used to 
detect wild type and mutant P-gp. The α-subunits of Na,K-ATPase, that were used as 
the loading control, were detected with the polyclonal antibody C356-M09 generated in 
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a rabbit (Koenderink et al., 2003) followed by donkey anti-rabbit IgG antibody IRDye 
680. Odyssey infrared imaging system (Li-Cor Biosciences, Lincoln, NE) was used to 
visualize signals.
Vesicular transport assay. The uptake of DLCs and NMQ into the membrane vesicles 
overexpressing P-gp was performed using a rapid fi ltration technique as described 
previously (Wittgen et al., 2011). Briefl y, the 30 μl reaction mix containing TS buffer, 10 
mM MgCl2, 4 mM AMP or ATP and 7.5 μg pre-warmed (at 37 °C) vesicles preparations 
was supplemented with NMQ (0.01 μM [3H]-NMQ plus 0.09 μM unlabeled NMQ) or 
DLCs (0.1 and 1 mM). The reaction was started by incubation of the samples at 37 °C 
and was stopped by transferring the samples on ice and adding 150 μl of ice-cold TS 
buffer. The diluted samples were fi ltered through TS-prewashed 0.65-μm pore, 96-well 
MultiscreenHTS glass fi ber fi lter plate using a MultiscreenHTS-Vacuum Manifold fi ltration 
device (Millipore, Etten-Leur, The Netherlands). After washing the fi lters with TS buffer 
(0.2 ml each time) twice, 2 ml scintillation fl uid was added to NMQ samples followed by 
liquid scintillation counting. The fi lter-associated radioactivity was used to determine 
the [3H]-NMQ uptake into vesicle membrane. As DLCs samples were not radio-labeled, 
they were prepared to precipitate the protein for LC-MS measurement. After above-
described washing steps with TS buffer, the fi lters were incubated with 0.2 ml mix of 
acetonitrile and formic acid (99.9%: 0.1%) for 30 min at room temperature and the 
protein was precipitated for 30 min at -20 °C. The samples were centrifuged for 5 min 
at 16000×g and supernatants were transferred to the new tubes for evaporation under 
N2 gas at 37 °C. The totally-evaporated samples were dissolved in methanol containing 
200 nM gitoxigenin as an internal standard to determine the concentration of DLCs 
using LC-MS. Ouabain was used as internal standard when gitoxigenin was the test 
compound. All experiments were performed in triplicates and were repeated with three 
different preparations of membrane vesicles.
Experimental Animals. For in vivo studies, male Wistar rats (Charles River, Kisslegg, 
Germany) of 240−270 g were used. The animals were permitted free access to tap water 
and standard lab chow. All experiments were approved by the local committee for care 
and use of laboratory animals and were performed according to strict governmental and 
international guidelines for the use of experimental animals.
Effect of P-gp on disposition of convallatoxin and quinidine in rats. Convallatoxin 
and quinidine with or without elacridar were dissolved in ethanol/PEG400/5% 
glucose solution (20: 60: 20). To study the involvement of P-gp in the disposition of 
convallatoxin, we investigated whether co-injection of a P-gp inhibitor would increase 
convallatoxin exposure of several tissues in which P-gp is known to play a role in 
clearance of xenobiotics from the tissue. The animals (n=12) were divided into two 
groups (n=6), each group was injected intravenously with convallatoxin (1.25 mg kg-1) 
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or convallatoxin plus elacridar (1.25 mg kg-1 + 6 mg kg-1) via the tail vein. As a control 
experiment, to investigate whether the administered dose of elacridar was suffi cient 
to inhibit P-gp in vivo, two additional groups of animals were injected intravenously 
with the known P-gp substrate quinidine (10 mg kg-1) with or without elacridar (6 mg 
kg-1, n=3 for each group). One hour after injection, the animals were sacrifi ced under 
i sofl urane anesthesia. Urine present in the bladder was collected, as well as plasma and 
relevant tissues (brain, kidney, liver, and muscle). Samples were stored at -80 °C until 
measurement. The frozen tissues were homogenized using a Mikro-dismembrator U 
(B. Braun Biotech International, Melsungen) followed by addition of Hank’s balanced 
salt solution (HBSS) supplemented with 10 mM HEPES (HBSS-HEPES), pH=7, 
(8 V: W). Proteins present in the samples were precipitated in two steps. First, a mix of 
acetonitrile with 0.1% formic acid (containing the fi rst internal standard) was added 
to tissue homogenate (4: 1 V/V) and plasma and urine (8: 1 V/V). The samples were 
centrifuged at 2000×g for 10 min and the supernatant was transferred to the new 
tubes to reconstitute the samples using evaporation under N2 gas at 37 °C. Second, the 
evaporated samples were dissolved in 0.2 ml methanol (containing the second internal 
standard) and centrifuged at 16000×g for 10 min. In the supernatant, the concentrations 
of quinidine and convallatoxin were determined using LC-MS, as described below. The 
concentrations of convallatoxin and quinidine were reported as nmol gr-1 tissues for the 
organs and nmol ml-1 for the plasma and the urine samples.
LC-MS quantifi cation of DLCs. The concentrations of DLCs in the vesicular transport 
assays and convallatoxin and quinidine in the samples from the rat study were measured 
using an LC-MS system that was described previously (Gozalpour et al., 2014b). For the 
quantitative analysis of 14 different digitalis-like compounds and quinidine, positive ion 
mode was used with single ion monitoring (SIM). The most abundant adducts (sodium 
[M+Na]+ or potassium [M+K]+) were used for quantifi cation of DLCs and protonated 
adduct ([M+H]+) was used to quantify quinidine (mass/charge ratio: 325.2 m/z).
Data analysis. To control the LC-MS system, Xcalibur® software (Thermo Scientifi c, 
San Jose, CA, USA) was used and LCquan® software (Thermo Scientifi c, San Jose, CA, 
USA) was used to analyse sample data. ATP-dependent convallatoxin transport (nmol 
mg protein-1 min-1) by P-gp and eYFP was determined by subtraction of AMP values 
from ATP values. Kinetic parameters were determined by nonlinear regression analysis 
of ATP-dependent transport according to the Michaelis–Menten equation. All data were 
expressed as mean ± S.E.M. and statistical differences were determined using an unpaired 
Student’s t-test using GraphPad Prism software (version 5.02; Graphpad Software Inc., 
San Diego, CA). A p < 0.05 was considered signifi cant. For the in vivo study, a one-sided 
unpaired Student’s t-test was used to compare accumulated convallatoxin in the tissues 
of animals administered with or without elacridar.
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Results
Identifi cation of P-gp substrates in vitro. First we determined if  DLCs are P-gp 
substrates, in vitro. Two concentrations (0.1 and 1 mM) of fourteen DLCs were 
incubated with P-gp overexpressing membrane vesicles in the absence and presence of 
ATP. Functional transport activity of this assay was established using NMQ as substrate 
of P-gp (Gozalpour et al., 2013). NMQ (0.1 μM) transport by P-gp was 0.042 ± 0.003 
nmol mg protein-1 min-1 in the presence of ATP compared to 0.0090 ± 0.0008 nmol mg 
protein-1 min-1 in the presence of AMP (normalized percentage and nmol mg protein-1 
min-1 scales were shown in Figure 2A and supplementary table A, respectively). 
In the presence of 0.1 mM convallatoxin we observed a signifi cant ATP-dependent 
uptake of convallatoxin (0.38 ± 0.06 versus 0.062 ± 0.009 nmol mg protein-1 min-1 in the 
presence of ATP and AMP, respectively) and in the presence of 1 mM convallatoxin we 
also observed a signifi cant ATP-dependent convallatoxin transport (2.2 ± 0.1 versus 0.42 
± 0.06 nmol mg protein-1 min-1 in the presence of ATP and AMP, respectively) (Figure 
2B, supplementary table A). No signifi cant ATP-dependent vesicular P-gp transport was 
observed for the other DLCs (Fig 2C-O).
Transport of convallatoxin in the absence and presence of P-gp. To confi rm the 
transport of convallatoxin by P-gp in the membrane vesicle assay, eYFP-overexpressing 
membrane vesicles as an additional negative control and elacridar as the P-gp inhibitor 
were used (Figure 3A and B). There was no signifi cant uptake of NMQ by eYFP- 
overexpressing vesicles, whereas NMQ uptake by P-gp in the presence of ATP (0.059 
± 0.002 nmol mg protein-1 min-1) was signifi cantly higher than when incubated with 
AMP (0.0070 ± 0.0002 nmol mg protein-1 min-1) (Figure 3A). Moreover, ATP-dependent 
uptake was signifi cantly decreased in the presence of 2 μM elacridar (Figure 3B). P-gp-
mediated convallatoxin transport in presence of ATP (2.77 ± 0.33 nmol mg protein-1 
min-1) was signifi cantly higher than transport in the presence of AMP (0.39 ± 0.03 nmol 
mg protein-1 min-1). No signifi cant ATP-dependent convallatoxin uptake was observed in 
eYFP-containing membrane vesicles (Figure 3C). In addition, ATP-dependent transport 
of convallatoxin was reduced signifi cantly in the presence of elacridar (Figure 3D).
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Figure 2. Uptake of DLCs in P-gp overexpressing membrane vesicles. Transport of NMQ (0.1 
μM) by P-gp in the absence and presence of ATP was measured after 1 min (A). P-gp-mediated 
uptake of DLCs (0.1 mM and 1 mM) in membrane vesicles was measured using LC-MS. 
Fourteen DLCs, convallatoxin (B), cymarin (C), digitoxigenin (D), digitoxin (E), digoxigenin 
(F), digoxin (G), dihydroouabain (H), gitoxigenin (I), ouabain (J), ouabagenin (K), peruvoside 
(L), strophanthidin (M), strophanthidol (N) and proscillaridin A (O) were incubated with P-gp 
overexpressing membrane vesicles for 5 min in the presence of AMP or ATP. The uptake of NMQ 
and DLCs in the presence of AMP for each DLCs concentration was set at 100%. Each condition 
was performed in triplicate and mean ± S.E.M. of three independent experiments are shown. 
An unpaired two-sided Student’s t-test was used to determine statistically signifi cance of DLCs 
uptake by membrane vesicles in the absence versus presence of ATP (*** p < 0.0001 and ### p 
= 0.0003).
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Convallatoxin: A New P-glycoprotein Substrate
85
4
Figure 3. Uptake of NMQ and convallatoxin by membrane vesicles in the absence and presence of 
P-gp. Uptake of 0.1 μM NMQ and 1 mM convallatoxin by P-gp and eYFP (Ctrl) overexpressing 
membrane vesicles was measured in the absence and presence of AMP and ATP (A and C). P-gp-
overexpressing membrane vesicles were incubated with 0.1 μM NMQ or 1 mM convallatoxin and 
AMP or ATP in the absence and presence of 2 μM elacridar (B and D). The incubation time for 
NMQ and convallatoxin experiments were 1 min and 5 min, respectively, and the mean ± S.E.M. 
of three independent experiments are shown. Statistically signifi cant differences were determined 
using an unpaired two-sided Student’s t-test: *** p < 0.0001 compared to the control condition 
and ### p < 0.0001 compared to the condition without elacridar.
Kinetic analysis of  P-gp-mediated convallatoxin transport. To study the kinetic 
characteristics of convallatoxin transport by P-gp, time- and concentration-dependent 
uptake were measured. ATP-dependent uptake of convallatoxin was linear up to 4 min of 
incubation time (Figure 4). A time point of 3 min was selected to measure convallatoxin 
uptake at increasing concentrations. We found an apparent affi nity of 1.07 ± 0.24 mM 
and Vmax of 5.2 ± 0.4 nmol mg protein
-1 min-1 for convallatoxin transport by P-gp (Figure 
4B). Previously, we determined the kinetics of P-gp-mediated NMQ transport in the 
membrane vesicles (Km: 2.2 ± 0.48 μM and Vmax: 0.9 ± 0.05 nmol mg protein
-1 min-1 
(mean ± S.E.M.)) (Gozalpour et al., 2013).
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Figure 4. Kinetic characterization of P-gp-mediated convallatoxin transport in membrane vesicles. 
ATP-dependent convallatoxin (1 mM) uptake by eYFP (open circles) and P-gp overexpressing 
membrane vesicles (fi lled circle) was measured at the indicated time points (A). Membrane vesicles 
overexpressing eYFP and P-gp were incubated with increasing concentrations of convallatoxin for 
3 min and ATP-dependent convallatoxin uptake is shown after subtraction of eYFP values (fi lled 
squares) (B). Mean ± S.E.M. of three independent experiments are shown.
Disposition of convallatoxin in rats. The concentrations of convallatoxin and the P-gp 
model substrate, quinidine, were determined in different tissues, plasma, and urine 1 hour 
after intravenous administration of the respective compounds to rats. Both convallatoxin 
and quinidine were administered in the absence and presence of elacridar. Based on the 
study of Wittgen et al., a dosage of 6 mg kg-1 elacridar was selected to inhibit P-gp 
transport activity (Wittgen et al., 2012). Administration of elacridar induced a 15-fold 
increase in brain tissue accumulation of quinidine from 0.3 ± 0.2 nmol g-1 to 4.5 ± 2.4 
nmol g-1, indicating that the selected dose of elacridar effectively inhibited P-gp in vivo 
(Table 1). 
In the absence and presence of elacridar, convallatoxin accumulated predominantly 
in the kidney. Moreover, the accumulation of convallatoxin in kidney cortex and brain 
increased when elacridar was co-administered (Table 2). Although the convallatoxin 
concentration was higher in the liver when co-administered with elacridar compared 
to administration of convallatoxin alone, this difference did not reach statistical 
signifi cance. In line with the high concentrations in the kidney, convallatoxin was also 
present in urine, both in the presence and absence of elacridar (Table 2).
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Table 1. Tissue, plasma, and urine concentrations of quinidine administered with and without 
elacridar.
Tissue     Ratio
  - Elacridar  + Elacridar (+ Elacridar/ - Elacridar)
Brain      0.3 ± 0.2 a 4.5 ± 2.4 15
Kidney   6.5 ± 1.9 8.5 ± 1.6 1.3
Liver   3.5 ± 1.5 4.0 ± 1.2 1.1
Muscle 1.4 ± 0.6 1.4 ± 0.6 1.0
       
Plasma      0.17 ± 0.07 b 0.28 ± 0.15 1.6
Urine 1.0 ± 0.4 1.3 ± 0.5 1.3
a nmol gr-1 tissue in all tissues, b nmol ml-1 in plasma or urine. Rats were dosed intravenously with 
quinidine (10 mg kg-1) or quinidine plus elacridar (10 mg kg-1 plus 6 mg kg-1). The concentrations 
of quinidine in the tissues, plasma, and urine were determined after 1 hour using LC-MS. Data are 
presented as mean ± S.E.M. of 3 rats for each group.
Expression and functional analysis of  P-gp mutants. The important amino acids of 
P-gp for transport of convallatoxin were determined using a mutagenesis study. Nine 
amino acids were replaced by alanine (I306A, F336A, I340A, F343A, F728A, F942A, 
T945A, L975A, and V982A) and P-gp mutants were expressed in HEK293 cells to 
produce membrane vesicles. First, expression levels of the mutants were compared to 
wild type enzyme using western blot analysis. The Na,K-ATPase α-subunit was used 
as a loading control for each vesicle preparation (Figure 5A). Next, NMQ was used to 
determine transport activity of the mutants (Figure 5B). Wild type P-gp transported 
NMQ at a rate of 0.058 ± 0.005 nmol mg protein-1 min-1, which was set at 100%. NMQ 
transport activity of P-gp mutants I306A, F343A, and F728A was less than 40% of 
wild type. The transport activity of F336A, F942A, T945A, and L975A for NMQ 
ranged from 49% to 57%, whereas I340A showed increased activity of 120% and V982A 
had about the same activity as wild type (Figure 5B). A similar plot was made for the 
convallatoxin data, for which wild type P-gp transport activity of 2.13 ± 0.14 nmol mg 
protein-1 min-1 was set at 100%.
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Table 2. The tissues, plasma and urine concentrations of convallatoxin administered with and 
without elacridar
Tissue     Ratio
  - Elacridar  + Elacridar (+ Elacridar/ - Elacridar)
Brain a 0.5 ± 0.2   1.0 ± 0.2 c 2
Kidney 8.6 ± 2.2 11.9 ± 1.4 1.4
Kidney (cortex) 5.0 ± 1.0 10.8 ± 2.9 c 2.2
Kidney (medulla) 3.2 ± 0.7   4.1 ± 1.6 1.3
Liver 1.1 ± 0.6   2.4 ± 1.4 2.2
Muscle 0.5 ± 0.1 0.7 ± 0.3 1.4
Plasma b 0.26 ± 0.10   0.39 ± 0.05 1.5
Urine 4.6 ± 0.9   4.5 ± 1.0 1.0
anmol gr-1 tissue in all tissues, b nmol ml-1 in plasma or urine, c The rats were administered with 
convallatoxin intravenously the tail vein (1.25 mg kg-1) or convallatoxin in combination with 
elacridar (1.25 mg kg-1 plus 6 mg kg-1). The concentrations of convallatoxin in tissues, plasma, and 
urine were determined 1 hour post injection using LC-MS. Data are presented as mean ± S.E.M. 
of 6 rats for each group. The convallatoxin concentrations in the tissues were compared in the 
absence and presence of elacridar using an unpaired one-sided Student’s t-test: p < 0.05.
Convallatoxin and NMQ transport activity were not signifi cantly different for I306A, 
F336A, I340A, F728A, F942A, T945A, and L975A (Figure 5C), whereas they differed 
signifi cantly for F343A and V982A (Figure 5D and E). The vesicles used for convallatoxin 
and NMQ transport were from the same batches, which excludes the possibility that the 
observed differences in transport rate are due to differences in P-gp expression. The data 
clearly demonstrates that transport activity of F343A for NMQ was abolished due to 
the mutagenesis, whereas it was partially preserved for convallatoxin. For the V982A 
mutant, NMQ transport was similar to that of the wild type; however, the convallatoxin 
transport activity was reduced two-fold.
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Figure 5. Western blot analysis and transport activity of P-gp mutants. Expression of wild type 
P-gp (WT), P-gp mutants and eYFP (Ctrl) as the negative control are shown using western blot 
analysis (A, top) and Na,K-ATPase was used as the loading control for each vesicle preparation 
(A, bottom). The ATP-dependent transport of NMQ and convallatoxin by wild-type and mutant 
P-gp was measured in the presence of NMQ (0.1 μM) for 1 min and 1 mM convallatoxin for 5 
min (B and C). Wild-type P-gp-mediated transport of NMQ and convallatoxin was set at 100% 
for (B) and (C), respectively. The transport activity of F343A and V982A mutants for NMQ and 
convallatoxin were compared using an unpaired Student’s t-test: *** p < 0.0001 (D and E).
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Discussion
P-gp can infl uence the digoxin concentration in plasma. The substrates and inhibitors 
of P-gp interfere with the plasma concentration of digoxin and its toxicity. As all DLCs 
have the same therapeutic target, knowledge about their interaction with P-gp could be 
valuable in the development of analogues that are less susceptible to pharmacokinetic 
drug-drug interactions and have a larger therapeutic index. 
In this study, we investigated the transport of fourteen DLCs in membrane vesicles 
isolated from HEK293 cells overexpressing P-gp. We showed that convallatoxin was 
taken up in these vesicles in an ATP-dependent fashion and that transport was inhibited 
by the P-gp-inhibitor elacridar. This is the fi rst time that convallatoxin is reported as a 
P-gp substrate. 
Convallatoxin is isolated from Convallaria majalis (Lily of the valley) and it inhibits 
Na,K-ATPase (Ozaki et al., 1985; Choi et al., 2006). Convallaria majalis extracts are used 
in herbal medicines to treat heart failure (Choi et al., 2006). Moreover, as ornamental 
plant in gardens, it causes a large number of cats and dogs poisonings (Cortinovis & 
Caloni, 2013). Human poisoning by exposure to this plant can occur in the case of 
accidental leaves ingestion or the incorrect use of herbal medicine (Alexandre et al., 
2012). Although it was shown that convallatoxin uptake by rat intestine is transporter-
mediated, there is no information about the effl ux transporters involved in the 
pharmacokinetics of this compound (Lauterbach, 1968). It was shown in Caco-2 cells 
that convallatoxin, unlike digitoxin and bufalin, hardly inhibited digoxin secretion 
(Cavet et al., 1996), which can be explained by the low affi nity we observed in this study 
(approximately 1 mM). 
As the purity of convallatoxin used in this study was more than 70%, it could be 
speculated that the remaining impurities infl uence the results. Previously, we showed 
that DLCs such as digitoxin, digoxin, peruvoside, proscillaridin A and strophanthidol 
could inhibit P-gp-mediated NMQ transport (Gozalpour et al., 2013). NMQ is a 
monoquaternary derivative of the P-gp substrate quinidine (Kusuhara et al., 1997; 
Fromm et al., 1999; Hooiveld et al., 2002) that has a very high P-gp affi nity (2.2 μM) 
compared to convallatoxin (1 mM). In our previous study, convallatoxin did not affect 
NMQ transport (Gozalpour et al., 2013), therefore, convallatoxin and its impurities 
do no inhibit P-gp. Moreover, convallatoxin impurities (30%) do not infl uence our 
conclusion that convallatoxin is a P-gp substrate, as this is based on a direct measurement 
of convallatoxin. However, we cannot exclude that it could infl uence our quantitative 
estimation of convallatoxin affi nity (Km) for P-gp. 
Interestingly, in this study digoxin, as the prototypical P-gp substrate, was not 
transported by P-gp in HEK membrane vesicles. The vesicular transport assay is not 
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suitable to study the transport of hydrophobic compounds like digoxin. In contrast 
to hydrophilic compounds like convallatoxin, hydrophobic compounds will diffuse 
extensively through the lipid membrane of the vesicle (von Richter et al., 2009; Szeremy 
et al., 2011). In our study, digoxin was highly accumulated in the membrane vesicles 
and its P-gp-mediated transport was concealed. The fact that digoxin is lipophilic and 
the vesicles are not suitable to study its transport is refl ected in the lack of other studies 
using the P-gp membrane vesicles for digoxin transport. In most studies, P-gp-mediated 
digoxin transport has been studied in transwell transport assays with polarized cells 
that contain uptake and effl ux transporters (Pauli-Magnus et al., 2001a; Balimane et 
al., 2004; Balimane & Chong, 2005). Hydrophobicity of the other DLCs tested here 
could be categorized based on their calculated octanol: water partition coeffi cient 
(clogP) (Gozalpour et al., 2014b) as follows: digitoxin (clogP: 2.85) > proscillaridin A 
(2.55) > digitoxigenin (2.48) > gitoxigenin (2.25) > digoxin (1.42) > digoxigenin (1.05) 
> peruvoside (0.32) > cymarin (0.22) > strophanthidol (- 0.28) > strophanthidin (- 0.30) 
> convallatoxin (- 0.67) > ouabagenin (- 1.32) > ouabain (- 1.66) > dihydroouabain 
(- 1.80), which indicates why convallatoxin transport could be well measured in the 
vesicular system in contrast to digoxin.
Our results pointing to the involvement of P-gp in the disposition of convallatoxin 
obtained in P-gp-overexpressing membrane vesicles were in line with the results obtained 
in the in vivo rat study. Although convallatoxin was previously used to determine the 
lethal dosage in rats (Lorenz & Stoeckert, 1958), its pharmacokinetics in rats have 
not been studied before nor have mechanistic investigations been conducted that 
studied P-gp as a determinant of convallatoxin disposition. The high accumulation of 
convallatoxin in rat kidney and its presence in urine illustrate that renal excretion is the 
main elimination route of convallatoxin. Moreover, a signifi cantly higher accumulation 
of convallatoxin in kidney cortex was found when convallatoxin was co-administered 
with elacridar, whereas kidney medulla exposure was not affected. This underlines the 
involvement of P-gp, as this transporter is expressed predominantly in renal proximal 
tubule cells situated in the kidney cortex and not in the medulla (Cordon-Cardo et al., 
1990). The large difference between the accumulation of quinidine and convallatoxin 
in rat tissues might refl ect the lower affi nity of convallatoxin for P-gp compared with 
quinidine. In contrast to human P-gp, there are two genes, mdr1a, and mdr1b, for P-gp 
in rodents. Mdr1a (Mdr3) is expressed in intestine, liver, brain and testis, whereas Mdr1b 
(Mdr1) is expressed in adrenal glands, placenta, ovaries, and uterus (Schinkel et al., 
1994; Schinkel et al., 1995). In this study, the high accumulation of quinidine in brain 
in the presence of elacridar, confi rms the role of Mdr1a in quinidine disposition that 
was reported previously (Kusuhara et al., 1997; Fromm et al., 1999). As both Mdr1a 
and Mdr1b are expressed in the kidney of rodents, we could not determine if  Mdr1a or 
Mdr1b was responsible for convallatoxin disposition in rat kidney. 
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It should be noted however, that the increased accumulation of convallatoxin in 
kidney cortex and brain, and the tendency towards a higher increase of convallatoxin in 
liver could also be related to an effect of elacridar on convallatoxin effl ux transporters 
other than P-gp. Elacridar is also known to inhibit BCRP (Cooray et al., 2002; Matsson 
et al., 2009), however, only limited information is available on DLC handling by BCRP. 
Digoxin has been found as BCRP inhibitor by Pavek et al., but it is not a substrate 
(Pavek et al., 2005). From pilot experiments from our lab there are also no indications 
that convallatoxin is a BCRP substrate, nor has it been reported as such in literature. The 
possibility of the involvement of BCRP in convallatoxin disposition nevertheless remains 
open and has to be further investigated. With regard to the liver, it could be hypothesized 
that the relatively limited (and non-signifi cant) increase of convallatoxin concentrations 
in the presence of elacridar may be due to a dual inhibition of uptake and effl ux systems. 
In this respect, we previously, showed that convallatoxin is transported by organic anion 
transporting polypeptide 1B3 (OATP1B3), however, it is not transported by OATP1B1 
and Na+-dependent taurocholate co-transporting polypeptide (NTCP) (Gozalpour et 
al., 2014b). At the same time, elacridar was found to be a potent inhibitor of OATP1B1-
mediated β-estradiol 17-β-D-glucuronide (E217βG) but did not inhibit OATP1B3 at the 
concentration of 20 μM (Karlgren et al., 2012a; Karlgren et al., 2012b). This suggests 
that if  dual inhibition on the level of liver infl ux and effl ux is taking place, other infl ux 
transporters than OATP1B3 may be involved.
To study the convallatoxin binding sites in human P-gp, nine amino acids were replaced 
by an alanine. The P-gp residues were selected based on recent refi ned crystal structure 
of mouse P-gp and biochemical studies and homology modeling that introduced drug-
binding sites of P-gp. Ile306, located in transmembrane helix 5 (TM5) of P-gp, plays an 
important role in binding of drugs such as verapamil and cyclic peptide inhibitor QZ59-
SSS and coupling of drug binding to ATPase activity (Loo & Clarke, 2005; Ravna et al., 
2009; Loo & Clarke, 2013; Li et al., 2014). Phe336 and Ile340 are located in hydrophilic 
face of TM6, the critical TM for P-gp-drug interaction. Both residues are binding sites 
for QZ59-SSS and QZ59-RRR (Loo et al., 2009; Ravna et al., 2009; Li et al., 2014) 
and Ile340 also binds to rhodamine (Loo & Clarke, 2002a). In addition, we showed 
that Phe336 and Ile340 are P-gp interaction sites with DLCs such as cymarin, digoxin, 
peruvoside, and proscillaridin A (Gozalpour et al., 2013). Like Phe336, Phe343 is one 
of nine conserved aromatic residues between mouse and human but not C. elegans and 
is a ligand binding residue for rhodamine, QZ59-SSS and QZ59-RRR (Loo et al., 2007; 
Ravna et al., 2009; Li et al., 2014). Phe728 of TM7 is a drug binding site for verapamil, 
colchicine, QZ59-SSS and QZ59-RRR (Loo et al., 2006b; Li et al., 2014). Phe942 and 
The945, located in TM11, have been found as verapamil binding sites (Loo & Clarke, 
2002b; Li et al., 2014). Furthermore, Leu975 and Val 982 located in TM12 have been 
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characterized as drug binding sites for verapamil, colchicine, vinblastine, and QZ59-SSS, 
additionally; Val982 binds to QZ59-RRR (Loo & Clarke, 2002a; b; Loo et al., 2009; 
Ravna et al., 2009; Li et al., 2014).
Transport activity of P-gp mutants was investigated using NMQ as a substrate 
(Hooiveld et al., 2002). The P-gp mutants, I306A, F343A, and F728A exhibited a NMQ 
transport activity that was less than 30% of the wild type activity. The transport activity 
of F336A, F942A, T945A, L975A and V982A, were conserved (45-100% of wild type) 
(Figure 5B) similar to our previous results (Gozalpour et al., 2013). Convallatoxin 
transport activity of most mutants (I306A, F336A, I340A, F728A, F942A, T945, and 
L975) was similar to that of NMQ. We conclude that Ile306, Phe336, Phe728, Phe942, 
Thr945, and Leu975, whose mutation to alanine reduced P-gp transport activity to 50% 
of wild type, are important residues for interaction with NMQ and convallatoxin. 
The type of sugar moiety at position C3 is the single difference between the structures 
of convallatoxin (L-rhamnose) and cymarin (D-cymarose), whereas unlike cymarin, 
convallatoxin is transported by P-gp. Interestingly, a single mutation of Ile340 decreased 
the cymarin inhibition (Gozalpour et al., 2013), but had little effect on the transport 
of convallatoxin. Consequently, the sugar moiety of DLCs seems to play an important 
role in the interaction with Ile340 and subtle changes to this moiety can determine if  the 
DLCs are transported by P-gp. 
The transport activities of NMQ and convallatoxin were signifi cantly different for 
the F343A and V982A mutant (Figure 5D and E). NMQ transport activity of F343A 
was completely diminished, whereas convallatoxin transport activity was conserved. 
Loo et al. observed that mutation of Phe343 to arginine reduced the affi nity of P-gp 
for rhodamine B and cyclosporine A, but not for vinblastine (Loo et al., 2007). Phe343 
seems to play an important role in the transport of NMQ, but is less important for 
convallatoxin transport. The V982A mutant lost 50% of its convallatoxin transport 
activity, whereas NMQ transport activity was not changed. This residue had been 
reported as the binding site for verapamil and rhodamine B (Loo et al., 2006b; 2009). We 
previously showed that V982A did not infl uence the affi nity of DLCs such as cymarin, 
digitoxin, digoxin, peruvoside, proscillaridin A and strophanthidol (Gozalpour et al., 
2013). As convallatoxin and cymarin only differ in their sugar moiety at position C3, this 
seems to play a key role in the interaction of convallatoxin with Val982.
It is the fi rst time that the extract of Convallaria majalis, convallatoxin, is shown to 
be transported by P-gp and its transport can be inhibited by elacridar both in vitro and 
in vivo. Our results indicate that Val982 is crucial for convallatoxin transport by P-gp, 
possibly through binding of its sugar moiety. Detailed understanding of the P-gp drug 
binding sites might aid to select DLCs with better pharmacokinetic profi les that are less 
prone to drug-drug interactions. 
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a The uptake at 0.1 μM NMQ, b The uptake at 100 μM DLC, c The uptake at 1000 μM DLC. The 
uptake of NMQ and DLCs in P-gp membrane vesicles (nmol mg protein-1 min-1) in the presence 
of AMP and ATP are shown. An unpaired two-sided Student’s t-test was used to determine 
statistically signifi cance of DLCs uptake by membrane vesicles in the absence versus presence of 
ATP (*** p < 0.0001, ### p = 0.003).
Supplementary Table A. DLCs uptake by P-gp membrane vesicles in the presence of AMP and ATP.
Compounds Uptake in the presence of AMP Uptake in the presence of ATP Ratio
      (ATP: AMP)
NMQ 0.0090 ± 0.0008 a 0.042 ± 0.003 *** 5
convallatoxin 0.062 ± 0.009 b 0.38 ± 0.06 ### 6
  0.42 ± 0.06 c 2.23 ± 0.11 *** 5
cymarin 0.21 ± 0.07 0.20 ± 0.06 0.9
  1.1 ± 0.1 1.4 ± 0.1 1
digitoxigenin 0.19 ± 0.03 0.15 ± 0.05 0.8
  45.6 ± 13.5 23.5 ± 7.0 0.5
digitoxin 0.66 ± 0.16 0.55 ± 0.12 0.8
  11.4 ± 0.8 5.3 ± 0.6 0.5
digoxigenin 0.060 ± 0.009 0.06 ± 0.02 1
  0.40 ± 0.05 0.23 ± 0.06 0.6
digoxin 0.11 ± 0.01 0.16 ± 0.02 1
  19 ± 2 18.5 ± 3.6 1
dihydroouabain 1.50 ± 0.07 1.50 ± 0.01 1
  1.7 ± 0.1 1.60 ± 0.05 0.9
gitoxigenin 0.040 ± 0.006 0.043 ± 0.003 1
  58 ± 4 54 ± 1 0.9
ouabain 0.012 ± 0.001 0.012 ± 0.001 1
  0.057 ± 0.007 0.093 ± 0.003 1.6
ouabagenin 1.063 ± 0.045 1.14 ± 0.06 1
  0.8 ± 0.2 0.7 ± 0.2 0.9
peruvoside 0.12 ± 0.02 0.13 ± 0.01 1
  0.43 ± 0.07 0.35 ± 0.05 0.8
strophanthidin 0.10 ± 0.02 0.09 ± 0.05 0.9
  0.42 ± 0.07 0.50 ± 0.14 1
strophanthidol 0.08 ± 0.01 0.070 ± 0.006 0.9
  0.37 ± 0.03 0.30 ± 0.03 0.8
proscillaridin A 0.33 ± 0.01 0.35 ± 0.01 1
  0.61 ± 0.02 0.56 ± 0.02 0.9
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Abstract
Digitalis-like compounds (DLCs), the ancient medication of heart failure and atrial 
fi brillation, are characterized by their toxicity and adverse effects. The main mode of 
action of DLCs, such as the structurally and pharmacokinetically diverse digoxin, 
digitoxin and ouabain is their inhibitory effect on Na,K-ATPase. Moreover, drug-drug 
interactions (DDIs) at the levels of absorption and excretion play a key role in their 
toxicity, hence, knowledge about the transporters involved might prevent these unwanted 
interactions. 
In the present study, the transport of fourteen DLCs with human P-glycoprotein 
(P-gp; ABCB1) was studied using a liquid chromatography-mass spectrometry (LC-MS) 
quantifi cation method. DLC transport of P-gp overexpressing Madin-Darby canine 
kidney (MDCK) and immortalized human renal cells (ciPTEC) were compared to 
vesicular DLC transport.
In a previous study, using membrane vesicles overexpressing P-gp, we identifi ed 
convallatoxin as a substrate; however, for the other DLCs tested we could not measure 
transport in this assay, probably because of their high lipophilicity (Gozalpour et al. 
2014a). In this study, cellular accumulation assays showed that digitoxin, digoxigenin, 
strophanthidin and proscillaridin A are also P-gp substrates. These lipophilic compounds 
could not be identifi ed as P-gp substrates in the vesicular assay, whereas the less lipophilic 
convallatoxin was not detected as P-gp substrate in the cellular accumulation assays. To 
observe the functionality of an effl ux transporter in the cellular accumulation assay, 
lipophilic compounds should enter by passive diffusion, whereas the vesicular transport 
assay is more appropriate for hydrophilic substrates that do not pass the vesicular 
membrane. In conclusion, we identifi ed digitoxin, digoxigenin, strophanthidin and 
proscillaridin A as P-gp substrates using cellular accumulation assays and recognized 
lipophilicity as an important factor in selecting a suitable transport assay. 
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Introduction
Digitalis-like compounds (DLCs), naturally-originated substances, are ancient 
medications that are used to treat heart failure, cardiac arrhythmias and atrial fi brillation 
due to their positive inotropic effect (Rahimtoola, 1996; Gheorghiade et al., 2006; Prassas 
et al., 2008). Inhibition of Na,K-ATPase by DLCs leads to increased intracellular Na+ 
and subsequently Ca2+ in cardiac myocytes, which results in stimulation of cardiac 
contraction (Schatzmann & Rass, 1965). DLCs share a steroid ring as the core structure 
responsible for their pharmacodynamic properties, with sugar and lactone moieties at 
positions C3 and C17, respectively (Schonfeld et al., 1985; Prassas et al., 2008). These 
compounds are categorized as drugs with a narrow therapeutic index that may cause 
toxicity symptoms, such as dizziness, fatigue, nausea, loss of appetite, vision disturbance 
and vomiting, when their plasma levels increase (Dick et al., 1991; Belz et al., 2001).
DDIs at absorption and excretion level are the most important factors causing 
elevated plasma concentrations of DLCs and subsequent toxicities (Rahimtoola, 1996; 
Gheorghiade et al., 2006). The concentration of digoxin, the most frequently-prescribed 
DLC, is increased when concomitantly administered with amiodarone, propafenone, 
verapamil, quinidine, or omeprazole (Pedersen, 1981; Belz et al., 1982; Nademanee et 
al., 1984; Marcus, 1985; Woodland et al., 1997; Laer et al., 1998; Fromm et al., 1999; 
Pauli-Magnus et al., 2001; Li et al., 2013). One of the most important reasons for this 
is inhibition of P-glycoprotein by the above mentioned drugs (De Lannoy et al., 1992; 
Tanigawara et al., 1992; Schinkel et al., 1995).
P-glycoprotein (P-gp, ABCB1), an ATP-dependent effl ux transporter, is expressed 
in the plasma membrane of epithelial cells in tissues playing a signifi cant role in drug 
disposition. Apical expression of P-gp in kidney and liver enhances drug elimination via 
urine and bile, respectively. In addition, the presence of P-gp in intestine and brain limits 
drugs absorption and central nervous system entrance, respectively (Cordon-Cardo et 
al., 1989; Gottesman & Pastan, 1993).
Transport of digoxin, digitoxin, and ouabain has been extensively studied (De Lannoy 
et al., 1992; Cavet et al., 1996; Noe et al., 1997; Reichel et al., 1999; Hagenbuch et al., 
2000; Kullak-Ublick et al., 2001; Pauli-Magnus et al., 2001; van Montfoort et al., 2002; 
Funakoshi et al., 2005). However, information about disposition of other DLCs with 
similar pharmacodynamic properties is lacking. Determination and characterization 
of the transporters involved in DLC disposition could provide more information 
about their pharmacokinetic profi les and possible DDIs. In vitro transport studies are 
frequently performed in cell lines over-expressing P-gp. The application of these cellular 
transport models is limited for compounds that cannot enter the cell via diffusion. 
Alternatively, isolated membrane vesicles in an inside-out orientation could be used, 
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allowing the substrates to be internalized by P-gp activity. To mimic the in vivo situation 
more closely, human cell lines expressing infl ux and effl ux transporter simultaneously 
could be used to study P-gp-mediated effl ux (Wilmer et al., 2010). The broad range 
of transporters present in the latter model, however, limits defi ning characteristics for 
individual transporters involved in drug handling. The limitations of each model may 
lead to different observations when studying P-gp substrate specifi cities and should be 
recognized (Taub et al., 2005; Rautio et al., 2006; von Richter et al., 2009). 
In this study, transport of fourteen DLCs was studied in a P-gp over-expressing 
MDCK cell line and ciPTEC, a human renal cell line expressing several infl ux and effl ux 
transporters including P-gp. Physicochemical properties were calculated to explain the 
differences in behavior of the DLCs in the drug transporter assays and to provide a tool 
that can be used in the selection of the appropriate assay to study substrate transport. 
Figure 1. Chemical structures of the digitalis-like compounds convallatoxin, digitoxin, digoxigenin, 
ouabain, strophanthidin, and proscillaridin A.
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Materials and Methods
Materials. [3H]-NMQ (specifi c activity, 80 Ci/mmol) and unlabeled NMQ were 
purchased from Solvo Biotechnology (Szeged, Hungary). Convallatoxin (>70% purity), 
cymarin (>96% purity), digitoxigenin (>98% purity), digitoxin (>96% purity), digoxigenin 
(>98% purity), digoxin (>95% purity), dihydroouabin (>95% purity), gitoxigenin (>95% 
purity), ouabagenin (>95% purity), ouabain (>95% purity), peruvoside (90% purity), 
strophanthidin (>90% purity), strophanthidol (>96% purity), proscillaridin A (>80% 
purity), elacridar (GF120918), Ko143 were purchased from Sigma (Zwijndrecht, The 
Netherlands). DMEM high glucose GlutaMAX™ culture medium, DMEM-HAM’s 
F12 medium, Hanks balanced salt solution (HBSS), L-glutamine, sodium pyruvate, 
100× penicillin/streptomycin solution were purchased from Life technologies (Breda, 
The Netherlands). A kit from Bio-Rad Laboratories was used to measure protein 
concentration (Veenendaal, The Netherlands). Ammonium formate (>99.0 purity) and 
formic acid (>98% purity) were purchased from Fluka (Steinheim, Germany). DMSO 
(dimethyl sulfoxide) was obtained from Merck (Darmstadt, Germany) and water was 
purifi ed with a Millipore® Milli-Q system (Millipore, Bedford, MA, USA). Methanol 
HPLC grade was purchased from Lab Scan (Dublin, Ireland) and acetonitrile super 
gradient grade was obtained from VWR (Leuven, Belgium).
Cell culture. Madin-Darby canine kidney (MDCK) and MDCK stably overexpressing 
human P-gp (MDCK-P-gp) were grown in DMEM high glucose GlutaMAX™. For 
MDCK cells, that were provide kindly by Dr. M. Gottesman from the National Cancer 
Institute (Bethesda, USA) (Pastan et al., 1988), the medium was supplemented with 10% 
FCS, 50 U/mL penicillin and 50 μg/mL streptomycin at 37 °C under 5% CO2-humidifi ed 
air. 
The human renal conditionally immortalized proximal tubule epithelial cell line 
(ciPTEC), was previously developed in our lab (Wilmer et al., 2010) and cultured in 
DMEM-HAM’s F12 with supplements as described previously at 33 °C for proliferation 
of cells. ciPTEC was transferred to 37 °C for 7 days to allow maturation of the renal 
epithelial phenotype. Both expression and activity of P-gp in matured ciPTEC was 
demonstrated, using the calcein-accumulation assay. 
Cellular accumulation assay. The accumulation of DLCs in MDCK-P-gp, MDCK 
as the negative control and ciPTEC was measured and compared to determine whether 
DLCs are transported by P-gp via the cellular accumulation assay. After cell growth 
in 24-well plates, Tris-HEPES buffer (10 mM HEPES, 132 mM NaCl, 4.2 mM KCl, 1 
mM CaCl2, 1 mM MgCl2, 5.5 mM D-(+)-glucose, adjusted to pH 7.4 using 1 M Tris 
solution) was used to wash the cells once. Subsequently, the cells were incubated with 
Tris-HEPES buffer containing 10 μM DLCs at 37 °C in the absence or presence of 2 or 
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5 μM elacridar (Figures 3 and 4) or 5 μM Ko143 (Figure 3 and 4) for 1 h. After washing 
cells once with Tris-HEPES containing 0.5% BSA, the cells were washed twice with Tris-
HEPES and lysed using 0.5 ml acetonitrile containing 0.1% formic acid for 30 min at 
room temperature and the protein was precipitated for 30 min at -20 °C. 
Sample preparation for LC-MS. Protein-precipitated samples of cellular accumulation 
assays were centrifuged for 5 min at 16000×g and supernatants were transferred to 
the new tubes for evaporation under N2 gas at 37 °C. The samples were completely 
evaporated and dissolved in methanol containing 200 nM gitoxigenin as an internal 
standard to determine the concentration of DLCs using LC-MS quantifi cation method. 
When gitoxigenin was the test compound, ouabain was used as internal standard. 
Protein concentration. In all cell accumulation assays, the amount of cellular protein 
per well was determined in a parallel plate. Distilled water was used to lyse MDCK 
cells and ciPTEC was lysed in RIPA buffer (1% Igepal CA630, 0.5% Nadeoxycholate, 
0.1% SDS, 0.01% phenylmethane sulphonylfl uoride, 3% aprotinin and 1 mM Na-
orthovanadate) and the cell lysate was stored at -20 °C upon protein concentration 
analysis using Bio-Rad protein assay kit. DLCs accumulation in ciPTEC and MDCK 
cells was expressed as nmol per mg protein.
LC-MS quantifi cation of DLCs. DLCs concentrations in the cell lysate samples were 
measured using the Accela® UPLC (Thermo Scientifi c, San Jose, CA, USA) coupled 
to a TSQ Vantage® (Thermo Scientifi c, San Jose, CA, USA) triple quadrupole mass 
spectrometer as it was previously described (Gozalpour et al., 2014b). Briefl y, the 
compounds were separated on a HSS T3 analytical column (1.8 μm; 100 × 2.1 mm, 
Acquity® UPLC, Waters, Ireland) coupled with a VanGuard® HSS T3 pre-column (1.8 
μm; 5 × 2.1 mm, Acquity® UPLC, Waters, Ireland). Positive ion mode was used with 
single ion monitoring (SIM) for the quantitative analysis of fourteen different digitalis-
like compounds. The most abundant adducts (sodium [M+Na]+ or potassium [M+K]+ 
were used for quantifi cation. 
Analysis. All the data are expressed as mean ± S.E.M for two or three independent 
experiments in the cellular accumulation assays. The unpaired Student’s t-test was 
performed to compare groups in the cellular accumulation assays using Graphpad Prism 
software (version 5.02; Graphpad Software Inc., San Diego, CA).
The physicochemical properties of DLCs, octanol: water partition coeffi cient (logP) 
and topological polar surface area (tPSA), were calculated using ChemBioOffi ce 
software package (CambridgeSoft, Cambridge, MA, USA) and DLCs molecular weights 
(MW) were obtained from the Pubchem database (National Centre for Biotechnology 
Information, Bethesda, MD, USA). 
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Results
Identifi cation of P-gp substrates in MDCK cells accumulation assay. In a previous 
study the uptake of fourteen DLCs by P-gp-membrane vesicles was measured and 
convallatoxin was identifi ed as P-gp substrate (Gozalpour et al., 2014a). However, no 
signifi cant ATP-dependent uptake of other DLCs was observed. Still, this may not 
be indicative of the DLCs not being a substrate for P-gp. Therefore, the intracellular 
accumulation of DLCs in MDCK and MDCK-P-gp cells was measured to determine 
possible P-gp substrates. In MDCK-P-gp, the accumulation of four DLCs, digitoxin (0.20 
± 0.04 nmol mg protein-1), digoxigenin (0.12 ± 0.03 nmol mg protein-1), strophanthidin 
(0.160 ± 0.005 nmol mg protein-1) and proscillaridin A (0.19 ± 0.01 nmol mg protein-1) 
was signifi cantly lower than in MDCK cells not expressing the effl ux pump (0.50 ± 
0.02, 0.32± 0.05, 0.550 ± 0.009, and 0.460 ± 0.008 nmol mg protein-1, respectively), 
whereas there was no signifi cant reduction in the accumulation of other DLCs in 
M DCK-P-gp compared to MDCK cells (Figure 2A-K). In addition, no accumulation 
of dihydroouabain, ouabain and ouabagenin in the cellular assay was observed (data not 
shown). As NMQ was previously used as P-gp substrate in the vesicle assays (Gozalpour 
et al., 2013), we also used it in the cellular accumulation assay. Remarkably, we did 
not observe a signifi cant difference between NMQ accumulation in MDCK-P-gp and 
MDCK cells (Figure 2L).
Effect of elacridar and Ko143 on DLC accumulation in MDCK-P-gp. As mentioned 
in the previous section, digitoxin, digoxigenin, strophanthidin and proscillaridin A were 
identifi ed as P-gp substrates in the MDCK cellular accumulation assay. We investigated 
further the effect of the P-gp inhibitor, elacridar, on their intracellular accumulation. The 
accumulation of digitoxin, digoxigenin, strophanthidin and proscillaridin A in MDCK-
P-gp cells was signifi cantly increased compared to control by 10, 5.6, 5.2, and 9 folds, 
respectively, in the presence of 2 μM elacridar (Figure 3A-D and Table 1). Since elacridar 
may also inhibit endogenously expressed breast cancer resistance protein (BCRP) 
(Cooray et al., 2002), the effect of a BCRP inhibitor, Ko143, on DLCs accumulation was 
also investigated. The presence of 5 μM Ko143 increased the accumulation of digitoxin 
and proscillaridin A by 2.25 and 1.5 folds, respectively, in MDCK-P-gp compared with 
MDCK cells. No signifi cant effect was observed for digoxigenin and strophanthidin 
accumulation in MDCK-P-gp (Figure 3A-D and Table 1).
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Figure 2. Accumulation of DLCs and NMQ in MDCK and MDCK-P-gp cells. The intracellular 
accumulation of fourteen DLCs was determined using LC-MS after one hour incubation of 
MDCK (Ctrl, white bars) and MDCK-P-gp (black bars) with 10 μM convallatoxin (A), cymarin 
(B), digitoxigenin (C), digitoxin (D), digoxigenin (E), digoxin (F), gitoxigenin (G), peruvoside (H), 
strophanthidin (I), strophanthidol (J) and proscillaridin A (K). [3H]-NMQ (1 μM) was used to 
determine the accumulation of NMQ in MDCK and MDCK-P-gp cells after one hour incubation. 
The mean ± S.E.M (nmol mg protein -1) of three experiments are shown and statistically signifi cant 
differences were determined using an unpaired Student’s t-test (***p < 0.0001).
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Figure 3. Effect of elacridar and Ko143 on DLC accumulation in MDCK-P-gp cells. Accumulation 
of digitoxin (A), digoxigenin (B), proscillaridin A (C) and strophanthidin (D) in MDCK-P-gp was 
determined after one hour incubation of these DLCs (10 μM) with the cells in the absence (Ctrl) 
and presence of 2 μM elacridar or 5 μM Ko143. The accumulation of DLCs in the absence of 
inhibitors was set at 100% and an unpaired Student’s t-test was used to compare elacridar and 
Ko143 conditions with those of Ctrl. Mean ± S.E.M of three independent experiments are shown 
(*p < 0.05, **p < 0.01 and ***p < 0.0001).     
      
DLC accumulation in ciPTEC. The accumulation of selected DLCs, convallatoxin, 
digoxin, ouabain, strophanthidin and proscillaridin A was analyzed in ciPTEC, in 
presence and absence of elacridar and Ko143. These DLCs were selected based on the 
observations in the cellular accumulation and vesicular transport assays (Gozalpour 
et al., 2014a). Digoxin, strophanthidin and proscillaridin A, were demonstrated to 
accumulate in the presence of elacridar (2.2, 1.5, and 2.0 fold increase, respectively) 
(Figure 4 and Table 1). Moreover, Ko143 increased accumulation of digoxin, 
strophanthidin and proscillaridin A by 1.7, 1.5, and 1.6 folds, respectively (Figure 4 
and Table 1). Convallatoxin, which was identifi ed as a P-gp substrate in the vesicular 
transport assay, did not accumulate in ciPTEC in presence of elacridar or Ko143 (Figure 
4A and Table 1). In addition, ouabain, which was not a P-gp substrate in both cellular 
and vesicular assays, did not accumulate in ciPTEC either (data not shown).
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Figure 4. Effect of elacridar and Ko143 on DLC accumulation in ciPTEC. Accumulation of 
convallatoxin (A), digoxin (B), proscillaridin A (C), and strophanthidin (D) in ciPTEC was 
determined after one hour incubation of these DLCs (10 μM) with the cells in the absence (Ctrl) 
and presence of 5 μM elacridar or Ko143. The accumulation of DLCs in the absence of inhibitors 
was set at 100% and an unpaired Student’s t-test was used to compare elacridar and Ko143 
conditions with those of Ctrl. Mean ± S.E.M of two independent experiments are shown (** p < 
0.01).
Table 1. Accumulation of DLCs in MDCK-P-gp and ciPTEC in the absence and presence of 
inhibitors.
Compounds Cellular Accumulation (nmol mg protein-1) a
    MDCK-P-gp       ciPTEC
  Ctrl Elacridar Ko143   Ctrl Elacridar
convallatoxin         46.1 ± 0.3 29 ± 8
digitoxin 0.19 ± 0.02 1.87 ± 0.15 0.423 ± 0.003      
digoxigenin 0.13 ± 0.01 0.71 ± 0.13 0.18 ± 0.01      
digoxin         10 ± 4 19 ± 8
strophanthidin 0.17 ± 0.02 0.9 ± 0.1 0.23 ± 0.02   27 ± 8 45 ± 16
proscillaridin A 0.23 ± 0.01 2.1 ± 0.13 0.35 ± 0.03   7.1 ± 0.4 14.3 ± 0.7
a The intracellular accumulation (nmol mg protein-1) of four DLCs in MDCK-P-gp and ciPTEC 
in the absence and presence of elacridar (2 μM in MDCK-P-gp and 5 μM in ciPTEC) and 5 μM 
Ko143 was determined using LC-MS quantifi cation after one hour incubation of cell lines with 10 
μM DLCs. The mean ± S.E.M of two experiments in triplicate are shown. 
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Comparison of physicochemical properties of P-gp substrates. To compare the results 
of P-gp vesicular transport assay and the cellular accumulation assays, physicochemical 
properties of DLCs such as molecular weight (MW), lipophilicity as calculated logP 
(clogP), and topological polar surface area (tPSA) were compared (Table 2). Of the P-gp 
substrates, convallatoxin with a clogP of -0.7 was the least lipophilic, whereas, digitoxin 
and proscillaridin A, were the most lipophilic P-gp substrates (with clogP values of 2.9 
and 2.6, respectively) (Table 2). 
To confi rm whether DLC lipophilicity infl uences the results of vesicular transport and 
cellular accumulation assays, the observed accumulation of fourteen DLCs in MDCK 
was plotted against calculated logP, molecular weight and calculated polar surface area. 
No signifi cant correlation was found between cellular accumulation and molecular 
weight or polar surface area (data was not shown), but a signifi cant correlation was 
found between the clogP and accumulation of DLCs in MDCK cells (r2 = 0.32, p = 
0.03) (Figure 5) indicating that lipophilic DLCs accumulate better in MDCK cells than 
hydrophilic congeners. Moreover, as gitoxigenin is highly accumulated in MDCK cells, 
if  gitoxigenin was excluded from the graph, the r2 and p values increased to 0.53 and 
0.005, respectively. 
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Table 2. P-gp transport characteristics and calculated physicochemical properties of DLCs.
Compounds P-gp-mediated transport a MW b clogP c tPSA d
  Membrane vesicle  MDCK ciPTEC      
convallatoxin +  -  - 550.6  -0.7 163.0
cymarin  -  - nd 548.7   0.2 131.8
digitoxigenin  -  - nd 374.5   2.5 66.8
digitoxin  - + nd 765.0   2.9 182.8
digoxigenin  - + nd 390.5   1.1 87.0
digoxin  -  - + 781.0   1.4 203.6
dihydroouabain  -  - nd 586.7  -1.8 206.6
gitoxigenin  -  - nd 390.5   2.3 87.0
ouabain  -  - nd 584.7  -1.7 206.6
ouabagenin  -  - nd 438.5  -1.3 147.7
peruvoside  -  - nd 548.7  0.3 131.8
strophanthidin  - + + 404.5  -0.3 104.1
strophanthidol  -  - nd 406.5  -0.28 107.2
proscillaridin A - + + 530.7  2.6 125.7
a P-gp substrates and non-substrates in each assay are shown by (+) and (-), respectively.
b Molecular weight, c Calculated octanol: water partition coeffi cient, d Calculated polar surface 
area and nd, not determined
Figure 5. Relationship between cellular accumulation of DLCs and their lipophilicity. The 
accumulation in MDCK cells was plotted against calculated logP values of DLCs (p < 0.05). 
Do, dihydroouabain, O, ouabain, Og, ouabagenin, Co, convallatoxin, Sn, strophanthidin, Sl, 
strophanthidol, Cy, cymarin, Pe, peruvoside, Dgn, digoxigenin, Dg, digoxin, Gt, gitoxigenin, Pr, 
proscillaridin A, Dtn, digitoxigenin and Dt, digitoxin.
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Discussion
In the present study, P-gp-mediated transport of fourteen DLCs was determined using 
cellular accumulation assays. We previously identifi ed convallatoxin as a P-gp substrate 
in the vesicular transport assay (Gozalpour et al., 2014a) and in this study we identifi ed 
four more DLCs to be substrates of P-gp in two different cellular accumulation assays. 
The results of these three assays were compared with the physicochemical properties of 
the DLCs used. Our data confi rm that clogP of the compounds should be taken into 
account when selecting a drug transporter assay. Digitoxin and digoxigenin were shown 
to be P-gp substrates, which is in line with other studies showing that digitoxin and 
digoxigenin are transported by P-gp in LLC-PKI and Caco-2 cell lines (Pauli-Magnus 
et al., 2001; Hughes & Crowe, 2010). However, this is the fi rst study that identifi es 
proscillaridin A and strophanthidin as P-gp substrates. Based on the expression of P-gp 
in canalicular membranes of hepatocytes (Thiebaut et al., 1987), our study elucidates 
a role for P-gp and probably BCRP in biliary excretion of digitoxin, strophanthidin 
and proscillaridin A that were shown to be excreted via liver.(Andersson et al., 1977a; 
Andersson et al., 1977b; Strobach et al., 1986; Belz et al., 2001).
In the current study, digitoxin, digoxigenin, strophanthidin and proscillaridin A 
were demonstrated to be P-gp substrates because their accumulation in MDCK-P-gp 
was signifi cantly less than control MDCK cells. Whereas digitoxin and proscillaridin 
A were also identifi ed as inhibitors, digoxigenin and strophanthidin did not or hardly 
inhibit P-gp transport, most likely refl ecting their low P-gp affi nity (Gozalpour et al., 
2013). In addition, the accumulation of these four DLCs was increased by the P-gp 
inhibitor elacridar. Accumulation of digitoxin and proscillaridin A in MDCK-P-gp 
was also reduced by Ko143, which suggests that these two DLCs are also transported 
by endogenous BCRP. It has, however, been reported that MDCK cells are lacking 
BCRP expression (Quan et al., 2012; Gartzke & Fricker, 2014). Moreover, digoxin, 
strophanthidin and proscillaridin A accumulation was also increased in ciPTEC in 
presence of Ko143, also suggesting the involvement of BCRP in effl ux of these DLCs, 
which is underscored by endogenous BCRP activity present in ciPTEC (Jansen et al., 
2014). 
In contrast to the results of vesicular transport assay, convallatoxin and NMQ 
were not identifi ed as P-gp substrates in the cellular accumulation assays. On the other 
hand, there was no evidence of P-gp-mediated transport of digitoxin, digoxigenin, 
strophanthidin and proscillaridin A by P-gp in the vesicular transport assay (Gozalpour 
et al., 2014a). This shows that assay properties affect the identifi cation of P-gp substrates. 
Interestingly, convallatoxin, the only P-gp substrate identifi ed in the vesicular transport 
assay, was ranked least lipophilic after dihydroouabain, ouabain, and ouabagenin of all 
DLCs tested. Previously, we identifi ed OATP1B3 as the transporter of convallatoxin, 
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dihydroouabain, ouabain, and ouabagenin (Gozalpour et al., 2014b). The absence of 
OATP1B3 in MDCK cell lines (Goh et al., 2002; Quan et al., 2012) and ciPTEC explain 
explains the lack of convallatoxin uptake and subsequent effl ux by P-gp in the cellular 
assays. Unlike the cellular accumulation assay, the inside-out vesicular transport assay 
is suitable to measure transport of low permeable (hydrophilic) compounds (Szeremy et 
al., 2011). Digitoxin and proscillaridin A, the most lipophilic DLCs, were transported in 
the cellular accumulation assay but not in the vesicular transport assay. Passive diffusion 
of these lipophilic DLCs into vesicles may lead to a high background that conceals 
P-gp-mediated uptake. The cellular accumulation assay is suitable for medium and high 
permeable compounds, because P-gp substrates require crossing the cell membrane by 
diffusion to interact with the effl ux transporter, provided no infl ux transporters are 
present (Figure 6) (Szeremy et al., 2011). P-gp substrates could be categorized based 
on their clogP as follows: convallatoxin (clogP: - 0.7) < strophanthidin (clogP: - 0.3) < 
digoxigenin (clogP: 1.1) < digoxin (clogP: 1.4) < proscillaridin A (clogP: 2.6) < digitoxin 
(clogP: 2.9). As P-gp-mediated strophanthidin transport could be detected in cellular 
assays and convallatoxin transport not, we suggest a threshold clogP value of - 0.3 to 
measure transport of DLCs in a cellular accumulation assay. The signifi cant relationship 
between the lipophilicity of DLCs and their cellular accumulation in MDCK cells is in 
line with studies showing high intestinal absorption of lipophilic DLCs (Haass et al., 
1972; Mooradian, 1988).
Figure 6. Behavior of DLCs in vesicular transport and cellular accumulation assays. P-gp 
mediated transport of lipophilic DLCs (black circle) and hydrophilic DLCs (black diamond) 
are shown in vesicular transport (A) and cellular accumulation (B) assays. DLCs which need an 
infl ux transporter (black one-way arrows) are shown by triangles in the cellular assay, black dotted 
arrows represent passive diffusion of DLCs. 
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Surpri singly, digoxin was only characterized as a P-gp substrate in ciPTEC and not in 
the MDCK-P-gp cells. Two factors could explain this observation. First, we sequenced 
the P-gp cDNA present in the MDCK-P-gp cell line and observed that the Gly185Val 
mutation present in the originally cloned P-gp was also present in this cell line (data 
not shown). It is known that this mutation affects the substrate affi nity (Safa et al., 
1990; Watanabe et al., 2000) and therefore might affect the digoxin transport. Secondly, 
only in ciPTEC, accumulation of digoxin could be demonstrated in the presence of 
elacridar and Ko143. It is known that infl ux of digoxin is enhanced by expression of 
infl ux transporters, such as the Solute Carrier Organic Anion Transporter (SLCO4C1, 
OATP4C1) (Mikkaichi et al., 2004). Previously, we demonstrated that SLCO4C1 mRNA 
is present in ciPTEC (Jansen et al., 2014) whereas, it has not been detected in MDCK 
cells (Goh et al., 2002; Szeremy et al., 2011). In addition to OATP4C1 at the basolateral 
membrane of the kidney, a Na-dependent uptake transporter at basolateral membrane 
of liver and kidney has been reported as digoxin uptake transporter (Taub et al., 2011). 
The presence of digoxin uptake transporters and their variable expression in different 
cell lines might explain the high variability in the measurement of net digoxin effl ux in 
different cell lines (Lee et al., 2014).
In con clusion, we assessed P-gp-mediated transport of fourteen DLCs in cellular 
transport assays and compared the results to that of a previous vesicular transport assay. 
Our results show that digitoxin, digoxigenin, strophanthidin, and proscillaridin A, like 
convallatoxin in the vesicular transport assay, are P-gp substrates. The importance of 
DLCs lipophilicity in the selection and outcome of the transport assay was confi rmed 
and we conclude that DLCs with a clogP of - 0.3 and higher should be used in cellular 
assays. 
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Abstract
Digitalis-like compounds (DLCs) such as digoxin, digitoxin, and ouabain, also 
known as cardiac glycosides, are among the oldest pharmacological treatments for 
heart failure. The compounds have a narrow therapeutic window, while at the same 
time; DLC pharmacokinetics is prone to drug-drug interactions at the transport level. 
Hepatic transporters organic anion transporting polypeptide (OATP)1B1, OATP1B3, 
and Na+-dependent taurocholate co-transporting polypeptide (NTCP) infl uence the 
disposition of a variety of drugs by mediating their uptake from blood into hepatocytes. 
The interaction of digoxin, digitoxin, and ouabain with hepatic uptake transporters has 
been studied before. However, here, we systematically investigated a much wider range 
of structurally related DLCs for their capability to inhibit or to be transported by these 
transporters in order to better understand the relation between the activity and chemical 
structure of this compound type. 
We studied the uptake and inhibitory potency of a series of 14 structurally related 
DLCs in Chinese hamster ovary cells expressing NTCP (CHO-NTCP) and human 
embryonic kidney cells expressing OATP1B1 and OATP1B3 (HEK-OATP1B1 and 
HEK-OATP1B3). The inhibitory effect of the DLCs was measured against taurocholic 
acid (TCA) uptake in CHO-NTCP cells and against uptake of β-estradiol 17-β-D-
glucuronide (E217βG) in HEK-OATP1B1 and HEK-OATP1B3 cells. 
Proscillaridin A was the most effective inhibitor of NTCP-mediated TCA transport 
(IC50 = 22 μM), whereas digitoxin and digitoxigenin were the most potent inhibitors 
of OATP1B1 and OAPTP1B3, with IC50 values of 14.2 and 36 μM, respectively. 
Additionally, we found that the sugar moiety and hydroxyl groups of the DLCs play 
different roles in their interaction with NTCP, OATP1B1, and OATP1B3. The sugar 
moiety decreases the inhibition of NTCP and OATP1B3 transport activity, whereas it 
enhances the inhibitory potency against OATP1B1. Moreover, the hydroxyl group at 
position 12 reinforces the inhibition of NTCP but decreases the inhibition of OATP1B1 
and OATP1B3. To investigate whether DLCs can be translocated, we quantifi ed their 
uptake in transporter-expressing cells by LC-MS. We demonstrated that convallatoxin, 
ouabain, dihydroouabain, and ouabagenin are substrates of OATP1B3. No transport 
was observed for the other compounds in any of the studied transporters. 
In summary, this work provides a step toward an improved understanding of the 
interaction of DLCs with three major hepatic uptake transporters. Ultimately, this can 
be of use in the development of DLCs that are less prone to transporter-mediated drug-
drug interactions.
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Introduction
Digoxin belongs to a large family of naturally derived compounds called digitalis-
like compounds (DLCs). The DLCs are the oldest cardiac medications that have been 
prescribed because of their inotropic effect (Poole-Wilson & Robinson, 1989). By 
inhibiting Na,K-ATPase, DLCs induce an increase in intracellular Na+ concentration 
followed by an increased intracellular Ca2+ concentration in cardiomyocytes, leading to 
a stronger contraction of the heart muscle (Ahmed et al., 2008; Prassas & Diamandis, 
2008). Currently, digoxin is applied for the treatment of heart failure and arrhythmia 
(DIG, 1997; Gheorghiade & Pitt, 1997); however, it has a narrow therapeutic window. 
Supra-therapeutic concentrations of digoxin in plasma rapidly lead to a range of adverse 
effects ranging from anorexia, fatigue, nausea, vomiting, and visual disturbances to 
ventricular fi brillation and ultimately death (Vivo et al., 2008).
Digoxin is partly metabolized in the liver, and digitoxin is mainly cleared via the 
hepatic route (Okita et al., 1955a; b; Doherty & Kane, 1975). Drug−drug interactions 
(DDIs) that result in lower clearance of digoxin from the body are among the most 
important factors causing toxicity. The majority of bioavailable digoxin (60−80%) is 
excreted via the kidney as unchanged drug, whereas the rest is metabolized and excreted 
via the liver (Hanratty et al., 2000). Inhibition of P-glycoprotein (P-gp), the effl ux 
transporter of digoxin and digitoxin (de Lannoy & Silverman, 1992; Pauli-Magnus et al., 
2001a), by coadministered medications such as quinidine, cyclosporine, and amiodarone 
leads to increased blood levels, causing toxicity (Belz et al., 1983; Warner et al., 1985; 
Robinson et al., 1989; de Lannoy & Silverman, 1992; Robieux et al., 1992; Hanratty et 
al., 2000; Vivo et al., 2008).
Next to the cellular effl ux of DLCs mediated by P-gp, cellular infl ux through SLC 
transporters may play a role in the disposition of these compounds in the liver and kidney. 
Among the hepatic uptake transporters, two members of the organic anion transporting 
polypeptide (OATP) family, OATP1B1 (SLCO1B1) and OATP1B3 (SLCO1B3), are 
predominantly expressed in human liver (Hsiang et al., 1999; Konig et al., 2000a; b). 
Moreover, Na+-dependent taurocholate co-transporting polypeptide (SLC10A1, NTCP) 
is an uptake transporter of bile salts and a number of other substrates with a steroid-
like structure (Hagenbuch & Meier, 1994; Meier et al., 1997; Alrefai & Gill, 2007). Next 
to digoxin and digitoxin, many structurally related DLCs exist, yet the excretion route 
of these compounds is unknown. The majority of naturally occurring DLCs have not 
been investigated with regard to their interaction with hepatic uptake transporters. In 
fact, only the hepatic uptake of the cardiac glycosides digoxin and ouabain has been 
well-characterized in mouse, rat, and human. In rats, Oatp2 and Oatp4 were found to 
be hepatic uptake transporters (Noe et al., 1997; Cattori et al., 2000; Hagenbuch et 
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al., 2001; Sugiyama et al., 2002; Funakoshi et al., 2005; Ose et al., 2010). In addition, 
murine and rat Oatp1 and Oatp2 were reported as ouabain uptake transporters (Meier 
et al., 1997; Reichel et al., 1999; Hagenbuch et al., 2000; van Montfoort et al., 2002). In 
human hepatocytes, digoxin uptake was shown to be transporter-dependent (Olinga et 
al., 1998; Kimoto et al., 2011; De Bruyn et al., 2013); moreover, digoxin and ouabain 
were reported as OATP1B3 substrates using Xenopus laevis oocytes (Kullak-Ublick et 
al., 2001) and polymorphisms in OATP1B3 have been suggested to be associated with 
increased concentrations of digoxin in plasma (Tsujimoto et al., 2008a). However, the 
same result was not obtained by Taub et al. using OATP2-transfected cell lines (Taub et 
al., 2011). Finally, it has been described that NTCP plays no role in ouabain transport, 
yet NTCP-mediated transport of Bamet could be inhibited by ouabain, indicating that 
the compound is capable of interacting with this transporter (Kouzuki et al., 1998; Briz 
et al., 2002).
Replacement of currently applied DLCs with alternative compounds that are less 
prone to drug-drug interactions occurring at the infl ux and effl ux transporter level may 
be facilitated by charting the interactions of this compound class with various infl ux and 
effl ux transporters (Shitara et al., 2005; Giacomini et al., 2010; Gozalpour et al., 2013). 
In previous work, we addressed the interaction of a range of DLCs with P-gp.
In the present study, we investigated the interaction of 14 DLCs (Figure 1) with 
human NTCP, OATP1B1, and OATP1B3 using cells overexpressing these transporters. 
First, we studied the inhibitory potency of DLCs on transporter activity and 
characterized structural features that are typical for inhibition of each transporter. We 
also determined if  the DLCs were actually transported, and we identifi ed convallatoxin, 
ouabain, dihydroouabain, and ouabagenin as new substrates for OATP1B3.
Materials and Methods
Materials. High-glucose Dulbecco’s modifi ed Eagle’s medium (DMEM) (NEAA, 
no glutamine), GlutaMAX high glucose DMEM, Hanks balanced salt solution 
(HBSS), L-glutamine, and sodium pyruvate were purchased from Life Technologies 
(Breda, The Netherlands). [6,7-3H(N)]Estradiol 17-β-D-glucuronide (34.3 Ci/mmol) 
and [3H(G)]taurocholic acid (5 Ci/mmol) were purchased from PerkinElmer Life and 
Analytical Sciences (Groningen, The Netherlands). Fetal calf  serum was purchased 
from Greiner (Alphen a/d Rijn, The Netherlands), and BD BioCoat poly-D-lysine 24-
well plates were purchased from VWR (Leuven, Belgium). The protein concentrations 
were determined using a protein assay kit from Bio-Rad Laboratories (Veenendaal, The 
Netherlands). Convallatoxin (>70% purity), proscillaridin A (>80% purity), peruvoside 
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and strophanthidin (>90% purity), cymarin, digitoxin, digoxin, dihydroouabain, 
gitoxigenin, ouabagenin, ouabain and strophanthidol (>96% purity), digitoxigenin 
and digoxigenin (>98% purity), and sodium butyrate were purchased from Sigma 
(Zwijndrecht, The Netherlands). Ammonium formate and formic acid were purchased 
from Fluka (Steinheim, Germany). Dimethyl sulfoxide (DMSO) was obtained from 
Merck (Darmstadt, Germany), and water was purifi ed with a Millipore Milli-Q system 
(Millipore, Bedford, MA, USA). HPLC grade methanol was purchased from Lab 
Scan (Dublin, Ireland), and super gradient grade acetonitrile was obtained from VWR 
(Leuven, Belgium).
Figure 1. Structural features of DLCs. The cardenolides and bufadienolides contain γ-butyrolactone 
(γ-lactone) and δ-valerolactone (δ-lactone) at the 17 position, respectively (A). DLCs have a steroid 
ring as their core structure that contains different chemical substitutions (B).
Cell culture. Chinese hamster ovary cells stably expressing NTCP (CHO-NTCP) 
were obtained from Solvo Biotechnologies (Budapest, Hungary), and human embryonic 
kidney cells (HEK293) stably expressing OATP1B1 or OATP1B3 (HEKOATP1B1 
and HEK-OATP1B3) were kindly provided by TNO (Zeist, The Netherlands). For 
all experiments, CHO-parent (CHO-P) and HEK-parent (HEK-P) were used as the 
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controls. CHO cells were cultured in high-glucose DMEM supplemented with 10% FCS, 
4 mM L-glutamine, and 1 mM sodium pyruvate. HEK cells were cultured in GlutaMAX 
high glucose DMEM supplemented with 10% FCS at 37 °C under 5% CO2 humidifi ed 
air.
Kinetic characterization of NTCP, OATP1B1, and OATP1B3. CHO and HEK 
cells were seeded at a density of 600,000 cells per well (Greiner, Alphen a/d Rijn, The 
Netherlands) and 400,000 cells per poly-D-lysine-coated well (VWR, Leuven, Belgium) 
in 24-well plates, respectively. To induce NTCP protein expression, 5 mM sodium butyrate 
was added to CHO cells. Twenty-four hours after CHO and 48 h after HEK cells were 
seeded, the medium was removed and the cells were washed twice with HBSS containing 
10 mM HEPES (HBSS-HEPES), pH 7, at 37 °C. Subsequently, CHO and HEK cells 
were incubated with 150 μl of HBSS-HEPES containing [3H]-labeled taurocholic acid 
or [3H]estradiol 17-β-D-glucuronide, respectively, at 37 °C for the incubation times 
indicated in the fi gure legends. To stop the incubation, the cells were placed on ice and 
washed twice with ice-cold HBSS-HEPES containing 0.5% BSA followed by washing 
with ice-cold HBSS-HEPES. Next, the CHO and HEK cells were lysed using 1 M NaOH 
and 0.5% Triton X-100 for 1 h, respectively. After homogenizing, lysed cells were mixed 
with 4 mL of scintillation liquid, and cell-associated radioactivity was measured using a 
Packard Tri-Carb liquid scintillation counter (Ramsey, MN, USA). In all experiments, 
transporter-dependent uptake was calculated by subtracting the values measured using 
parent cells from the corresponding values measured in CHO and HEK cells expressing 
transporters. All experiments were performed in triplicate.
Inhibition studies. To screen DLCs for inhibitory effects against NTCP, OATP1B1, 
and OATP1B3, the CHO and HEK cells were incubated with HBSS-HEPES containing 
trace amounts of [3H]-labeled taurocholic acid (0.03 μM) and [3H]estradiol 17-β-D-
glucuronide (0.0043 μM), respectively. Experiments were performed at 37 °C in 
the presence of the various DLCs at 10 and 100 μM. Stock solutions of DLCs were 
made in DMSO, and the fi nal concentration of DMSO was 1% in all incubates. The 
incubation solutions were supplemented with unlabeled estradiol 17-β-D-glucuronide 
or taurocholic acid to the concentrations indicated in the fi gure legends. In addition, 1% 
DMSO and 100 μM TCA (for NTCP) or 100 μM E217βG (for OATP1B1 and OATP1B3) 
were used as negative and positive controls, respectively. Furthermore, the IC50 of 
DLCs on NTCP-mediated TCA transport, OATP1B1-mediated E217βG transport, and 
OATP1B3-mediated E217βG transport was determined by coincubation with increasing 
concentrations of DLCs (Figure 4).
DLC uptake assays. To determine whether the DLCs are transported by NTCP, 
OATP1B1, and OATP1B3, the uptake of DLCs was determined in CHO-NTCP, HEK-
OATP1B1, and HEK-OATP1B3 as well as in CHO-P and HEK-P as negative controls. 
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The CHO and HEK cells were incubated with HBSS-HEPES containing 10 μM DLCs 
at 37 °C for 1 h at a 1% fi nal concentration of DMSO in the absence and presence of 
the inhibitor rifampicin (100 μM). After the previously described washing steps with 
HBSS-HEPES (without and with 0.5% BSA), the cells were lysed using 0.5 mL of 99.9% 
acetonitrile and 0.1% formic acid for 30 min. After addition of the acetonitrile/formic 
acid mixture, proteins were allowed to precipitate for 30 min at -20 °C. After 5 min 
of centrifugation at 16000g, the supernatants were transferred to new tubes and the 
acetonitrile/formic acid was evaporated under a gentle stream of N2 gas at 37 °C. The 
pellets were dissolved in methanol containing 200 nM gitoxigenin as an internal standard 
to analyze the samples using LC−MS. Ouabain was used standard when gitoxigenin was 
the test compound.
Protein Concentration. In all inhibition and accumulation assays, the amount 
of cellular protein per well was determined in a parallel plate. Cells were lysed using 
distilled water and stored -20 °C upon analysis. Protein concentrations were determined 
using the Bio-Rad protein assay kit. The uptake of substrates in CHO and HEK cells 
was expressed as picomoles per milligram of protein.
LC-MS Quantifi cation of DLCs. The concentration of DLCs in the cell lysate 
samples was measured using an Accela UPLC (Thermo Scientifi c, San Jose, CA, USA) 
coupled to a TSQ Vantage (Thermo Scientifi c, San Jose, CA, USA) triple quadrupole 
mass spectrometer. The compounds were separated on a HSS T3 analytical column (1.8 
μm; 100 × 2.1 mm, Acquity UPLC, Waters, Ireland) coupled with a VanGuard HSS T3 
precolumn (1.8 μm; 5 × 2.1 mm, Acquity UPLC, Waters, Ireland). The mobile phase 
consisted of solvent A (10 mM ammonium formate, pH 3.0) and solvent B (methanol). 
The elution gradient was 0 min, 90% A; 0.5 min, 90% A; 12.5 min, 15% A; 13.5 min, 
90% A; and 20 min. 90% A for convallatoxin, cymarin, digitoxigenin, digoxigenin, 
dihydroouabain, gitoxigenin, ouabagenin, ouabain, peruvoside, strophanthidin, 
and strophanthidol and 0 min, 70% A; 0.5 min, 70% A; 12.5 min, 15% A; 13.5 min, 
70% A; and 20 min, 70% A for digitoxin, digoxin, gitoxigenin, and proscillaridin A. 
Gitoxigenin as the internal standard was measurable under both conditions. The column 
temperature was set at 60 °C, and the fl ow rate was 500 μl/min. In addition, the sample 
injection volume was 20 μl, the analysis run time was 20 min, and the samples were 
stored at a tray temperature of 8 °C. The effl uent from the UPLC was passed directly 
into the heated electrospray ion source. The capillary temperature and the vaporizer 
temperature were set at 225 and 382 °C, respectively. With ionization voltage at +3.5 kV, 
heated electrospray ionization (HESI) was achieved using nitrogen gas as the sheath and 
auxiliary gases, with pressures of 30 and 35 AU (Arbitrary Units), respectively.
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Positive ion mode was used with single ion monitoring (SIM) for the quantitative 
analysis of 14 different DLCs. The most abundant adducts (sodium [M+Na]+ or 
potassium [M+K]+) were used for quantifi cation. Adducts with their corresponding 
mass/charge ratio (m/z) are shown in Table 1.
Table 1. Mass Fragment of most abundant adducts for the detection of DLCs by LC−MS
Compounds [M+Na]+ [M+K]+
  (m/z) (m/z)
convallatoxin 573.3  
cymarin 571.3  
digitoxigenin 397.2  
digitoxin 787.5  
digoxigenin   492.2
digoxin 803.4  
dihydroouabain 609.3  
gitoxigenin   429.3
ouabain 461.2  
ouabagenin 607.3  
peruvoside 571.2  
strophanthidin 553.3  
strophanthidol   443.2
proscillaridin A 429.1  
The LC-MS method was validated as follows. The linearity was evaluated by 
analyzing three batches of standard curves of all 14 DLCs over the concentration range 
of 1.0-400 nM. Good linearity was observed over the quantifi cation range when a linear 
regression was used with least-squares regression (1/χ2). The correlation coeffi cients 
(r) were greater than 0.9900 for all analytical batches, with a bias within ± 10%. The 
intra- and interassay accuracy and precision were determined at the LLOQ (1.0 nM), 
low (10 nM), medium (50 nM), and high (250 nM) QC levels by analyzing three separate 
analytical batches in fi ve replicates for each concentration. The intra- and interassay 
precision was less than 10 and 11%, respectively, and the bias ranged from -4.8 to 9.0% 
and -9.2 to 11.1%, respectively. These results were within an acceptable range, and the 
analytical method proved to be reproducible in terms of intra- and interassay accuracy 
and precision.
Analysis. All of the data are expressed as the mean ± SD of three independent 
experiments after correction for the uptake in CHO-parent and HEK-parent cells. To 
determine Km and Vmax of the transporters, concentration-dependent uptake data were 
fi tted to the Michaelis-Menten equation using Graphpad Prism software (version 5.02; 
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GraphPad Software Inc., San Diego, CA). DLCs were screened for inhibitory properties 
using one-way ANOVA followed by Dunnett’s post-hoc multiple comparisons. The 
unpaired Student’s t test was used to compare groups in the DLC uptake assays. 
Inhibition curves were analyzed with a one-site binding model fi tted to the equation 
y = bottom + (top – bottom) / (1 + 10 (logIC50− x). Hill slope) using GraphPad Prism. In this 
equation, x and y indicate log values of inhibitor concentration and uptake versus 
control, respectively.
Xcalibur software (Thermo Scientifi c, San Jose, CA, USA) was used to control the 
LC-MS system, and LCquan software (Thermo Scientifi c, San Jose, CA, USA) was used 
for sample data analysis.
The physicochemical properties of DLCs such as octanol: water partition coeffi cient 
(clogP) and polar surface area (tPSA) were calculated using the ChemBioOffi ce software 
package (CambridgeSoft, Cambridge, MA, USA), and H-bond donors and acceptors 
were obtained from the PubChem database (National Center for Biotechnology 
Information, Bethesda, MD, USA).
Results
Kinetic Characterization of NTCP, OATP1B1, and OATP1B3. Previously, CHO-
NTCP, HEK-OATP1B1, and HEK-OATP1B3 cell lines were characterized at the 
functional and/or protein expression levels (Greupink et al., 2011; Bosgra et al., 2013; 
van de Steeg et al., 2013). In the present study, to characterize the function of the 
transporters in the cell lines, the time- and concentration-dependent uptake of TCA by 
NTCP and E217βG by OATP1B1 and OATP1B3 was measured (Figure 2). Uptake of 
TCA by CHO-NTCP and CHO-P was measured in the presence of 1 μM TCA. NTCP-
mediated uptake of TCA was linear over 4 min (Figure 2A). Concentration-dependent 
uptake of TCA by NTCP, measured after 1 min of incubation, was characterized by an 
apparent affi nity (Km) of 5.4 ± 1.8 μM and a maximum rate (Vmax) of 229 ± 24 pmol/
mg protein/min (Figure 2B), and this was comparable to the values previously shown by 
others (Hagenbuch & Meier, 1994; Meier et al., 1997; Kim et al., 1999; Greupink et al., 
2011). Time-dependent uptake of 2 μM E217βG was measured in HEK-P and HEK-
OATP1B1 cells (Figure 2C). Because the uptake activity of HEK-OATP1B1 was linear 
over a time period of 4 min, an incubation time of 2 min was selected to study the kinetic 
characteristics of E217βG uptake by OAPTP1B1. The Km and Vmax values of E217βG 
for OATP1B1 were 10 ± 3.4 μM and 151 ± 14 pmol/mg protein/min, respectively. The 
kinetics of E217βG uptake by OATP1B1 was in accordance with the literature (Hsiang et 
al., 1999; Tamai et al., 2001; Hirano et al., 2004). Uptake of E217βG (2 μM) in HEK-P 
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and HEK-OATP1B3 was also linear over the fi rst 4 min. Km and Vmax of OATP1B3-
mediated E217βG uptake measured at 3 min were 31 ± 8.5 μM and 67 ± 6.8 pmol/mg 
protein/min, respectively (Figures 2E, F), which is also in line with previously reported 
values (Hirano et al., 2004).
Effect of DLCs on NTCP-Mediated Uptake of TCA and OATP1B1- and OATP1B3-
Mediated Uptake of E217βG. To investigate the infl uence of DLCs on transporter 
activity, uptake rates of TCA by NTCP and of E217βG by OATP1B1 and OATP1B3 
were measured in the absence and presence of 14 DLCs. We can exclude a cell toxicity 
effect, as we did not observe a DLC inhibitory pattern that was similar in all three cell 
lines. Figure 3A represents the effect of 10 and 100 μM of the individual DLCs on NTCP-
mediated TCA uptake. The uptake of TCA by NTCP in the absence of DLCs was set at 
100% (Ctrl: 48 ± 7 pmol/mg protein/min). The most potent inhibitor, proscillaridin A, 
inhibited transport activity by 77% at 100 μM. Digoxin inhibited uptake by 25 and 46% 
at concentrations of 10 and 100 μM, respectively. Convallatoxin, digitoxin, and ouabain 
(100 μM) inhibited TCA uptake by approximately 20%. Digoxigenin and gitoxigenin 
stimulated NTCP-mediated TCA uptake at 100 μM. Digoxin inhibited uptake by 25 
and 46% at concentrations of 10 and 100 μM, respectively. Convallatoxin, digitoxin, 
and ouabain (100 μM) inhibited TCA uptake by approximately 20%. Digoxigenin 
and gitoxigenin stimulated NTCP-mediated TCA uptake at 10 μM by 32 and 43%, 
respectively, whereas they hardly affected transporter activity at 100 μM. TCA itself  
(100 μM unlabeled) inhibited NTCP by 90%.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Interaction of Digitalis-Like Compounds with NTCP, OATP1B1, and OATP1B3
121
6
Figure 2. Time- and concentration-dependent transport of taurocholic acid and estradiol 17-
β-D glucuronide in CHO-NTCP (A, B), HEK-OATP1B1 (C, D), and HEK-OATP1B3 (E, F), 
respectively. The NTCP-mediated transport of taurocholic acid (TCA) in CHO-NTCP was 
measured in the presence of 1 μM TCA (A) and at increasing concentrations of TCA (B) during 
1 min incubation. Time course of the transport of 17-β-D-glucuronide (E217βG) by OAP1B1 (C) 
and OATP1B3 (E) in HEK cells was measured in the presence of 2 μM E217βG. The concentration-
dependent transport of E217βG by OAP1B1 (D) and OATP1B3 (F) was measured during 2 and 3 
min incubation times, respectively. CHO-P and HEK-P were used as controls (empty circles in A, 
C, and E), and their values were subtracted in panels B, D, and F. Data points represent the mean 
± SD of experiments performed in triplicate.
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Figure 3. Effect of DLCs on TCA uptake by NTCP (A) and E217βG uptake by OATP1B1 (B) 
and OATP1B3 (C). Uptake was measured during 1 min at a concentration of 1 μM TCA for 
NTCP (A), during 2 min at a concentration of 2 μM E217βG for OATP1B1, and during 3 min at a 
concentration of 2 μM E217βG for OATP1B3. For all three transporters, uptake was measured in 
the absence (Ctrl) or presence of 14 DLCs at 10 and 100 μM. NTCP-, OATP1B1-, and OATP1B3-
mediated uptake in the absence of DLCs (Ctrl) was set at 100% and was also measured in the 
presence of 100 μM of the corresponding unlabeled substrate. The mean ± SD values of three 
independent experiments are shown, and statistically signifi cant differences are indicated (*, p < 
0.05; **, p < 0.01; and ***, p < 0.001).
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The uptake activity of OATP1B1 in the absence of DLCs was set at 100% (Ctrl: 
57.8 ± 20 pmol/mg protein/min) (Figure 3B). Digitoxin, the most potent inhibitor 
of OATP1B1, inhibited uptake of E217βG by 95% at 100 μM. In addition, 100 μM 
digitoxigenin, digoxin, and proscillaridin A inhibited OATP1B1 by 58 and 66%, 
respectively. The inhibitory effect of 100 μM convallatoxin, digoxigenin, gitoxigenin, 
peruvoside, strophanthidin, and strophanthidol was less than 50%. The inhibitory 
potency of DLCs on OATP1B1-mediated transport can be summarized as digitoxin 
> digoxin = proscillaridin A > digitoxigenin > peruvoside > gitoxigenin. OATP1B3-
mediated E217βG uptake was 17.2 ± 4.5 pmol/mg protein/min (Ctrl: 100%) (Figure 
3C). The most potent inhibitor of OATP1B3, digitoxigenin, inhibited uptake by 65% 
at 100 μM. Digitoxin and digoxigenin inhibited uptake up to 50% at 100 μM, but most 
of the tested DLCs, such as cymarin, gitoxigenin, strophanthidin, strophanthidol, 
and proscillaridin A, inhibited OATP1B3 by less than 30%. Gitoxigenin stimulated 
OATP1B3 activity by 23% at 10 μM and inhibited transport by 20% at 100 μM. At the 
tested concentrations, DLCs were less potent inhibitors of OATP1B3 than OATP1B1.
Concentration-Dependent Inhibition of NTCP, OATP1B1, and OATP1B3 by DLCs. 
To analyze the inhibitory potency of DLCs against NTCP, OATP1B1, and OATP1B3 
activity, DLCs with an inhibitory effi cacy of 50% or more at 100 μM were selected 
for further study. The uptake rates of TCA by NTCP and E217βG by OATP1B1 and 
OATP1B3, expressed as the percentage of control, were plotted against the log value 
of increasing DLC concentrations (Figure 4). Proscillaridin A, the most potent NTCP 
inhibitor, exhibited an IC50 value of 22.0 ± 4.0 μM. Inhibitory potency against OATP1B1 
could be ranked as follows: digitoxin (14.2 ± 0.3 μM) > proscillaridin A (47.0 ± 13.0 
μM) > digoxin (63.0 ± 15.7 μM) > digitoxigenin (73.5 ± 16.2 μM) > peruvoside (90.3 ± 
6.8 μM). Digitoxigenin was the most potent inhibitor of OATP1B3 (36.0 ± 12.8 μM), 
whereas the inhibitory potencies of digitoxin and digoxigenin were 3 times lower (129.0 
± 53.0 and 130.0 ± 54.4 μM, respectively).
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Figure 4. Concentration-dependent inhibition of NTCP (A), OATP1B1 (B-F), and OATP1B3 (G-
I) by selected DLCs. CHO-P and CHO-NTCP were incubated with 1 μM TCA in the absence 
and presence of increasing concentrations of proscillaridin (A) for 1 min. E217βG (2 μM) was 
incubated with HEK-P and HEK-OATP1B1 in the presence of increasing concentrations (1-1000 
μM) of digitoxigenin (B), digitoxin (C), digoxin (D), peruvoside (E), and proscillaridin A (F) 
for 2 min and with HEK-P and HEK-OATP1B3 in the presence of increasing concentrations of 
digitoxigenin (G), digitoxin (H), and digoxigenin (I) for 3 min. NTCP-mediated uptake of TCA 
and OATP1B1- and OATP1B3-mediated uptake of E217βG in the absence of DLCs was 48 ± 6, 
50 ± 10.6, and 19 ± 8 pmol/mg protein/min, respectively, which were set at 100%. The mean ± SD 
of three independent experiments is shown.
Identifi cation of NTCP, OATP1B1, and OATP1B3 Substrates. Absolute uptake of 
DLCs (10 μM) after 1 h in parent and transporter-expressing cell lines was measured using 
LC-MS. Signifi cant differences in DLC uptake could not be detected when comparing 
CHO-NTCP and CHO-parent cell lines (Figure 5 and Table 2). Also, no signifi cant 
differences in DLC uptake could be detected when comparing HEK-OATP1B1 and 
HEK-parent cell lines (Figure 6 and Table 2). OATP1B3 showed statistically signifi cant 
uptake of convallatoxin (230 ± 40% compared to control cells, p < 0.001), dihydroouabain 
(381 ± 14% of control, p < 0.001), ouabain (1140 ± 210% of control, p < 0.001), and 
ouabagenin (212 ± 10% of control, p < 0.001) (Figure 7 and Table 2). The OATP1B3 
inhibitor rifampicin (Cui et al., 2001) reduced the uptake of E217βG, convallatoxin, 
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dihydroouabain, ouabain, and ouabagenin in HEK-OATP1B3 cells, whereas it had no 
effect on the uptake of these compounds in HEK-parent cells (Figure 8). Transport 
activity of OATP1B3 and its inhibition by rifampicin was confi rmed by using E217βG as 
the probe substrate in our assay (Figure 8E). 
Figure 5. Uptake of DLCs in CHO-P and CHO-NTCP. Uptake of 14 DLCs was measured by 
LC-MS after a 1 h incubation of CHO-P and CHO-NTCP with convallatoxin (A), cymarin (B), 
digitoxigenin (C), digitoxin (D), digoxigenin (E), digoxin (F), dihydroouabain (G), gitoxigenin 
(H), ouabain (I), ouabagenin (J), peruvoside (K), strophanthidin (L), strophanthidol (M), and 
proscillaridin A (N). Each condition was performed in triplicate, and the mean ± SD of three 
independent experiments is shown. 
Discussion
To understand the variation in the pharmacokinetic profi le of different DLCs, we 
studied the interaction of 14 DLCs with liver uptake transporters NTCP, OATP1B1, 
and OATP1B3. Whereas we found little interaction with NTCP, several DLCs inhibited 
OATP1B1 and OATP1B3 transport activity. Moreover, OATP1B3 transported four 
DLCs. 
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Looking more closely at the interactions of DLCs with NTCP, the presence of a 
sugar moiety appears to improve inhibition of NTCP activity (based on the comparison 
of sugar-conjugated DLCs digitoxin, digoxin, ouabain, and convallatoxin to that of 
unconjugated congeners digitoxigenin, digoxigenin, ouabagenin, and strophanthidin). 
This effect was most clearly observed for the digoxin/digoxigenin pair, whereas it was less 
prominent for other glycone/aglycone pairs. Furthermore, a hydroxyl group at position 
12 (digoxin) increases the inhibitory effi cacy compared to digitoxin (no hydroxyl group 
in the 12 position). Among the 14 tested DLCs, proscillaridin A was the most potent 
inhibitor of NTCP. Proscillaridin A’s IC50 (22 μM) exceeded plasma concentrations 
reported in the clinic (systemic concentration, 1 nM; portal vein concentration, 3.5 nM) 
(Andersson et al., 1977a), so no clinically relevant inhibitory effect on bile salt transport 
is expected for this compound. Although NTCP is known to be capable of transporting 
drug-like molecules, none of the tested DLCs was an NTPC substrate; hence, DDIs on 
the level of NTCP with DLCs as a victim drug are unlikely to occur.
OATP1B1-mediated uptake of E217βG was inhibited by digitoxin, digoxin, 
proscillaridin A, digitoxigenin, peruvoside, and gitoxigenin, whereas convallatoxin, 
cymarin, digoxigenin, strophanthidin, and strophanthidol hardly inhibited transporter 
activity. Inhibition of OATP1B1 by digoxin was also reported in previous studies 
(Badolo et al., 2010; Karlgren et al., 2012a; Karlgren et al., 2012b). Badolo et al. showed 
that 20 μM digoxin inhibited E217βG uptake in hepatocytes by 56% and in HEKO-
ATP1B1 cells by 36% (Badolo et al., 2010), which is in line with our study. Karlgren 
et al. reported a 50% reduction of OATP1B1 activity in HEK293 by 20 μM ouabain 
(Karlgren et al., 2012a). However, we did not observe any inhibition of OATP1B1 by 
ouabain (10 and 100 μM).
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Figure 6. Uptake of DLCs in HEK-P and HEK-OATP1B1. The cell lines were incubated with 
convallatoxin (A), cymarin (B), digitoxigenin (C), digitoxin (D), digoxigenin (E), digoxin (F), 
dihydroouabain (G), gitoxigenin (H), ouabain (I), ouabagenin (J), peruvoside (K), strophanthidin 
(L), strophanthidol (M), and proscillaridin A (N) for 1 h, and uptake was measured by LC-MS. 
Each condition was performed in triplicate, and the mean ± SD of three independent experiments 
is shown.
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Figure 7. Uptake of DLCs in HEK-P and HEK-OATP1B3. Uptake of convallatoxin (A), 
cymarin (B), digitoxigenin (C), digitoxin (D), digoxigenin (E), digoxin (F), dihydroouabain (G), 
gitoxigenin (H), ouabain (I), ouabagenin (J), peruvoside (K), strophanthidin (L), strophanthidol 
(M), and proscillaridin A (N) in HEK-P and HEK-OATP1B1 was measured after a 1 h incubation 
by LC-MS. Each condition was performed in triplicate, and the mean ± SD of three independent 
experiments is shown. An unpaired Student’s t test was used to compare DLC uptake in HEK-
OATP1B1 versus HEK-P (**, p < 0.01; ***, p < 0.001).
Reported plasma concentrations for digoxin and digitoxin are 3 and 20 nM, respectively 
(portal vein concentration of 1.5 nM for digoxin (Andersson et al., 1975)), whereas we 
found their IC50 values to be ∼1000-fold higher. The chance of these compounds causing 
a relevant inhibition of OATP1B1-mediated drug transport is therefore very small and 
is, in fact, also in line with the absence of clinical reports of such an event (Shapiro et 
al., 1970; Reitbrock & Woodcock, 1989). Whether the inhibitory potencies determined 
for the other DLCs against OATP1B1 are clinically relevant depends on the therapeutic 
plasma concentration windows for these compounds. To date, such clinical effi cacy and 
safety data have not been reported to our knowledge.
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Figure 8. Inhibition of OATP1B3-mediated DLC transport. Uptake of DLCs was determined 
after incubation of 10 μM convallatoxin (A), dihydroouabain (B), ouabain (C), and ouabagenin 
(D) with HEK-P and HEK-OATP1B3 for 1 h in the absence (black bars) and presence (white 
bars) of rifampicin (100 μM). Uptake of E217βG (2 μM) in HEK-P and HEK-OATP1B3 was 
measured in the absence and presence of rifampicin (100 μM) after a 3 min incubation. The mean 
± SD value of three independent experiments is shown. Uptake in HEK-OATP1B3 was compared 
to HEK-P (***, p < 0.001) and to the condition without rifampicin (###, p < 0.001) using an 
unpaired Student’s t test. 
In addition, the comparison of the inhibitory potencies against OATP1B1 by different 
DLCs also revealed structural features critical for interaction with the transporter. 
Digitoxin and digitoxigenin appeared to be more potent inhibitors than digoxin and 
digoxigenin, respectively, which demonstrated that the hydroxyl group at position 12 
decreases inhibitory potency. Digoxin and digitoxin carry a sugar moiety at position 3, 
and they are better inhibitors of OATP1B1 than digoxigenin and digitoxigenin, which 
have a hydroxyl group at this position. This shows that the presence of a sugar moiety 
at position 3 could enhance the inhibitory effect of DLCs on OATP1B1 activity. This 
effect was not observed for the weak inhibitors, convallatoxin, and strophanthidin. 
Moreover, convallatoxin and cymarin have identical steroid bodies and slightly different 
sugar moieties; still, they share a low inhibitory potency against OATP1B1. In addition, 
the presence of a hydroxyl group at position 16 seems to lower the inhibitory potency of 
DLCs (gitoxigenin vs digitoxigenin).
Among the tested DLCs, digitoxigenin, digitoxin, and digoxigenin were the most 
potent inhibitors of OATP1B3. We show that digoxin and ouabain hardly infl uence the 
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transport activity of OATP1B3; however, Baldes et al. have shown that ouabain and 
digoxin inhibited OATP1B3-mediated Fluo-3 transport (Baldes et al., 2006). Because 
the inhibitory effect of inhibitors on a transporter could be substrate-dependent (Tamai 
et al., 2001; Noe et al., 2007; Seithel et al., 2007), the different OATP1B3 substrates 
(E217βG vs Fluo-3) could provide an explanation for the differing results. Moreover, 
Karlgren et al. reported 20 μM ouabain to be an inhibitor of OATP1B3-mediated 1 
μM E217βG uptake (with 20% inhibition), whereas 20 μM digoxin did not inhibit 2 
μM E217βG uptake by OATP1B3 in the present study, which is possibly related to the 
different substrate concentration used (Karlgren et al., 2012b).
The absence of a sugar moiety at position 3 of DLCs appeared to improve binding to 
OATP1B3, because digitoxigenin, digoxigenin, and strophanthidin are better inhibitors 
than digitoxin, digoxin, and convallatoxin. Moreover, a cymarose sugar seems to be more 
favorable for binding than a rhamnose sugar (cymarin vs convallatoxin). In addition, the 
hydroxyl group at position 12 decreases the inhibitory potency (digoxin and digoxigenin 
vs digitoxin and digitoxigenin). Comparing gitoxigenin with digitoxigenin indicates 
that a hydroxyl group at position 16 reduces the inhibitory potency. Comparison of 
strophanthidin and strophanthidol indicates that a hydroxyl group at position 19 is 
better than a ketone for DLC binding.
It was shown previously that molecular weight, lipophilicity, polar surface, and 
presence of hydrogen-bond acceptors are the key factors for OATP1B1 and OATP1B3 
inhibition (Gui et al., 2009; Badolo et al., 2010; Karlgren et al., 2012a; Karlgren et al., 
2012b; Soars et al., 2012; De Bruyn et al., 2013). In previous studies, we found a similar 
correlation between lipophilicity and inhibitory potency of various statins against NTCP 
(Greupink et al., 2011). Here, we did not observe an association between the inhibitory 
potency of DLCs against OATP1B1 and OATP1B3 and their physicochemical properties 
(molecular weight, octanol: water partition coeffi cient (clogP), polar surface area (PSA), 
and number of H donors and acceptors. Although no statistically signifi cant correlation 
was found, our fi ndings did show a tendency of lipophilic DLCs to be better inhibitors 
of OATP1B1 and OATP1B3 (Table 3).
Although none of the DLCs was a transporter substrate, we demonstrated that 
convallatoxin, dihydroouabain, ouabain, and ouabagenin are substrates of OATP1B3. It 
is the fi rst time that convallatoxin, dihydroouabain, and ouabagenin have been reported 
as the substrates of OATP1B3. In a previous study by Kullak-Ublick et al., digoxin 
and ouabain uptake by OATP1B3 in X. laevis oocytes was shown (Kullak-Ublick et 
al., 2001), but Kimoto et al. and Taub et al. did not observe any digoxin transport by 
OATP1B3 (Kimoto et al., 2011; Taub et al., 2011). Convallatoxin has been shown as 
an inhibitor of digoxin uptake in Caco-2 cells (Cavet et al., 1996), and its uptake by rat 
intestine seemed to be transporter-dependent (Lauterbach, 1968).
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Table 3. C alculated physicochemical properties of DLCs
Compounds C ogP a tPSA b
convallatoxin   -0.67 162.98
cymarin    0.22 131.75
digitoxigenin    2.48 66.76
digitoxin    2.85 182.83
digoxigenin    1.05 86.99
digoxin    1.42 203.6
dihydroouabain   -1.8 206.6
gitoxigenin    2.25 86.99
ouabain  -1.66 206.6
ouabagenin  -1.32 147.68
peruvoside   0.32 131.75
strophanthidin  -0.3 104.06
strophanthidol  -0.28 107.22
proscillaridin A   2.55 125.68
l
a Calculated octanol: water partition coeffi cient.
b Calculated polar surface area.
The four DLCs that have been found as OATP1B3 substrates (convallatoxin, ouabain, 
dihydroouabain, and ouabagenin) do not inhibit the transporter under the conditions 
tested and are more hydrophilic than the other congeners (Table 2), which might be a 
characteristic of OATP1B3 substrates. Among newly found substrates of OATP1B3, 
ouabain (reported plasma concentration 0.7 nM) has been applied in therapy. Given the 
present data, ouabain pharmacokinetics may be affected by concomitant administration 
of potent OATP1B3 inhibitors (Selden & Smith, 1972). Such DDI have, however, not 
been reported. We are not aware of clinical studies investigating the potential for DDI 
of convallatoxin, dihydroouabain, and ouabagenin either.
In summary, we identifi ed new DLC inhibitors of the liver uptake transporters, 
NTCP, OATP1B1, and OATP1B3. We showed that structural features such as the sugar 
moiety and hydroxyl groups play different roles in the interaction with these transporters. 
The sugar moiety decreases the interaction with OATP1B3, whereas it enhances the 
interaction with NTCP and OATP1B1. The hydroxyl group at position 12 enhances the 
interaction with NTCP, but it decreases the interaction with OATP1B1 and OATP1B3. 
In addition, we found that convallatoxin, dihydroouabain, ouabain, and ouabagenin are 
novel substrates of OATP1B3.
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Introduction
Digitalis-like compounds (DLCs) are ancient medications for heart failure, and are 
ranked in the top ten drugs leading to hospitalization due to their adverse effects. This is a 
result of their narrow therapeutic index, which is infl uenced at different pharmacokinetic 
levels such as absorption, metabolism, plasma-protein binding, and excretion. 
Infl ux and effl ux transport proteins play a key role in drug excretion and the 
consequent drug concentrations in plasma. Since the function of these transporters 
could be infl uenced by other drugs (substrates or inhibitors), drug-drug interaction 
(DDI) at the level of carrier-mediated DLC infl ux and effl ux could occur. Therefore, a 
DLC that has a low interaction potential with infl ux and effl ux transporters, would be 
less prone to DDI. In this study, different assays have been developed and used to study 
the interactions of DLCs with infl ux and effl ux transporters. These assays were used to 
study DLCs for their properties as inhibitors and/or substrates of these transporters.
In this thesis, the interaction of DLCs with the ATP binding cassette (ABC) 
effl ux transporters, multidrug resistance-associated proteins (MRP1, MRP2, MRP3 
and MRP4), breast cancer resistant protein (BCRP), bile salt export pump (BSEP) 
and P-glycoprotein (P-gp) and the Solute Carrier (SLC) infl ux transporters, organic 
anion-transporting polypeptide (OATP1B1 and OATP1B3) and Na+-taurocholate co-
transporting polypeptide (NTCP) was studied (chapters 2-6). In addition, the amino 
acids that play a key role in the interaction of DLCs with P-gp were described in chapters 
3 and 4. Here, the role of infl ux and effl ux transporters to decrease DLC toxicity and 
prevent DDI was discussed. In addition, chemical substitutions that are important 
for the interaction of DLCs with the transporters are highlighted. Furthermore, after 
comparison of in vitro assays, key factors that should be considered in the selection of 
suitable assays to determine P-gp substrates were described.
Perspective of DLC toxicity management
The medical application of DLCs and their toxic effects were described by William 
Withering in “An account of the Foxglove, and some of its medical uses: with practical 
remarks on dropsy, and other diseases” in 1785 (Rahimtoola, 1975; Krikler, 1985; 
Rossner, 2006). Manifestations of DLC toxicity such as nausea, anorexia, abdominal 
pain, diarrhea, dizziness, headache, muscular weakness, visual complaints, psychic 
complaints and vomiting have been described when the plasma concentration of digoxin 
is above 4 nmol/L (3 μg/L) (Lely & van Enter, 1970; Rawlins, 1974; GAXS, 1988; Bauman 
et al., 2006; Vivo et al., 2008). 
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The therapeutic plasma concentration range of digoxin was reported between 1.0-
2.5 nmol/L (0.8-2.0 μg/L) and concentrations above 2.5 nmol/L were considered toxic 
(Smith & Haber, 1970; Beller et al., 1971). It has been shown that digoxin concentrations 
of 0.6–1.0 nmol/L (or 0.5–0.8 μg/L) were associated with a better cardiac outcome and 
less mortality (Adams et al., 2002; Rathore et al., 2003). Accordingly, a therapeutic 
digoxin concentration of 0.6–1.2 nmol/L (or 0.5–1.0 μg/L) was suggested for patients 
with heart failure. Currently, three clinical improvements have decreased digoxin and 
digitoxin toxicity: access to kits to monitor serum concentrations of digoxin and digitoxin 
(Duhme et al., 1974), dosing guidelines using pharmacokinetic methods (Smith et al., 
1984; Vivo et al., 2008), and the development of digoxin and digitoxin antibodies for 
toxicity treatment (Antman et al., 1990).
In 1991, Beller et al. reported that more than 20% of the patients using digoxin showed 
probable to defi nite toxicity (Beller et al., 1971). In the DIG (Digoxin Investigation 
Group) study in 1997, 12% toxicity was observed in patients using digoxin compared 
to 8% in the placebo group (DIG, 1997). It has been reported that 31% of patients, 
who were hospitalized because of heart failure, were prescribed with digoxin in 2001 
in the United States. Although this percent has been decrease to 24% in 2004, showing 
a decline in digoxin usage, the number of toxic exposures to digoxin has not changed 
during this time period (Hussain et al., 2006).
In modern era, digoxin toxicity still occurs because drug dosing fails frequently 
in patients with renal dysfunction and concomitant use of digoxin-interacting drugs 
(Gheorghiade et al., 2006; Vivo et al., 2008). Body weight, age, renal function, and 
concomitant medications are the key determinants that should be considered in digoxin 
dosing (Ehle et al., 2011). The distribution volume of digoxin is large; therefore, patients 
with a lower lean body weight have less tissue for drug distribution and consequently 
need a lower dosage of digoxin (Gheorghiade et al., 2004; Gheorghiade et al., 2006). 
Furthermore, aging is often associated with a lower lean body weight and renal 
impairments that can infl uence digoxin distribution and excretion, respectively. The 
complete gastrointestinal absorption of digitoxin, its renal-independent excretion, 
and lower incidence of toxic side effects have ranked digitoxin less toxic than digoxin 
although the elimination half-life of digitoxin is longer than digoxin. In the United 
States, digoxin is still the most prescribed DLC (Roever et al., 2000; Belz et al., 2001), 
while in some countries such as Germany, Norway and France, digoxin has been replaced 
by digitoxin to decrease the incidence of digoxin toxicity. Although digitoxin is less toxic 
than digoxin, drug-drug interactions (DDIs) can occur for both cardiac glycosides. 
Several drugs such as diuretics, beta-blockers, antiarrhythmic agents, calcium channel 
blockers, and antibiotics increase the plasma concentration of digoxin and digitoxin and 
consequently their toxicity in the case of concomitant prescription (Steiness, 1978; Klein 
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et al., 1980; Bajaj et al., 1991; Hanratty et al., 2000; Belz et al., 2001). In chapter 1 of this 
thesis, digoxin and digitoxin DDIs were extensively discussed. 
After the identifi cation of P-glycoprotein as digoxin and digitoxin transporter (de 
Lannoy & Silverman, 1992; Schinkel et al., 1995; Pauli-Magnus et al., 2001a), the 
underlying mechanism of DDIs at the transport level was revealed and it opened a new 
door to decrease these unwanted interactions. In conclusion, identifi cation of DLCs 
transporters expands our knowledge of possible DDI sites and could be helpful to select 
DLCs that have similar therapeutic effects as digoxin and digitoxin, but are less prone to 
interactions and toxicity. To explore their therapeutic potential, we investigated potential 
interactions with DLCs at the level of infl ux and effl ux transporters. 
The role of effl ux transporters in excretion of DLCs 
The distribution and function of two transporter families, ATP-binding cassette effl ux 
transporters (ABC) and solute-linked carriers (SLC) infl ux transporters play a key role in 
the absorption, distribution, metabolism, and excretion of drugs. These transporters are 
expressed in a many different organs with a barrier function, such as placenta, prostate, 
small intestine, brain, colon, liver, and kidney to protect against xenobiotics (Flens et 
al., 1996; Maliepaard et al., 2001; Doyle & Ross, 2003; Trauner & Boyer, 2003; Bart et 
al., 2004; Fetsch et al., 2006; Hilgendorf et al., 2007; Huls et al., 2008; Keppler, 2011; 
Garzel et al., 2014). The induction or inhibition of these transporters is the underlying 
mechanism of drug-drug interactions and adverse drug effects. 
In chapters 2, 3 and 4 of this thesis, the interaction of fourteen structurally related 
DLCs with effl ux transporters BCRP, BSEP, MRP1, MRP2, MRP3, MRP4, and P-gp 
was described using membrane vesicles isolated from HEK293 cells overexpressing 
these transporters. We showed that digitoxin is the most potent inhibitor of BCRP-
mediated estrone sulfate, BSEP-mediated taurocholic acid (TCA) and MRP4-mediated 
β-estradiol 17β-D-glucuronide (E217βG) transport. In addition, transport of E217βG 
by MRP1 and MRP3 was inhibited most potently by strophanthidol, whereas MRP2-
mediated E217βG transport was not inhibited by DLCs, but its transport activity was 
stimulated by digitoxigenin more than 3-fold (chapter 2). 
In chapter 3, we showed that P-gp-mediated N-methyl- quinidine (NMQ) transport 
was inhibited most potently by digitoxin and proscillaridin A. The comparison of 
chemical structures and inhibition of above-mentioned effl ux transporters revealed the 
DLCs substitutions that infl uence their inhibitory potency (Figure 1). The presence of 
the sugar moiety at position C3 increased the inhibitory effect on BCRP, MRP1 and 
P-gp, whereas the presence of a hydroxyl group at this position increased the inhibitory 
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potency and the stimulatory effect on MRP4 and MRP2, respectively (chapter 2 and 3). 
In addition, the presence of the hydroxyl groups at the positions C12 and C16 reduced 
the inhibitory effect of DLCs on BCRP, BSEP, and P-gp, and interestingly, they also 
reduced the stimulatory effect on MRP2. The 12β hydroxyl group had a similar effect 
on MRP1 and MRP4, but this inhibitory and stimulatory effect was not observed for 
the 16β hydroxyl group. Moreover, the inhibitory potency of DLCs on BCRP, BSEP, 
MRP1, MRP3, and P-gp was reduced in the simultaneous presence of hydroxyl groups 
at positions C1 and C11. A hydroxyl group at position C19, however, increased the 
inhibitory potency (chapters 2 and 3). In chapters 2 and 3 of this thesis, we have shown 
that chemical substitutions at the positions C1, C3, C11, C12, C16, and C19 play a 
key role in the interaction of DLCs with the effl ux transporters BCRP, BSEP, MRP1, 
MRP2, MRP3, MRP4, and P-gp (Figure 1). In addition, gitoxigenin is the DLC with 
the lowest interaction potential with effl ux transporters (except stimulation of MRP2). 
To determine whether DLCs are transported by BCRP, BSEP, MRP1, MRP2, 
MRP3, and MRP4, we have developed an indirect assay using the DLC affi nity for Na, 
K-ATPase. The inhibitory effect on Na,K-ATPase has been used to demonstrate the 
presence of DLCs in different biological samples (Fishman, 1979; Whitmer et al., 1982; 
Cloix et al., 1984; Lichtstein et al., 1999; De Pont et al., 2009). In chapter 2, the extract 
of HEK293 membrane vesicles overexpressing BCRP, BSEP, MRP1, MRP2, MRP3 and 
MRP4 separated by fi ltration after incubation with DLCs in the absence and presence 
of ATP was used in a Na,K-ATPase-[3H]ouabain replacement assay. Inhibition of [3H]
ouabain binding by the fi ltered membrane vesicles could demonstrate the transporter-
mediated uptake of DLCs in these vesicles. Convallatoxin was accumulated in P-gp 
membrane vesicles confi rming that convallatoxin is a P-gp substrate (further discussed 
in chapter 4), but we did not observe a signifi cant accumulation of other DLCs in 
transporter-overexpressing membrane vesicles. High accumulation of digitoxigenin, 
digitoxin, and digoxin in control membrane vesicles implied that these lipophilic DLCs 
pass or enter the vesicle membrane by passive diffusion (chapter 2).
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Figure 1. Interacting positions of cardenolides with infl ux and effl ux transporters. The positions, 
C1, C3, C11, C12, C16, and C19 whose chemical substitutions (a hydroxyl group or a sugar moiety) 
infl uence the interaction of cardenolides with the infl ux (NTCP, OATP1B1, and OATP1B3) and 
the effl ux (BCRP, BSEP, MRP1, MRP2, MRP3, MRP4, and P-gp) transporters are presented. 
Dashed arrows represent the simultaneous role of positions C1 and C11 of cardenolides. 
In chapter 4, we investigated the transport of fourteen DLCs in membrane vesicles 
isolated from HEK293 cells overexpressing P-gp. We developed a liquid chromatography-
mass spectrometry (LC-MS) method to quantify DLCs in the samples directly. We 
showed that convallatoxin was transported into these vesicles ATP-dependently and 
its transport was inhibited by the P-gp-inhibitor elacridar. It is the fi rst time that 
convallatoxin, derived from Convallaria majalis (Lily of the valley), is reported as a P-gp 
substrate. An in vivo study in rats revealed that convallatoxin was highly accumulated 
in rat kidney cortex in presence of elacridar. As P-gp is expressed predominantly in 
renal proximal tubule cells, which are situated in the kidney cortex (Cordon-Cardo et al., 
1990), the high renal cortical accumulation in presence of elacridar underlined the P-gp 
involvement in the renal excretion of convallatoxin (chapter 4).
In addition, we studied the transport of structurally-related DLCs by P-gp in a cellular 
accumulation assay using a Madin-Darby canine kidney (MDCK) cell line constitutively 
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overexpressing human P-gp (MDCK-P-gp) (chapter 5). The cellular accumulation of 
DLCs in MDCK-P-gp was measured and compared with control MDCK using LC-
MS. In contrast to the results obtained with the vesicular transport assay (chapter 4), 
digitoxin, digoxigenin, strophanthidin and proscillaridin A were transported by P-gp 
in the cellular accumulation assay (chapter 5) and their transport was signifi cantly 
inhibited by elacridar. Since digitoxin and proscillaridin A accumulation in MDCK-
P-gp was increased in the presence of the BCRP inhibitor Ko143 (Cooray et al., 2002), 
these two DLCs might also be transported by endogenously expressed BCRP in the 
MDCK-P-gp cell line. P-gp-mediated transport of strophanthidin and proscillaridin A 
and their inhibition by elacridar was confi rmed using the cellular accumulation assay 
in a conditionally immortalized proximal tubule epithelial cell line (ciPTEC) (chapter 
5). In addition, BCRP-mediated proscillaridin A transport was also confi rmed in the 
ciPTEC cellular accumulation assay. P-gp and BCRP have an overlapping function and 
a number of studies have indeed discussed the interaction of BCRP with digoxin. As it 
was shown by our in vitro studies (chapter 2), digoxin is an inhibitor of BCRP, however, 
it is not transported by BCRP (Table 1) (Pavek et al., 2005; Huang et al., 2012). In 
chapters 2, 3, 4, and 5 of this thesis, the DLCs interactions with the effl ux transporters, 
BCRP, BSEP, MRP1, MRP2, MRP3, and MRP4 were investigated. 
P-glycoprotein amino acid residues interacting with DLCs
To elucidate the role of amino acid residues in DLC-P-gp interactions, the effect 
of DLCs on the transport of NMQ by ten P-gp alanine mutants was investigated in a 
HEK293 membrane vesicular assay (chapter 3). We showed that Ile306, Phe343, Phe728, 
Thr945 and Leu975 are the key residues for P-gp-mediated transport of NMQ (Figure 
2), which is in agreement with previous studies that showed the involvement of these 
amino acids in the interaction of P-gp with verapamil, vinblastine, cyclosporine A and 
colchicine (Aller et al., 2009; Loo et al., 2009). The conserved NMQ transport activity 
of P-gp mutants, L65A, F336A, I340A, F942A and V982A, exhibited that NMQ could 
be transported by P-gp lacking these residues, however, Leu65, Phe942 and Val982 do 
play a key role in verapamil transport (Loo et al., 2006a; Aller et al., 2009; Loo et al., 
2009).
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Figure 2. Positions of P-gp residues in the mutagenesis study. The positions of ten residues that 
were mutated to alanine are located in the P-gp transmembrane domains (left). The amino acids 
(Leu975 and Thr 945) that are important for NMQ transport activity of P-gp are shown in red and 
the key residues (Phe336 and Val982) for the convallatoxin transport are depicted in purple. The 
necessary residues (Ile306, Phe343, and Phe728) for transport of both NMQ and convallatoxin 
are shown in green. 
The comparison of the inhibitory potency of structurally related DLCs underlined 
the importance of P-gp residues, Phe336 and Ile340, for interaction with the C3 and C12 
positions of DLCs. It was also shown previously that the sugar moiety at position C3 
infl uences the pharmacokinetic properties of DLCs (Thomas et al., 1974; Smith et al., 
1984; Brown et al., 1986).
In chapter 4 of this thesis, convallatoxin was introduced as a new substrate of P-gp in 
the vesicular transport assay and in vivo. Next, we investigated the role of P-gp residues in 
the transport of convallatoxin as a substrate. Interestingly, Ile306, Phe343, and Phe728, 
which were key residues for NMQ transport activity of P-gp, were also important 
for convallatoxin transport. However, the mutation of Phe343 to alanine altered the 
transport activity of P-gp for convallatoxin less than that for NMQ. Although, P-gp 
transport activity of NMQ was conserved after mutation of Val982 to alanine, it resulted 
in a reduction of P-gp-mediated convallatoxin transport by 50%. The involvement of 
Phe336 residue in the interaction of P-gp with DLCs, which was found in chapter 3, was 
also confi rmed for convallatoxin in chapter 4. It was concluded that Phe336 and Ile340 
interact with cymarin, digoxin, peruvoside, and proscillaridin A, and Phe336 and Val982 
are necessary for P-gp-mediated transport of convallatoxin (Figure 2).
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The role of hepatic infl ux transporters in DLCs uptake
In chapter 6, the interaction of DLCs with SLC transporters was studied. A 
cellular accumulation assay was used to study the effect of DLCs on OATP1B1 and 
OATP1B3-mediated E217βG uptake and NTCP-mediated TCA uptake. A number of 
DLCs could inhibit OATP1B1 and OATP1B3, but only proscillaridin A was a potent 
inhibitor of NTCP. The interaction of structurally-related DLCs with these transporters 
provided information about the chemical features of DLCs for inhibition of the uptake 
transporters. The sugar moiety at the C3 position increased the inhibitory potency 
against NTCP and OATP1B1, whereas inhibition of OATP1B3 was observed in the 
presence of a hydroxyl group at the C3 position. The presence of a hydroxyl group at 
the C12 position reduced inhibition of OATP1B1 and OATP1B3, but increased NTCP 
inhibition. Moreover, a hydroxyl group at C16 decreased the interaction of DLCs with 
OATP1B1 and OATP1B3. However, if  a hydroxyl group was present at position C19 it 
increased the inhibitory potency against OATP1B3 (Figure 1). 
Next, we showed that the hydrophilic DLCs, convallatoxin, dihydroouabain, ouabain, 
and ouabagenin were transported by OATP1B3 and their transport was inhibited in 
the presence of rifampicin (chapter 6). The OATP1B3-mediated uptake of digoxin 
and ouabain was also reported by Kullak-Ublick et al., however, we and others did 
not observe digoxin as an OATP1B3 substrate (Kullak-Ublick et al., 2001; Kimoto et 
al., 2011; Taub et al., 2011). Since the hydrophilic DLCs could not pass the plasma 
membrane by passive diffusion, the presence of an uptake transporter for the entrance 
of these compounds into excretory organs such as the liver is necessary. The lipophilic 
DLCs, digitoxin, digoxin, and digitoxigenin were highly taken up in membrane vesicles 
as was observed using ouabain-Na,K-ATPase replacement (chapter 2) and LC-MS 
quantifi cation (chapter 4). This suggests that lipophilic DLCs do not need an uptake 
transporter to enter liver cells. In addition, the minor accumulation of convallatoxin and 
the absence of ouabain, dihydroouabain and ouabagenin accumulation in MDCK and 
ciPTEC cell lines (chapter 5) imply the requirement of an uptake transporter for these 
hydrophilic DLCs (Table 1).
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
General Discussion
143
7
T
ab
le
 1
. I
nt
er
ac
ti
on
 o
f 
D
L
C
s 
w
it
h 
dr
ug
 e
ffl
 u
x 
an
d 
in
fl u
x 
tr
an
sp
or
te
rs
.
 D
L
C
s
E
ffl
 u
x 
tr
an
sp
or
te
rs
In
fl u
x 
tr
an
sp
or
te
rs
B
C
R
P
B
S
E
P
M
R
P
1
M
R
P
2
M
R
P
3
M
R
P
4
P
-g
p
N
T
C
P
O
A
T
P
1B
1
O
A
T
P
1B
3
C
on
va
lla
to
xi
n
In
hi
bi
to
r 
2 
 
 
 
 
 
In
hi
bi
to
r 
3
 
 
 
 
 
 
 
 
 
Su
bs
tr
at
e 
4  (
ve
si
cu
la
r 
tr
an
sp
or
t)
 
 
 
Su
bs
tr
at
e 
6
 
 
 
 
 
 
Su
bs
tr
at
e 
4  (
in
 v
iv
o)
 
 
 
C
ym
ar
in
 
 
St
im
ul
at
or
 2
 
 
In
hi
bi
to
r 
3
 
 
 
D
ig
it
ox
ig
en
in
In
hi
bi
to
r 
2
 
 
St
im
ul
at
or
 2
 
In
hi
bi
to
r 
2
 
 
In
hi
bi
to
r 
6
In
hi
bi
to
r 
6
D
ig
it
ox
in
In
hi
bi
to
r 
2
In
hi
bi
to
r 
2
In
hi
bi
to
r 
2
St
im
ul
at
or
 2
 
 
In
hi
bi
to
r 
3
 
In
hi
bi
to
r 
6
In
hi
bi
to
r 
6
 
 
 
 
 
 
Su
bs
tr
at
e 
5  (
ce
llu
la
r 
ac
cu
m
ul
at
io
n 
*)
 
 
 
 
 
 
 
 
 
Su
bs
tr
at
e 
A
 (
tr
an
sw
el
l t
ra
ns
po
rt
 #
) 
 
 
 
D
ig
ox
ig
en
in
 
St
im
ul
at
or
 2
 
 
 
Su
bs
tr
at
e 
5  (
ce
llu
la
r 
ac
cu
m
ul
at
io
n)
 
 
 
 
 
 
 
 
 
 
Su
bs
tr
at
e 
B
 (
tr
an
sw
el
l t
ra
ns
po
rt
) 
 
 
 
D
ig
ox
in
In
hi
bi
to
r 
2
 
 
 
 
 
In
hi
bi
to
r 
3
 
In
hi
bi
to
r 
6
In
hi
bi
to
r 
6
 
In
hi
bi
to
r 
C
 
 
 
 
 
Su
bs
tr
at
e 
5  (
ci
P
T
E
C
 a
cc
um
ul
at
io
n)
 
In
hi
bi
to
r 
D
 
In
hi
bi
to
r 
E
 
 
 
 
 
 
Su
bs
tr
at
e 
F
-G
 (
tr
an
sw
el
l t
ra
ns
po
rt
) 
 
 
Su
bs
tr
at
e 
H
 
 
 
 
 
 
Su
bs
tr
at
e 
I  (
in
 v
iv
o)
 
 
 
 
D
ih
yd
ro
ou
ab
ai
n
 
 
 
 
 
 
 
 
Su
bs
tr
at
e 
6
G
it
ox
ig
en
in
 
 
St
im
ul
at
or
 2
 
 
 
 
 
 
O
ua
ba
ge
ni
n
 
 
 
 
 
 
 
 
Su
bs
tr
at
e 
6
O
ua
ba
in
 
In
hi
bi
to
r 
J   
 
 
 
 
 
In
hi
bi
to
r 
K
 
In
hi
bi
to
r 
E
 
 
 
 
 
 
 
 
 
 
Su
bs
tr
at
e 
6
 
 
 
 
 
 
 
 
 
Su
bs
tr
at
e 
H
 
P
er
uv
os
id
e
In
hi
bi
to
r 
2
In
hi
bi
to
r 
2
In
hi
bi
to
r 
2
St
im
ul
at
or
 2
 
 
In
hi
bi
to
r 
3
 
 
 
S
tr
op
ha
nt
hi
di
n
In
hi
bi
to
r 
2
 
St
im
ul
at
or
 2
St
im
ul
at
or
 2
In
hi
bi
to
r 
2
 
Su
bs
tr
at
e 
5  (
ce
llu
la
r 
ac
cu
m
ul
at
io
n)
 
 
 
S
tr
op
ha
nt
hi
do
l
In
hi
bi
to
r 
2
 
In
hi
bi
to
r 
2
 
In
hi
bi
to
r 
2
 
In
hi
bi
to
r 
3
 
 
 
P
ro
sc
ill
ar
id
in
 A
 
 
 
 
 
In
hi
bi
to
r 
3
In
hi
bi
to
r 
6
In
hi
bi
to
r 
6
 
 
 
 
 
 
 
 
Su
bs
tr
at
e 
5  (
ce
llu
la
r 
ac
cu
m
ul
at
io
n)
 
 
 
 
* 
U
np
ol
ar
iz
ed
 c
el
ls
 o
ve
re
xp
re
ss
in
g 
tr
an
sp
or
te
rs
 su
ch
 a
s M
D
C
K
-P
-g
p,
 #  
Po
la
ri
ze
d 
ce
lls
 o
ve
re
xp
re
ss
in
g 
tr
an
sp
or
te
rs
 su
ch
 a
s L
L
C
-P
K
1 
or
 M
D
C
K
-P
-g
p.
 2-
6  R
ef
er
en
ce
d 
to
 c
ha
pt
er
s 
in
 t
hi
s 
th
es
is
, 
A
-K
 R
ef
er
en
ce
s 
to
 l
it
er
at
ur
e:
 A
 (
P
au
li-
M
ag
nu
s 
et
 a
l.,
 2
00
1a
),
 B
 (
H
ug
he
s 
&
 C
ro
w
e,
 2
01
0)
, 
C
 (
P
av
ek
 e
t 
al
., 
20
05
),
 D
 (
B
ad
ol
o 
et
 a
l.,
 2
01
0)
, 
E
 
(B
al
de
s 
et
 a
l.,
 2
00
6)
, F
-G
 (
de
 L
an
no
y 
&
 S
ilv
er
m
an
, 1
99
2;
 P
au
li-
M
ag
nu
s 
et
 a
l.,
 2
00
1a
),
 H
 (
K
ul
la
k-
U
bl
ic
k 
et
 a
l.,
 2
00
1)
, I
 (
Sc
hi
nk
el
 e
t 
al
., 
19
95
),
 J  
(V
al
en
te
 e
t 
al
., 
20
07
),
 
K
 (
K
ar
lg
re
n 
et
 a
l.,
 2
01
2b
).
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Chapter 7
144
The vesicular transport assay versus the cellular accumulation assay 
The vesicular transport assay has been used extensively to investigate the interaction 
of compounds with the carrier-mediated transport of a substrate (Leslie et al., 2001; 
Hooiveld et al., 2002; Breedveld et al., 2004; El-Sheikh et al., 2007; Pedersen et al., 2008; 
Matsson et al., 2009). In this thesis, the vesicular transport assay was used to study the 
interaction of DLCs with various effl ux transporters (chapters 2 and 3), to identify P-gp 
substrates (chapter 4) and to analyze transport activity of P-gp mutants (chapters 3 and 
4). 
In the vesicle transport assay, digoxin, an established substrate of P-gp (de Lannoy & 
Silverman, 1992; Schinkel et al., 1995), was not recognized as a P-gp substrate using [3H]
ouabain-Na,K-ATPase replacement and LC-MS methods to determine and quantify 
digoxin. Because of its relatively high lipophilicity digoxin likely diffuses passively into 
the membrane vesicles, leading to high background levels and a small difference between 
uptake into control and P-gp vesicles (Figure 3). The high uptake values of digoxin in 
control vesicles were also observed using [3H]ouabain-Na,K-ATPase replacement and 
LC-MS methods (chapter 2 and 4). This confi rms that the vesicular transport assay is not 
suitable for studying digoxin as a P-gp substrate. Only one study reports P-gp-mediated 
digoxin transport in a vesicular transport assay using trophoblast membrane vesicles 
isolated from human placenta (Ushigome et al., 2003). Ushigome et al. showed that the 
uptake of digoxin by P-gp membrane vesicles is signifi cantly higher in the presence of 
ATP than AMP, however, digoxin uptake by a control vehicle, which contains no P-gp 
expression, was not demonstrated. 
The vesicular transport assay is often used to characterize the kinetics of a transporter 
by determining parameters such as Vmax, Km and IC50 (chapters 3 and 4) (Schlemmer 
& Sirotnak, 1994; Karlsson et al., 2010; Elsby et al., 2011; Heredi-Szabo et al., 2013; 
Marchetti et al., 2013). It is also a suitable model to study the effect of individual amino 
acid residues on the activity and inhibition of a transporter using mutagenesis studies 
(chapter 3) (Zelcer et al., 2003; Schaefer et al., 2006; El-Sheikh et al., 2008; Wittgen et 
al., 2012).
Effl ux transporters protect cells from toxins and this function has been applied to 
develop an assay in which the cellular accumulation of DLCs was quantifi ed using 
LC-MS to identify P-glycoprotein substrates (chapter 5). As this assay is based on the 
passive diffusion of test compounds into cells, it is appropriate for lipophilic compounds 
and not for hydrophilic membrane impermeable compounds. Also for highly lipophilic 
compounds it could be diffi cult to identify transporter involvement, because the rate of 
passive diffusion out of the cells can be higher than the rate of P-gp-mediated effl ux or 
P-gp can be saturated by high intracellular concentration of these compounds (Figure 
3) (Eytan et al., 1996; Polli et al., 2001).
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Figure 3. Behaviour of lipophilic and hydrophilic DLCs as transporter substrates in the vesicular 
transport (A) and the cellular accumulation (B) assays. Lipophilic and hydrophilic DLCs are 
depicted by green and red circles, respectively, and the DLCs that were effl uxed by a transporter 
have been marked with black star. The blue and dashed arrows represent the effl ux transporter and 
passive diffusion, respectively.
Furthermore, digoxin was not identifi ed as a P-gp substrate in the MDCK cellular 
accumulation assay; however, it was in the ciPTEC accumulation assay. The expression 
of OATP4C1 in ciPTEC (Jansen et al., 2014) but not in M DCK cell line (Goh et al., 
2002; Quan et al., 2012; Gartzke & Fricker, 2014) could explain this difference in 
results. Although the high lipophilicity of digoxin and the active uptake of digoxin are 
contradictory, in most studies, a transwell transport assay is used to study vectorial P-gp-
mediated digoxin transport. Because in this assay, the permeability of the test compound 
can be determined in the polarized cells with localized uptake and the effl ux transporters 
(Pauli-Magnus et al., 2001a; Rathore et al., 2003; Balimane et al., 2004; Balimane & 
Chong, 2005). It seems that, lipophilicity of digoxin is not the only factor playing a role 
in cellular uptake and there might be other physicochemical properties involved (Pastan 
et al., 1988; Polli et al., 2001; Yamazaki et al., 2001). Another explanation for lack of 
digoxin transport by P-gp in MDCK cell might be the presence of Gly185Val mutation 
in the originally cloned P-gp in our MDCK cell line. It is known that this mutation 
affects the substrate affi nity (Safa et al., 1990; Watanabe et al., 2000) and therefore might 
affect the digoxin transport.
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Since MDCK cell lines originated from canine kidney, they contain endogenous 
transporters that may lead to false-positive or false negative results for detection of a 
substrate (Kuteykin-Teplyakov et al., 2010). Based on FDA suggestions (Food and Drug 
Administration (FDA), 2006; Gartzke & Fricker, 2014), we have used both MDCK 
and MDCK-P-gp cell lines to prevent this effect (chapter 5). Moreover, to specify the 
transporters that were involved in the DLCs transport in the MDCK and ciPTEC cellular 
assays, the inhibitors elacridar and Ko143 were used. Although BCRP expression is 
lacking in MDCK (Quan et al., 2012; Gartzke & Fricker, 2014), it is present in ciPTEC 
(Jansen et al., 2014), and the inhibition of digitoxin and proscillaridin A transport in the 
presence of Ko143 could be an indication for the transport of these DLCs by BCRP.  
Future perspective
In this thesis, we have applied different in vitro models to study the transport and 
the interaction of DLCs by drug infl ux and effl ux transporters. We showed that the 
physicochemical properties of DLCs such as lipophilicity could infl uence the results of 
in vitro assays and therefore should be considered in the selection of the in vitro assays 
to study their transport. 
We argued that the membrane vesicular transport assay is an appropriate tool for 
screening of transport inhibitors, but neither this assay nor the cellular accumulation 
assay alone would be suffi cient to detect all substrates of the ATP-dependent effl ux 
transporters studied. Since different in vitro models are available, these different models 
should be used and the presence of effl ux and infl ux transporters should be discussed. 
To improve the narrow therapeutic index of DLCs, it would be interesting to focus 
on DLCs that are not transported by the infl ux and effl ux transporters, because these 
compounds would not be victim of DDIs and resulting toxicity. Based on our studies, 
gitoxigenin has the least interaction with the infl ux and effl ux transporters. Gitoxigenin, 
however, is a less potent inhibitor of Na,K-ATPase compared to digitoxigenin, digitoxin, 
digoxigenin, digoxin and gitoxin (De Pover & Godfraind, 1982; Cornelius et al., 2013). 
The ideal candidate should contain these structural criteria to interact with Na,K-
ATPase: a cis conformation of the C/D rings, an unsaturated lactone ring, a β attachment 
of the lactone ring to C17, a β attachment of the hydroxyl group at positions C3 and 
C14, and a β attachment of C3 with the sugar moiety (Chen & Henderson, 1954; Brown 
et al., 1962; Thomas et al., 1974; Sevillano et al., 2002). Additionally in the gitoxigenin 
structure, the presence of a hydroxyl group at C16 position facilitates the formation of a 
hydrogen bond between C14 and C16 leading to the formation of a D-ring.
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Figure 4. Gitoxigenin. Chemical structure of gitoxigenin has been presented.
This unusual ring alters the position of the lactone ring in the binding pocket of 
Na,K-ATPase and therefore, decreases the affi nity of gitoxigenin for its receptor but 
still conserves the inhibitory effect on Na,K-ATPase (Griffi n et al., 1986; Hashimoto 
et al., 1986). In addition, the 16β-formate and 16β-acetate derivatives of gitoxigenin 
have a higher affi nity for Na,K-ATPase compared to their parent compound (Griffi n 
et al., 1986; Hashimoto et al., 1986). Like digoxin and digitoxin, gitoxigenin has been 
extracted from Digitalis lanata (Caspi & Lewis, 1967; Go & Bhandary, 1989) and it was 
recently shown to be a component of the essential oil and methanol extracts of sweet 
basil Ocimum basilicum L. (Lamiaceae) and an Indian seed oil called sal (Shorea robusta) 
that are applied in food industry (Dhara et al., 2010; Hossain et al., 2010).
Information about application of gitoxigenin and its derivatives in therapy and 
relevant DDI is lacking. Based on Lipinski’s rule of fi ve (Lipinski et al., 2001), the 
molecular weight of 390.5, calculated logP of 2.25, existence of 3 and 5 hydrogen bond 
donors and acceptors, respectively and the lack of interaction with infl ux and effl ux 
transporters characterize gitoxigenin and its derivatives as good candidates for further 
investigation to replace digoxin and digitoxin, and reduce DLCs adverse effect and 
toxicity. 
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Introduction
Digitalis-like compounds (DLCs), also named cardiac glycosides, are produced as 
protective agents against herbivores or predators by plants and animals, such as fox 
glove (Digitalis purpurea) and Bufo Bufo toad, respectively. Moreover, they are known 
as the ancient treatment of heart failure and atrial fi brillation and currently digoxin 
and digitoxin are still applied in the clinic. Apart from their different physicochemical 
and pharmacological properties, DLCs share the inhibitory effect on Na,K-ATPase. 
Digoxin and digitoxin are characterized by their narrow therapeutic index and adverse 
effects, which rank them among the top ten drugs leading to hospitalization. Particularly, 
drug-drug interactions (DDI) at the transporter level play a key role in high plasma 
concentrations of these DLCs leading to toxicity. 
Transport proteins, located in blood-brain barrier, liver, intestine and kidney, prevent 
accumulation of drugs and potentially toxic compounds in the body. The ATP-binding 
cassette (ABC) protein superfamily consists of effl ux transporters that translocate drugs 
from inside of the cells to the blood, bile, intestinal lumen and urine. Infl ux transporters, 
like organic anion-transporting polypeptides (OATPs) in the liver, translocate drugs 
from the blood side of the cells to the inside thereby facilitating excretion via effl ux 
transporters. DDI may occur at the level of effl ux and infl ux transporters thereby 
infl uencing drug disposition, which is one of the key determinants of drugs safety and 
effi cacy.
In this thesis, we studied the interaction of effl ux and infl ux transporters with a 
group of structurally related DLCs. Moreover, we investigated the chemical features 
of DLCs that are important for the interaction with transporters. In addition, we have 
explored the role of different amino acids in the transport activity of the major drug 
effl ux transporter P-glycoprotein/ ABCB1 (P-gp). We have also identifi ed DLCs that 
are poor substrates or inhibitors of effl ux and infl ux transporters and introduced DLCs 
that had the least interactions with transporters, as they might be safer therapeutic 
alternatives to digoxin and digitoxin.
The role of effl ux transporters in DLC excretion
The distribution and function of ABC transporters play a key role in the absorption, 
distribution, metabolism, and excretion of drugs. Induction or inhibition of these 
transporters is the underlying mechanism of many drug-drug interactions and adverse 
drug effects. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Chapter 8
152
In chapter 2, we showed that most DLCs interact with BCRP/ABCG2, BSEP/
ABCB11, MRP1/ABCC1, MRP2/ABCC2, MRP3/ABCC3, and MRP4/ABCC4 
in inside-out membrane vesicles overexpressing the respective transporters. BCRP-
mediated transport activity was completely inhibited by 1000 μM digitoxin, digoxin, 
and peruvoside. Digitoxin was the only potent BSEP inhibitor among the tested DLCs, 
whereas peruvoside and strophanthidol inhibited BSEP by 50%. Strophanthidol was the 
strongest MRP1 and MRP3 inhibitor and digitoxigenin was the most potent MRP2 and 
MRP4 stimulator and inhibitor, respectively. 
The typical DLC structure consists of a core steroid ring, which contains a sugar 
moiety or a hydroxyl group on position C3 and a lactone ring at position C17. In addition, 
there can be substitutions like a hydroxyl group or a carbonyl group at positions C1, 
C5, C11, C12, C16, and C19. We showed that chemical substitutions at C1, C3, C11, 
C12, C16, and C19 positions infl uence the interaction of DLCs with BCRP, BSEP, and 
MRPs. Furthermore, the inhibitory effect of DLCs on Na,K-ATPase activity was used 
to develop a Na,K-ATPase-[3H]ouabain replacement assay to determine their uptake by 
BCRP, BSEP and MRPs expressing membrane vesicles. Although most DLCs inhibited 
the activity of the effl ux transporters, none of them were transported as a substrate 
in the vesicle assay, except for convallatoxin by P-gp, which was further confi rmed in 
chapter 4.     
In chapter 3, we studied the interaction of a series of DLCs with P-gp in a vesicular 
transport assay. Digitoxin and proscillaridin A were the most potent inhibitors of P-gp 
and digoxin, peruvoside, and strophanthidol inhibited transport activity by more than 
50%. We found that a δ-lactone ring and a sugar moiety at the 3β position of the steroid 
body are favorable for inhibition of P-gp. In addition, although hydroxyl groups at 
positions 5β and 19 increased the inhibitory effect of DLCs, inhibition is decreased by 
a hydroxyl at positions 1β, 11α, 12β, and 16β. To determine the key amino acids of 
P-gp for interaction with DLCs, ten of them were mutated to alanine. The mutations 
I306A, F343A, F728A, T945A, and L975A abolished P-gp-mediated transport of the 
model substrate N-methyl quinidine (NMQ). The affi nities of digoxin, proscillaridin 
A, peruvoside, and cymarin for mutants F336A and I340A were decreased 2- to 4-fold 
compared to wild type, whereas those of digitoxin and strophanthidol were unaltered. 
Moreover, the presence of a hydroxyl group at position 12β (digoxin vs. digitoxin) seems 
to reduce the apparent affi nity when the side chain of Phe336 and Phe942 is absent.
In chapter 4, we investigated the transport of fourteen DLCs by P-gp in the 
vesicular transport assay using liquid chromatography-mass spectrometry (LC-MS) for 
quantifi cation. We identifi ed convallatoxin, Lily of the Valley toxin, as a P-gp substrate. In 
rat, convallatoxin co-administration with elacridar resulted in increased concentrations 
in brain and kidney cortex, which confi rmed P-gp-mediated convallatoxin transport 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
English Summary
153
E
in vivo. To determine interacting P-gp residues with convallatoxin, the effect of nine 
alanine mutations on NMQ transport was compared. We found that Phe343 appeared 
to be more important for transport of NMQ than convallatoxin, whereas Val982 plays 
an important role in convallatoxin transport. 
In chapter 5, a cellular accumulation assay was developed using Madin-Darby canine 
kidney (MDCK) cells and conditionally immortalized proximal tubular epithelial cells 
(ciPTECs) of human origin, to study the role of the effl ux transporters as gatekeepers 
to protect cells from toxins. We found that digitoxin, digoxigenin, strophanthidin, 
and proscillaridin A were substrates of P-gp in both the ciPTEC and MDCK cellular 
accumulation assays, but not in the vesicular transport assay. In chapter 4, we identifi ed 
convallatoxin as a P-gp substrate; however, it was not transported by P-gp in the cellular 
accumulation assay. The function of an effl ux transporter in the cellular accumulation 
assay depends on the passive entrance of lipophilic compounds, whereas the vesicular 
transport assay is more appropriate for hydrophilic compounds that do not cross the 
vesicular membrane by passive diffusion. Therefore, lipophilic DLCs such as digitoxin, 
digoxigenin, strophanthidin, and proscillaridin A could not be identifi ed as P-gp 
substrates in the vesicular assay, whereas the less lipophilic convallatoxin was not 
detected as P-gp substrate in the cellular accumulation assays. Here, we showed that the 
transport of substrates with a clogP of - 0.3 and higher could be assessed in a cellular 
assay, whereas the vesicular assay is suitable for substrates with a lower clogP.
The role of infl ux transporters in DLC excretion
In chapter 6, the interaction of DLCs with the SLC transporters, NTCP/SLC10A1, 
OATP1B1/SLCO1B1, and OATP1B3/SLCO1B3 were studied in a cellular uptake 
assay. NTCP transport activity was inhibited most potently by proscillaridin A, 
however, digitoxin, and digitoxigenin were the most potent inhibitors of OATP1B1 and 
OAPTP1B3, respectively. Moreover, the presence of a sugar moiety at the C3 position 
enhanced the inhibition of OATP1B1 transport, whereas it decreased the inhibition 
of NTCP and OATP1B3 transport. Although the hydroxyl group at position 12 
increased the inhibition of NTCP, it reduced the inhibitory potency against OATP1B1 
and OATP1B3 activity. Here, we showed for the fi rst time that convallatoxin, ouabain, 
dihydroouabain, and ouabagenin are substrates of OATP1B3, which implies that this 
liver uptake transporter could be a potential site of DDI. 
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Conclusion and future perspectives
In this thesis, we used in vitro and in vivo models to study the interaction of 
structurally-related DLCs with clinically relevant drug effl ux and infl ux transporters. 
In chapter 7, we discussed that DLCs, which have the least interactions with these 
transporters, could be selected as candidate drugs that are less prone to DDIs. Based on 
our studies, gitoxigenin fulfi lls these criteria and it could be considered as a replacement 
for digoxin and digitoxin, which have a high incidence of DDIs and toxicity. In addition, 
we concluded that the application of one type of in vitro transport assay is not suffi cient 
to screen for substrates, because the functionality of vesicular and cellular transport 
assays depend on the lipophilicity of the substrate.
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Introductie
Digitalisachtige verbindingen (Digitalis-like compounds, DLCs) of hartglycosiden 
worden geproduceerd door planten en dieren, zoals vingerhoedskruid (Digitalis purpurea) 
en bruine pad (Bufo Bufo), als beschermende stoffen tegen herbivoren en roofdieren. 
Digoxine en digitoxine zijn bekend als klassieke geneesmiddelen bij de behandeling van 
hartfalen en atrium fi brilleren en worden nog steeds voorgeschreven. DLCs verschillen 
in farmacokinetische kenmerken maar delen alle hetzelfde werkingsmechanisme, 
namelijk remming het enzym Na,K-ATPase. Ze worden gekenmerkt door een smalle 
therapeutische index waardoor ze behoren tot de top tien van medicijnen die leiden tot 
ziekenhuisopname. Geneesmiddeleninteracties (drug-drug interactions, DDIs) op het 
niveau van de transporteiwitten spelen een belangrijke rol bij het ontstaan van hoge 
plasmaconcentraties van DLCs welke kunnen leiden tot levensbedreigende toxiciteit. 
Transporteiwitten komen onder meer voor in de bloed-hersenbarrière, lever, darmen 
en nieren en hebben als functie om accumulatie van geneesmiddelen en potentieel 
schadelijke stoffen in het lichaam te voorkomen. Transportereiwitten die tot de ATP-
binding-cassette (ABC) superfamilie behoren, zijn zogenaamde effl uxtransporters 
die stoffen vanuit de cellen actief  naar bloed, gal, darmlumen en urine transporteren. 
Daarnaast zijn er ook infl uxtransporters zoals de ‘organic anion transporting 
polypeptides’ (OATPs) in de lever, die zorgen voor opname van stoffen uit het bloed in de 
cel, zodat ze vervolgens via effl uxtransporters uitgescheiden kunnen worden. Zowel op 
het niveau van effl ux- als infl uxtransporters kunnen DDIs plaatsvinden die de eliminatie 
en daarmee de veiligheid van een geneesmiddel nadelig beïnvloeden.
In dit proefschrift hebben we de moleculaire interactie van effl ux- en infl uxtransporters 
met een groep DLCs met verschillende chemische structuren bestudeerd en hebben we 
onderzocht hoe de verschillende chemische zijgroepen van de DLCs hierop invloed 
hebben. Verder hebben we gekeken naar de rol van een aantal aminozuren in de 
substraatbindingplaats van de effl uxtransporter P-glycoproteïne/ABCB1 (P-gp). We 
hebben ook bepaald welke DLCs substraten van de effl ux- en infl uxtransporters zijn en 
welke juist de minste interacties met deze transporters geven, omdat dit mogelijk goede 
kandidaten zijn om interactiegevoelige geneesmidelen zoals digoxine en digitoxine te 
vervangen.
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De rol van effl uxtransporters in de eliminatie van DLCs
De lokalisatie en functie van ABC-transporters spelen een belangrijke rol bij de 
absorptie, distributie, biotransformatie en eliminatie van geneesmiddelen. Inductie of 
remming van de activiteit van deze transporters is een belangrijk mechanisme voor 
DDIs en daaruit voortkomende bijwerkingen.
In hoofdstuk 2 hebben we laten zien dat de meeste DLCs een interactie aangaan 
met BCRP/ABCG2, BSEP/ABCB11, MRP1/ABCC1, MRP2/ABCC2, MRP3/ABCC3 
en MRP4/ABCC4. Deze interacties werden bepaald in membraanblaasjes (vesikels) 
geïsoleerd van cellen waarin deze transporteiwitten tot overexpressie zijn gebracht. De 
transportactiviteit van BCRP werd volledig geremd door 1000 μM digitoxine, digoxine 
en peruvoside. Digitoxine was de sterkste remmer van BSEP, terwijl peruvoside en 
strophanthidol 50% remming gaven. Strophantidol was de sterkste remmer van MRP1 
en MRP3, terwijl digitoxigenine de sterkste remmer en stimulator van respectievelijk 
MRP2 en MRP4 is. 
De typiche structuur van een DLC bestaat uit een steroïdring die de kern vormt, 
een suiker- of hydroxylgroep op positie C3 en een lactonring op positie C17. Op de 
posities C1, C5, C11, C12, C16 en C19 kunnen substituenten als een hydroxyl- of een 
carbonylgroep voorkomen. Wij hebben laten zien dat substituenten op posities C1, C3, 
C11, C12, C16 en C19 de interacties met BCRP, BSEP en de MRPs beïnvloeden. Het 
principe van Na,K-ATPase remming door DLCs werd gebruikt om een  Na,K-ATPase-
[3H]ouabain-inhibitie-test te ontwikkelen. Met deze test kunnen we de opname van 
remmende DLCs in BCRP-, BSEP- en MRPs-vesikels bepalen. Hoewel de meeste DLCs 
een interactie met een effl ux transporter aangaan, werd geen van deze DLCs als substraat 
opgenomen in de vesikels, behalve convallatoxine door P-gp dat verder is uitgezocht in 
hoofdstuk 4.
In hoofdstuk 3 hebben we de interactie van een groep DLCs met P-gp in 
membraanvesikels onderzocht. Digitoxine en proscillaridine-A waren de sterkste 
remmers van P-gp en digoxine, maar ook peruvoside en strophanthidol, remden P-gp 
meer dan 50%. We toonden aan dat een δ-lactonring en een suikergroep op de 3β-positie 
van de DLCs gunstig is voor remming van P-gp. De aanwezigheid van hydroxylgroepen 
op posities 5β en 19 verhogen het remmende effect, terwijl hydroxylgroepen op posities 1β, 
11α, 12β, en 16β de remming verminderen. Tien aminozuren van P-gp werden gemuteerd 
naar alanine om hun rol in de interactie met DLCs te bepalen. De mutaties I306A, 
F343A, F728A, T945A en L975A blokkeerden het transport van het modelsubstraat 
N-methyl quinidine (NMQ) door P-gp. De affi niteit voor digoxine, proscillaridin A, 
peruvoside en cymarin van de mutanten F336A en I340A was 2- tot 4-keer afgenomen 
in vergelijking met de controle (wild-type), terwijl de affi niteiten van digitoxine en 
strophanthidol niet waren veranderd. Bovendien zorgde een hydroxylgroep op positie 
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12β (digoxine vs digitoxine) voor een vermindering van de affi niteit bij afwezigheid van 
de zijketen van Phe336 en Phe942.
In hoofdstuk 4 is de opname van veertien DLCs door P-gp in membraanvesikels 
met behulp van vloeistofchromatografi e-massaspectrometrie (LC-MS) gemeten. We 
identifi ceerden convallatoxine, het lelietje-van-dalen-toxine, als een P-gp substraat. In 
ratten verhoogde elecridar de convallatoxine-concentratie in de hersenen en de niercortex, 
hetgeen bevestigt dat deze DLC in vivo ook door P-gp wordt getransporteerd. Om de 
aminozuren te bepalen die een rol in de convallatoxin-P-gp-interactie spelen, werd van 
negen alaninemutanten het convallatoxine-transport vergeleken met dat van N-methyl 
quinidine (NMQ). We vonden een belangrijke rol voor Phe343 in het NMQ-transport, 
terwijl Val982 juist een belangrijke rol had bij het transport van convallatoxine.
In hoofdstuk 5 is een meetmethode ontwikkeld om met Madin-Darby canine kidney 
II (MDCK) cellen en conditionally immortalized proximal tubular epithelial cells 
(ciPTECs) van humane afkomst de rol van de effl uxtransporters die de cellen beschermen 
tegen toxines te onderzoeken. In ciPTEC- en MDCK-cellen waren digitoxine, 
digoxigenine, strophanthidin en proscillaridin A substraten van P-gp, terwijl dit uit de 
vesikelexperimenten niet bleek. In hoofdstuk 4 hebben we laten zien dat convallatoxin 
een P-gp-substraat was, maar dit kwam niet naar voren in de cellulaire assays. De 
functie van een effl uxtransporter in de cellulaire assays is afhankelijk van de opname 
van lipofi ele substraten in de cellen, terwijl de vesikels juist geschikt zijn voor hydrofi ele 
DLCs omdat deze de membranen niet passief  kunnen passeren. Daarom konden lipofi ele 
DLCs zoals digitoxine, digoxigenine, strophanthidine en proscillaridine-A niet worden 
geïdentifi ceerd als P-gp-substraten in de vesikulaire assay, terwijl het minder lipofi ele 
convallatoxine niet als P-gp-substraat in cellen werd gedetecteerd. We concluderen dat 
transport van substraten met een clogP van -0,3 en hoger in cellen kan worden bepaald, 
terwijl bij een lagere clopP de vesikulaire assay moet worden gebruikt.
De rol van infl uxtransporters in de eliminatie van DLCs
In hoofdstuk 6 hebben we onderzocht of DLCs een interactie hebben met de SLC-
transporters, NTCP/SLC10A1, OATP1B1/SLCO1B1 en OATP1B3/SLCO1B3. 
Proscillaridine-A was de sterkste remmer van NTCP-transportactiviteit, terwijl digitoxine 
en digitoxigenine de sterkste remmers van respectievelijk OATP1B1 en OAPTP1B3 
waren. Een suikergroep op de C3-positie verbeterde de remming van OATP1B1, terwijl de 
remming van NTCP en OATP1B3 hierdoor juist minder werd. Bovendien versterkte een 
hydroxylgroep op positie 12 de remming van NTCP, maar verminderde het de remming 
van OATP1B1 en OATP1B3. We toonden hier voor het eerst aan dat convallatoxine, 
ouabaïne, dihydroouabaïne en ouabagenine substraten zijn van OATP1B3, waardoor 
DDIs met deze middelen op het niveau van deze infl uxtransporter kunnen optreden.
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Conclusie en toekomstperspectieven
In dit proefschrift hebben we in vitro- en in vivo-modellen gebruikt om de interactie 
van verschillende DLCs met effl ux- en infl uxtransporters te onderzoeken. In hoofdstuk 
7 beschrijven we hoe een DLC met de minste transporterinteracties geselecteerd kan 
worden als kandidaat geneesmiddel met minimale DDIs. Op basis van ons onderzoek 
had gitoxigenine de minste interacties met effl ux- en infl uxtransporters en is het daarom 
een mogelijk alternatief  voor digoxine en digitoxine, welke een hoge incidentie van DDIs 
en toxiciteit hebben. Daarnaast hebben we geconcludeerd dat het gebruik van alleen 
cellen of membraanvesikels niet voldoende is om de substraten van een transporter te 
onderzoeken. Het resultaat van de assay is namelijk afhankelijk van de lipofi liciteit van 
de substraten.
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  ﺧﻼﺻﮫ ﻓﺎرﺳﯽ
 ﺧﻼﺻﮫ ﻓﺎرﺳﯽ
 ﻣﻘﺪﻣﮫ
ﺳﯽ ھﺎ( ﯾﺎ ﮔﻠﯿﮑﻮزﯾﺪھﺎی ﻗﻠﺒﯽ ﺑﮫ ﻋﻨﻮان ﯾﮏ وﺳﯿﻠﮫ دﻓﺎﻋﯽ ﺗﻮﺳﻂ ﮔﯿﺎھﺎﻧﯽ ﭼﻮن ﮔﻞ اﻧﮕﺸﺘﺎﻧﮫ و  ال ﻣﻮاد ﺷﺒﮫ دﯾﺠﯿﺘﺎﻟﯿﺲ )دی
ﺳﻨﺘﯽ ﻧﺎرﺳﺎﯾﯽ ﻗﻠﺒﯽ و ﻓﯿﺒﺮﯾﻼﺳﯿﻮن دھﻠﯿﺰی ﺷﻨﺎﺧﺘﮫ  ﺷﻮﻧﺪ. اﯾﻦ ﻣﻮاد ﺑﮫ ﻋﻨﻮان درﻣﺎن ﺟﺎﻧﻮراﻧﯽ ﭼﻮن وزغ ﺑﻮﻓﻮﺑﻮﻓﻮ ﺗﻮﻟﯿﺪ ﻣﯽ
ﺗﻮﮐﺴﯿﻦ ﺟﮭﺖ اھﺪاف درﻣﺎﻧﯽ ﻣﻮرد اﺳﺘﻔﺎده ﻗﺮار  ھﺎﯾﯽ از اﯾﻦ ﻣﻮاد ﻣﺎﻧﻨﺪ دﯾﮕﻮﮐﺴﯿﻦ و دﯾﺠﯽ ﻧﻤﻮﻧﮫاﻧﺪ. در ﺣﺎل ﺣﺎﺿﺮ،  ﺷﺪه
ھﺎی  ﻓﯿﺰﯾﮑﯽ و ﻓﺎرﻣﺎﮐﻮﻟﻮژﯾﮑﯽ، ھﻤﮕﯽ ﺟﺰو ﻣﮭﺎرﮐﻨﻨﺪه-ھﺎی ﻣﺘﻔﺎوت ﺷﯿﻤﯽ ﮔﯿﺮﻧﺪ. ﻣﻮاد ﺷﺒﮫ دﯾﺠﯿﺘﺎﻟﯿﺲ ﺑﺎ وﺟﻮد وﯾﮋﮔﯽ ﻣﯽ
ی اﯾﻦ ﻣﻮاد و اﺛﺮات ﺟﺎﻧﺒﯽ آﻧﮭﺎ ﺳﺒﺐ ﺷﺪه ﺗﺎ  ﮐﺸﻨﺪه ﺷﻮﻧﺪ. ﺗﻔﺎوت ﻧﺎﭼﯿﺰ ﺑﯿﻦ دوز درﻣﺎﻧﯽ و دوز ﭘﺘﺎﺳﯿﻢ ﻣﺤﺴﻮب ﻣﯽ-ﭘﻤﭗ ﺳﺪﯾﻢ
. ﺗﺪاﺧﻼت داروﯾﯽ در ﺳﻄﺢ ﻧﺎﻗﻠﯿﻦ ﻧﺪﮔﺮدﻧﺪ، ﻗﺮار ﮔﯿﺮ اﯾﻦ ﻣﻮاد در ﺑﯿﻦ ده داروﯾﯽ ﮐﮫ ﻣﻨﺠﺮ ﺑﮫ ﺑﺴﺘﺮی ﺷﺪن در ﺑﯿﻤﺎرﺳﺘﺎن ﻣﯽ
و ﻣﺮگ ﺣﺎﺻﻞ  ﺳﯽ ھﺎ در ﭘﻼﺳﻤﺎ و ﻧﮭﺎﯾﺘﺎ ﻣﺴﻤﻮﻣﯿﺖ ال ﺗﺮﯾﻦ ﻋﻮاﻣﻞ ﺑﺎﻻ رﻓﺘﻦ ﻏﻠﻈﺖ دی داروﯾﯽ )ﺗﺮاﻧﺴﭙﻮرﺗﺮھﺎ( ﯾﮑﯽ از ﻣﮭﻢ
 ﺷﻮد.  از اﯾﻦ داروھﺎ ﻣﺤﺴﻮب ﻣﯽ
ﮐﻨﻨﺪ.  در ﺑﺪن ﺟﻠﻮﮔﯿﺮی ﻣﯽ و ﻣﻮاد ﺳﻤﯽ ﻣﻐﺰی، ﮐﺒﺪ، روده و ﮐﻠﯿﮫ ﻗﺮار ﮔﺮﻓﺘﮫ و از ﺗﺠﻤﻊ داروھﺎ-ﻧﺎﻗﻠﯿﻦ داروﯾﯽ در ﺳﺪ ﺧﻮﻧﯽ
 داروھﺎ را از ﮐﮫ ﯾﻨﺪآ ( ﺟﺰو ﻧﺎﻗﻠﯿﻦ داروﯾﯽ اﻓﻼﮐﺲ ﺑﮫ ﺷﻤﺎر ﻣﯽCBA ,ettessac gnidnib-PTAھﺎی ) ﺧﺎﻧﻮاده ﭘﺮوﺗﺌﯿﻦ
دھﻨﺪه  ﭘﻠﯽ ﭘﭙﺘﯿﺪھﺎی اﻧﺘﻘﺎل ﻣﺎﻧﻨﺪاﯾﻨﻔﻼﮐﺲ  ﯾﯽ. ﻧﺎﻗﻠﯿﻦ داروﮐﻨﻨﺪ ھﺎ ﺑﮫ ﺧﻮن، ﺻﻔﺮا، ﻟﻮﻣﻦ روده و ادرار ﻣﻨﺘﻘﻞ ﻣﯽ داﺧﻞ ﺳﻠﻮل
ھﺎ ﺗﻮﺳﻂ ﮐﺒﺪ و ﮐﻠﯿﮫ اﻧﺘﻘﺎل  ھﺎ ﺟﮭﺖ دﻓﻊ آن ( داروھﺎ را از ﻣﺤﯿﻂ ﺧﺎرج ﺳﻠﻮﻟﯽ ﺑﮫ داﺧﻞ ﺳﻠﻮلPTAOھﺎی ارﮔﺎﻧﯿﮏ ) آﻧﯿﻮن
در ھﺮ دو ﺳﻄﺢ ﻧﺎﻗﻠﯿﻦ اﯾﻔﻼﮐﺲ و اﯾﻨﻔﻼﮐﺲ رخ دھﻨﺪ و دﻓﻊ داروھﺎ را ﮐﮫ ﯾﮑﯽ از ﻋﻮاﻣﻞ  ﺗﻮاﻧﻨﺪ دھﻨﺪ. ﺗﺪاﺧﻼت داروﯾﯽ ﻣﯽ ﻣﯽ
 ﮐﻠﯿﺪی در اﯾﻤﻨﯽ و اﺛﺮﺑﺨﺸﯽ داروھﺎ اﺳﺖ، ﺗﺤﺖ ﺗﺎﺛﯿﺮ ﻗﺮار دھﻨﺪ. 
ﮐﻨﺶ ﻣﻮاد ﺷﺒﮫ دﯾﺠﯿﺘﺎﻟﯿﺲ و ﻧﺎﻗﻠﯿﻦ داروﯾﯽ اﻓﻼﮐﺲ و اﯾﻨﻔﻼﮐﺲ ﭘﺮداﺧﺘﯿﻢ. ھﻤﭽﻨﯿﻦ، اﺛﺮ  ﻧﺎﻣﮫ، ﺑﮫ ﻣﻄﺎﻟﻌﮫ ﺑﺮھﻢ در اﯾﻦ ﭘﺎﯾﺎن
ﺑﮫ   ﻧﯿﺰ ﺳﯽ ھﺎﯾﯽ ال ﮐﻨﺶ ﺑﯿﻦ ﻧﺎﻗﻠﯿﻦ داروﯾﯽ و اﯾﻦ ﻣﻮاد ﻣﻮردﺑﺮرﺳﯽ ﻗﺮار ﮔﺮﻓﺘﮫ و دی ﺳﯽ ھﺎ ﺑﺮ ﺑﺮھﻢ ال ﺎر ﺷﯿﻤﯿﺎﯾﯽ دیﺳﺎﺧﺘ
 ﺷﻨﺎﺳﺎﯾﯽ آﻣﯿﻨﻮاﺳﯿﺪ ھﺎﯾﯽ ﮐﮫ در ﻋﻤﻠﮑﺮد ردر ﮐﻨﺎ ﻋﻨﻮان ﺳﻮﺑﺴﺘﺮای ﻧﺎﻗﻠﯿﻦ اﻓﻼﮐﺲ و اﯾﻨﻔﻼﮐﺲ ﺷﻨﺎﺳﺎﯾﯽ ﺷﺪﻧﺪ. ﻋﻼوه ﺑﺮاﯾﻦ،
ﮐﻨﺶ ﺑﺎ ﻧﺎﻗﻠﯿﻦ داروﯾﯽ، ﺑﮫ ﻋﻨﻮان  ﻼش ﺷﺪه اﺳﺖ ﺗﺎ ﻣﻮاد ﺷﺒﮫ دﯾﺠﯿﺘﺎﻟﯽ ﺑﺎ ﺣﺪاﻗﻞ ﺑﺮھﻢ، ﺗﻧﻘﺶ داﺷﺘﻨﺪ (pg-Pﮔﻠﯿﮑﻮﭘﺮوﺗﺌﯿﻦ )-ﭘﯽ
 ﺗﻮﮐﺴﯿﻦ اراﺋﮫ ﺷﻮﻧﺪ.  ﺟﺎﯾﮕﺰﯾﻦ ﻣﻨﺎﺳﺐ ﺑﺮای دﯾﮕﻮﮐﺴﯿﻦ و دﯾﺠﯽ
 
 ﻧﻘﺶ ﻧﺎﻗﻠﯿﻦ اﻓﻼﮐﺲ در دﻓﻊ ﻣﻮاد ﺷﺒﮫ دﯾﺠﯿﺘﺎﻟﯿﺲ از ﺑﺪن
ﻧﺤﻮه ﺗﻮزﯾﻊ و ﻋﻤﻠﮑﺮد ﻧﺎﻗﻠﯿﻦ اﻓﻼﮐﺲ در ﺑﺪن ﻧﻘﺶ ﮐﻠﯿﺪی در ﺟﺬب، ﺗﻮزﯾﻊ، ﻣﺘﺎﺑﻮﻟﯿﺴﻢ و دﻓﻊ داروھﺎ دارد. اﻟﻘﺎ ﯾﺎ ﻣﮭﺎر ﻧﺎﻗﻠﯿﻦ 
ھﺎی  ، ﺑﺎ اﺳﺘﻔﺎده از وزﯾﮑﻮلﻓﺼﻞ دوداروﯾﯽ، ﻣﮑﺎﻧﯿﺴﻢ اﺻﻠﯽ ﺗﺪاﺧﻼت داروﯾﯽ و اﺛﺮات ﺟﺎﻧﺒﯽ ﺣﺎﺻﻞ از آﻧﮭﺎ اﺳﺖ. ﻣﺎ در 
،  2GCBA/PRCBﮐﮫ ﺑﯿﺸﺘﺮ دی ال ﺳﯽ ھﺎ ﺑﺎ ﻧﺎﻗﻠﯿﻦ داروﯾﯽ ﮐﺮدﻧﺪ، ﻧﺸﺎن دادﯾﻢ ﻣﯽھﺎی ﻧﺎﻗﻞ را ﺑﯿﺎن  ﻏﺸﺎﯾﯽ ﮐﮫ ﭘﺮوﺗﺌﯿﻦ
ﺑﺮھﻤﮑﻨﺶ  4CCBA/4PRM و 2CCBA/2PRM ، 3CCBA/3PRM،1CCBA/1PRM، 11BCBA/PESB
ﻧﻤﻮدﻧﺪ.   را ﮐﺎﻣﻼ ﻣﮭﺎر ﻣﯽ PRCBﭘﺮوﺗﺌﯿﻦ  ﻋﻤﻠﮑﺮد ﺗﻮﮐﺴﯿﻦ و ﭘﺮواوﺳﺎﯾﺪ ﻣﯿﮑﺮوﻣﻮﻻر دﯾﮕﻮﮐﺴﯿﻦ، دﯾﺠﯽ ٠٠٠١. دارﻧﺪ
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درﺻﺪ  ٠۵را ﺗﺎ  PESBﺑﻮد درﺣﺎﻟﯽ ﮐﮫ ﭘﺮواوﺳﺎﯾﺪ و اﺳﺘﺮوﻓﺎﻧﺘﯿﺪول ﻋﻤﻠﮑﺮد  PESBﻨﮭﺎ ﻣﮭﺎرﮐﻨﻨﺪه ﭘﺮوﺗﺌﯿﻦ ﺗﻮﮐﺴﯿﻦ ﺗ دﯾﺠﯽ
ﻧﻤﻮد. اﮔﺮﭼﮫ  ﻣﮭﺎر ﻣﯽ 4PRMرا ﺑﺎ ﻗﺪرت ﺑﯿﺸﺘﺮی در ﻣﻘﺎﯾﺴﮫ ﺑﺎ  3PRMو  1PRMﻣﮭﺎر ﻧﻤﻮدﻧﺪ. ھﻤﭽﻨﯿﻦ اﺳﺘﺮوﻓﺎﻧﺘﯿﺪول، 
را  2PRMﺗﻮﮐﺴﯽ ژﻧﯿﻦ ﻋﻤﻠﮑﺮد  ﮫ ﯾﺎﻓﺖ ﻧﺸﺪ، دﯾﺠﯽدرﻣﯿﺎن داروھﺎی ﻣﻮرد ﻣﻄﺎﻟﻌ 2PRMای ﺑﺮای ﭘﺮوﺗﺌﯿﻦ  ھﯿﭻ ﻣﮭﺎرﮐﻨﻨﺪه
 ﻧﻤﻮد. ﺑﺮاﺑﺮ ﮐﻨﺘﺮل، ﺗﺤﺮﯾﮏ ﻣﯽ ۶٫٣
ﺳﺎﺧﺘﺎر ﺷﯿﻤﯿﺎﯾﯽ دی ال ﺳﯽ ھﺎ از ﯾﮏ ﺣﻠﻘﮫ ﻣﺮﮐﺰی اﺳﺘﺮوﺋﯿﺪی ﺗﺸﮑﯿﻞ ﺷﺪه ﮐﮫ دارای ﯾﮏ ﮔﺮوه ﻗﻨﺪی ﯾﺎ ﯾﮏ ﮔﺮوه 
و  ۶١، ٢١، ١١، ۵، ١ﺷﻤﺎره  ﻣﯽ ﺑﺎﺷﺪ. ﮐﺮﺑﻦ ھﺎی ٧١ و ﯾﮏ ﺣﻠﻘﮫ ﻻﮐﺘﻮﻧﯽ روی ﮐﺮﺑﻦ ٣ﺷﻤﺎره  ھﯿﺪروﮐﺴﯿﻞ روی ﮐﺮﺑﻦ
ھﺎی  ﻣﺎ ﻧﺸﺎن دادﯾﻢ ﮐﮫ ﮔﺮوه .ﻧﯿﺰ ﻣﯽ ﺗﻮاﻧﻨﺪ دارای ﮔﺮوه ھﺎی ھﯿﺪروﮐﺴﯿﻞ و در ﺑﻌﻀﯽ ﻣﻮرد دارای ﮔﺮوه ﮐﺮﺑﻮﻧﯿﻞ ﺑﺎﺷﻨﺪ ٩١
، ﺑﺮھﻢ ﮐﻨﺶ ٩١و  ۶١، ٢١، ٣ھﺎی ﺷﻤﺎره  ﺑﮫ ﺻﻮرت ھﻤﺰﻣﺎن، و ﮐﺮﺑﻦ ١١و  ١ھﺎی ﺷﻤﺎره  ﮐﺮﺑﻦ رویﺷﯿﻤﯿﺎﯾﯽ ﻣﻮﺟﻮد 
-ﺳﯽ ھﺎ ﺑﺮ ﭘﻤﭗ ﺳﺪﯾﻢ ال دھﻨﺪ. ھﻤﭽﻨﯿﻦ اﺛﺮ ﻣﮭﺎری دی ھﺎ را ﺗﺤﺖ ﺗﺎﺛﯿﺮ ﻗﺮار ﻣﯽPRMو  PESB، PRCBﺳﯽ ھﺎ ﺑﺎ  ال دی
ھﺎ PRMو  PESB، PRCBﮐﻨﻨﺪه  ھﺎی ﻏﺸﺎﯾﯽ ﺑﯿﺎن وزﯾﮑﻮل ﺗﻮﺳﻂﺳﯽ ھﺎ  ال دی ﺟﺬبﭘﺘﺎﺳﯿﻢ ﻣﻮرد اﺳﺘﻔﺎده ﻗﺮار ﮔﺮﻓﺖ ﺗﺎ 
ﮐﺪام ﺑﮫ ﺟﺰ ﮐﻮﻧﻮاﻻﺗﻮﮐﺴﯿﻦ  اﺷﺘﻨﺪ، اﻣﺎ ھﯿﭻﮐﻨﺶ د ﺳﯽ ھﺎ ﺑﺎ ﻧﺎﻗﻠﯿﻦ اﻓﻼﮐﺲ ذﮐﺮﺷﺪه در ﺑﺎﻻ ﺑﺮھﻢ ال ﺑﺮرﺳﯽ ﺷﻮد. اﮔﺮﭼﮫ اﮐﺜﺮ دی
 ﮔﺮدﯾﺪ، ﺑﮫ ﻋﻨﻮان ﺳﻮﺑﺴﺘﺮا ﺷﻨﺎﺳﺎﯾﯽ ﻧﺸﺪﻧﺪ.  )ﻓﺼﻞ ﭼﮭﺎر( ﻣﻨﺘﻘﻞ ﻣﯽ pg-Pﮐﮫ ﺗﻮﺳﻂ 
ﮔﻠﯿﮑﻮﭘﺮوﺗﺌﯿﻦ ﭘﺮداﺧﺘﯿﻢ. -ﮐﻨﻨﺪه ﭘﯽ ھﺎی ﻏﺸﺎﯾﯽ ﺑﯿﺎن ﺳﯽ ھﺎ در وزﯾﮑﻮل ال ، ﻣﺎ ﺑﮫ ﻣﻄﺎﻟﻌﮫ ﮔﺮوھﯽ از دیﻓﺼﻞ ﺳﮫدر 
ﮔﻠﯿﮑﻮﭘﺮوﺗﺌﯿﻦ ﺷﻨﺎﺳﺎﯾﯽ ﺷﺪﻧﺪ و دﯾﮕﻮﮐﺴﯿﻦ، ﭘﺮواوﺳﺎﯾﺪ و -ھﺎی ﭘﯽ ﺮﯾﻦ ﻣﮭﺎرﮐﻨﻨﺪهﺗ ﺗﻮﮐﺴﯿﻦ و ﭘﺮاﺳﯿﻼرﯾﺪﯾﻦ ﺑﮫ ﻋﻨﻮان ﻗﻮی دﯾﺠﯽ
دﻟﺘﺎ و ﮔﺮوه ﻗﻨﺪی ﻣﻮﺟﻮد -درﺻﺪ ﻣﮭﺎر ﻧﻤﻮدﻧﺪ. ﻣﺎ ﻧﺸﺎن دادﯾﻢ ﮐﮫ ﺣﻠﻘﮫ ﻻﮐﺘﻮﻧﯽ ٠۵اﺳﺘﺮوﻓﺎﻧﺘﯿﺪول ﻋﻤﻠﮑﺮد اﯾﻦ ﭘﺮوﺗﺌﯿﻦ را ﺗﺎ 
ھﺎی ھﯿﺪروﮐﺴﯿﻞ  . ھﻤﭽﻨﯿﻦ، اﮔﺮﭼﮫ ﮔﺮوهﮐﻨﻨﺪ ﮔﻠﯿﮑﻮﭘﺮوﺗﺌﯿﻦ را ﺗﺴﮭﯿﻞ ﻣﯽ-ﺳﯽ ھﺎ ﺑﺎ ﭘﯽ ال ﺑﺘﺎ، ﺑﺮھﻢ ﮐﻨﺶ دی-٣روی ﮐﺮﺑﻦ 
، ١ھﺎی دھﻨﺪ، در ﺻﻮرت ﻗﺮارﮔﯿﺮی روی ﮐﺮﺑﻦ  ﺳﯽ ھﺎ را اﻓﺰاﯾﺶ ﻣﯽ ال ، اﺛﺮ ﻣﮭﺎری دی٩١و  ۵ﻣﻮﺟﻮد روی ﮐﺮﺑﻦ ھﺎی 
 ﺳﯽ ھﺎ را ﮐﺎھﺶ دھﻨﺪ. ال ﺗﻮاﻧﻨﺪ اﺛﺮ ﻣﮭﺎری دی ﻣﯽ ۶١و  ٢١، ١١
ﺑﮫ آﻻﻧﯿﻦ ﺟﮭﺶ داده ﺷﺪﻧﺪ. ﺟﮭﺶ  pg-P، ده آﻣﯿﻨﻮاﺳﯿﺪ pg-Pﺳﯽ ھﺎ ﺑﺎ  ال ھﺎی ﮐﻠﯿﺪی در ﺑﺮھﻢ ﮐﻨﺶ دی ﺟﮭﺖ ﺗﻌﯿﯿﻦ آﻣﯿﻨﻮاﺳﯿﺪ
-Pﺑﮫ آﻻﻧﯿﻦ، ﺳﺒﺐ از دﺳﺖ رﻓﺘﻦ ﻋﻤﻠﮑﺮد  ۵٧٩و ﻟﻮﺳﯿﻦ  ۵۴٩، ﺗﺮﺋﻮﻧﯿﻦ ٨٢٧آﻻﻧﯿﻦ  ، ﻓﻨﯿﻞ٣۴٣آﻻﻧﯿﻦ  ، ﻓﻨﯿﻞ۶٠٣اﯾﺰوﻟﻮﺳﯿﻦ 
ﻣﺎرﯾﻦ  ( ﺷﺪﻧﺪ. ﺗﻤﺎﯾﻞ دﯾﮕﻮﮐﺴﯿﻦ، ﭘﺮاﺳﯿﻼرﯾﺪﯾﻦ، ﭘﺮواوﺳﺎﯾﺪ و ﺳﯽQMNﻣﺘﯿﻞ ﮐﯿﻨﯿﺪﯾﻦ )-، انﺳﻮﺑﺴﺘﺮای ﻣﺪل آن در اﻧﺘﻘﺎل pg
ﺑﮫ آﻻﻧﯿﻦ، دو ﺗﺎ ﭼﮭﺎر ﺑﺮاﺑﺮ ﻧﺴﺒﺖ ﺑﮫ ﺣﺎﻟﺖ وﺣﺸﯽ ﭘﺮوﺗﺌﯿﻦ  ٠۴٣و اﯾﺰوﻟﻮﺳﯿﻦ  ۶٣٣آﻻﻧﯿﻦ  ھﺎی دارای ﺟﮭﺶ ﻓﻨﯿﻞ ﺑﮫ ﭘﺮوﺗﺌﯿﻦ
ﻓﺎﻗﺪ ﺗﻐﯿﯿﺮ ﺑﻮد. ھﻤﭽﻨﯿﻦ در ھﺎی ﺟﮭﺶ ﯾﺎﻓﺘﮫ  ﺗﻮﮐﺴﯿﻦ و اﺳﺘﺮوﻓﺎﻧﺘﯿﺪول ﺑﺮای اﯾﻦ ﭘﺮوﺗﺌﯿﻦ ﮐﺎھﺶ ﯾﺎﻓﺖ. درﺣﺎﻟﯽ ﮐﮫ ﺗﻤﺎﯾﻞ دﯾﺠﯽ
ﺑﺘﺎ ﺳﺒﺐ ﮐﺎھﺶ -٢١رﺳﺪ ﮐﮫ وﺟﻮد ﮔﺮوه ھﯿﺪروﮐﺴﯿﻞ در ﻣﻮﻗﻌﯿﺖ  ﺗﻮﮐﺴﯿﻦ، ﺑﮫ ﻧﻈﺮ ﻣﯽ ی دﯾﮕﻮﮐﺴﯿﻦ ﺑﺎ دﯾﺠﯽ ﺻﻮرت ﻣﻘﺎﯾﺴﮫ
 ﺷﻮد.  ﺑﮫ آﻻﻧﯿﻦ ﻣﯽ ٢۴٩آﻻﻧﯿﻦ  و ﻓﻨﯿﻞ ۶٣٣آﻻﻧﯿﻦ  ھﺎی دارای ﺟﮭﺶ ﻓﻨﯿﻞ ﺳﯽ ھﺎ ﺑﮫ ﭘﺮوﺗﺌﯿﻦ ال ﺗﻤﺎﯾﻞ دی
-ھﺎی ﻏﺸﺎﯾﯽ ﺑﺎ اﺳﺘﻔﺎده از ﺗﮑﻨﯿﮏ ﮐﺮوﻣﺎﺗﻮﮔﺮاﻓﯽ ﻣﺎﯾﻊ ﺳﯽ ھﺎ در وزﯾﮑﻮل ال دیﮔﯿﺮی ﻏﻠﻈﺖ  ﺑﺎ اﻧﺪازهﻓﺼﻞ ﭼﮭﺎر در 
ﭘﺮداﺧﺘﯿﻢ. ﮐﻮﻧﻮاﻻﺗﻮﮐﺴﯿﻦ، ﺳﻢ ﻣﻮﺟﻮد در  pg-Pﺳﯽ ﺗﻮﺳﻂ  ال (، ﺑﮫ ﺑﺮرﺳﯽ اﻧﺘﻘﺎل ﭼﮭﺎرده دیSM-CLﺳﻨﺠﯽ ﺟﺮﻣﯽ ) طﯿﻒ
ﺑﮫ ھﻤﺮاه اﻻﮐﺮﯾﺪار ھﺎی ﻏﺸﺎﯾﯽ ﺷﻨﺎﺳﺎﯾﯽ ﺷﺪ. ﺗﺰرﯾﻖ ﮐﻮﻧﻮاﻻﺗﻮﮐﺴﯿﻦ  در وزﯾﮑﻮل pg-Pﮔﻞ ﻣﻮﮔﮫ، ﺑﮫ ﻋﻨﻮان ﺳﻮﺑﺴﺘﺮای 
ھﺎی ﺻﺤﺮاﯾﯽ، ﺳﺒﺐ اﻓﺰاﯾﺶ ﻏﻠﻈﺖ ﮐﻮﻧﻮاﻻﺗﻮﮐﺴﯿﻦ در ﻣﻐﺰ و ﮐﻮرﺗﮑﺲ ﮐﻠﯿﮫ ﮔﺮدﯾﺪ ﮐﮫ  ( ﺑﮫ ﻣﻮشpg-P)ﻣﮭﺎرﮐﻨﻨﺪه 
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  ﺧﻼﺻﮫ ﻓﺎرﺳﯽ
ﮐﮫ در اﻧﺘﻘﺎل ﮐﻮﻧﻮاﻻﺗﻮﮐﺴﯿﻦ ﻧﻘﺶ دارﻧﺪ، ﻧﮫ  pg-Pدر اﻧﺘﻘﺎل اﯾﻦ ﻣﺎده ﺑﻮد. ﺑﺮای ﺗﻌﯿﯿﻦ آﻣﯿﻨﻮاﺳﯿﺪھﺎی  pg-Pدھﻨﺪه ﻧﻘﺶ  ﻧﺸﺎن
ھﺎ در  ﯾﺎﻓﺘﮫ در اﻧﺘﻘﺎل ﮐﻮﻧﻮاﻻﺗﻮﮐﺴﯿﻦ ﺑﺎ ﻋﻤﻠﮑﺮد آن ھﺎی ﺟﮭﺶ ﺶ داده ﺷﺪﻧﺪ و ﻋﻤﻠﮑﺮد ﭘﺮوﺗﺌﯿﻦﺑﮫ آﻻﻧﯿﻦ ﺟﮭ pg-Pآﻣﯿﻨﻮاﺳﯿﺪ 
، pg-Pﻧﺴﺒﺖ ﺑﮫ اﻧﺘﻘﺎل ﮐﻮﻧﻮاﻻﺗﻮﮐﺴﯿﻦ ﺗﻮﺳﻂ  QMNدر اﻧﺘﻘﺎل  ٣۴٣آﻻﻧﯿﻦ  ﻣﻘﺎﯾﺴﮫ ﮔﺮدﯾﺪ. ﻣﺎ درﯾﺎﻓﺘﯿﻢ ﮐﮫ ﻓﻨﯿﻞ QMNاﻧﺘﻘﺎل 
 رود.  ﺘﻘﺎل ﮐﻮﻧﻮاﻻﺗﻮﮐﺴﯿﻦ ﺑﮫ ﺷﻤﺎر ﻣﯽآﻣﯿﻨﻮاﺳﯿﺪ ﺿﺮوری ﺟﮭﺖ اﻧ ،٢٨٩ﺗﺮی دارد درﺣﺎﻟﯽ ﮐﮫ واﻟﯿﻦ  ﻧﻘﺶ ﻣﮭﻢ
ﮐﻨﻨﺪﮔﺎن ﺳﻠﻮﻟﯽ درﺑﺮاﺑﺮ ﺗﺠﻤﻊ  ﻧﻘﺶ ﻧﺎﻗﻠﯿﻦ اﻓﻼﮐﺲ ﺑﮫ ﻋﻨﻮان ﻣﺤﺎﻓﻈﺖ ﺑﺮرﺳﯽ، از ﺗﺴﺖ ﺗﺠﻤﻊ ﺳﻠﻮﻟﯽ ﺟﮭﺖ ﻓﺼﻞ ﭘﻨﺞدر 
ژﻧﯿﻦ،  ﺗﻮﮐﺴﯿﻦ، دﯾﮕﻮﮐﺴﯽ ( و اﻧﺴﺎن اﺳﺘﻔﺎده ﺷﺪ. ﻣﺎ ﻧﺸﺎن دادﯾﻢ ﮐﮫ دﯾﺠﯽKCDMﺳﮓ ) ﮐﻠﯿﻮیھﺎی  ﺳﯽ ھﺎ در ﺳﻠﻮل ال دی
ھﺎی ﮐﻠﯿﻮی ﺳﮓ و اﻧﺴﺎن ھﺴﺘﻨﺪ، درﺣﺎﻟﯽ ﮐﮫ اﯾﻦ ﻣﻮاد ﺑﮫ ﻋﻨﻮان  در ﺳﻠﻮل pg-Pﭘﺮاﺳﯿﻼرﯾﺪﯾﻦ، ﺳﻮﺑﺴﺘﺮای  اﺳﺘﺮوﻓﺎﻧﺘﯿﺪﯾﻦ و
در ﻓﺼﻞ ﭼﮭﺎر  pg-Pھﺎی ﻏﺸﺎﯾﯽ ﺷﻨﺎﺳﺎﯾﯽ ﻧﺸﺪﻧﺪ. ﮐﻮﻧﻮاﻻﺗﻮﮐﺴﯿﻦ ﮐﮫ ﺑﮫ ﻋﻨﻮان ﺳﻮﺑﺴﺘﺮای  در وزﯾﮑﻮل pg-Pﺳﻮﺑﺴﺘﺮای 
ھﺎ ﻧﯿﺎزﻣﻨﺪ  ﺪ. ﻋﻤﻠﮑﺮد ﯾﮏ ﻧﺎﻗﻞ اﯾﻔﻼﮐﺲ در ﺳﻠﻮلﺷﻨﺎﺳﺎﯾﯽ ﺷﺪه ﺑﻮد، در ﺗﺴﺖ ﺗﺠﻤﻊ ﺳﻠﻮﻟﯽ ﺑﮫ ﻋﻨﻮان ﺳﻮﺑﺴﺘﺮا ﺷﻨﺎﺳﺎﯾﯽ ﻧﺸ
ھﺎی ﻏﺸﺎﯾﯽ ﺑﯿﺸﺘﺮ ﺑﺮای ﻣﻮاد  ﺑﺎﺷﺪ درﺣﺎﻟﯽ ﮐﮫ وزﯾﮑﻮل دوﺳﺖ ﺑﮫ داﺧﻞ ﺳﻠﻮل ﺑﮫ ﺻﻮرت ﻏﯿﺮﻓﻌﺎل ﻣﯽ ورود ﻣﻮاد ﭼﺮﺑﯽ
دوﺳﺘﯽ ﻣﺎﻧﻨﺪ  ﺳﯽ ھﺎی ﭼﺮﺑﯽ ال ﺗﻮاﻧﻨﺪ از ﻏﺸﺎ ﺑﮫ ﺻﻮرت ﻏﯿﺮﻓﻌﺎل ﻋﺒﻮر ﮐﻨﻨﺪ، ﻣﻨﺎﺳﺐ اﺳﺖ. ﺑﻨﺎﺑﺮاﯾﻦ دی آﺑﺪوﺳﺘﯽ ﮐﮫ ﻧﻤﯽ
ھﺎی ﻏﺸﺎﯾﯽ ﻗﺎﺑﻞ  در وزﯾﮑﻮل pg-Pژﻧﯿﻦ، اﺳﺘﺮوﻓﺎﻧﺘﯿﺪﯾﻦ و ﭘﺮاﺳﯿﻼرﯾﺪﯾﻦ ﺑﮫ ﻋﻨﻮان ﺳﻮﺑﺴﺘﺮای  ﺗﻮﮐﺴﯿﻦ، دﯾﮕﻮﮐﺴﯽ دﯾﺠﯽ
ﺳﻠﻮﻟﯽ ﻋﻤﻞ  ﺗﺴﺖدر  pg-Pﺷﻨﺎﺳﺎﯾﯽ ﻧﯿﺴﺘﻨﺪ درﺣﺎﻟﯽ ﮐﮫ ﻣﻮاد آﺑﺪوﺳﺘﯽ ﭼﻮن ﮐﻮﻧﻮاﻻﺗﻮﮐﺴﯿﻦ ﻧﯿﺰ ﺑﮫ ﻋﻨﻮان ﺳﻮﺑﺴﺘﺮای 
ھﺎی ﺳﻠﻮﻟﯽ ﻗﺎﺑﻞ  ـ و ﯾﺎ ﺑﺎﻻﺗﺮ در ﺗﺴﺖ٣٫٠ﯿﮏ اﮐﺘﺎﻧﻮل ﺑﮫ آب ﮐﻨﻨﺪ. ھﻤﭽﻨﯿﻦ ﻣﺎ ﻧﺸﺎن دادﯾﻢ ﮐﮫ ﺳﻮﺑﺴﺘﺮاھﺎﯾﯽ ﺑﺎ ﺿﺮﯾﺐ ﺗﻔﮑ ﻧﻤﯽ
 ﻣﻄﺎﻟﻌﮫ و ﺷﻨﺎﺳﺎﯾﯽ ھﺴﺘﻨﺪ.
 
 ھﺎ از ﺑﺪن ﻧﻘﺶ ﻧﺎﻗﻠﯿﻦ اﯾﻨﻔﻼﮐﺲ در دﻓﻊ ﺳﻠﻮل
و  1B1OCLS/1B1PTAO، 1A01CLS/PCTNﮐﻨﺶ ﻧﺎﻗﻠﯿﻨﯽ ﭼﻮن  ، ﺑﮫ ﻣﻄﺎﻟﻌﮫ ﺑﺮھﻢﻓﺼﻞ ﺷﺶدر 
ﺗﺮﯾﻦ ﻣﮭﺎرﮐﻨﻨﺪه  ﻣﻄﺎﻟﻌﮫ، ﭘﺮاﺳﯿﻼرﯾﺪﯾﻦ ﺑﮫ ﻋﻨﻮان ﻗﻮیدر اﯾﻦ ﺳﯽ ھﺎ در ﺳﻠﻮل ﭘﺮداﺧﺘﯿﻢ.  ال ﺑﺎ دی 3B1OCLS/3B1PTAO
 3B1PTAOو  1B1PTAOھﺎی  ﺗﺮﯾﻦ ﻣﮭﺎرﮐﻨﻨﺪه ﺑﮫ ﻋﻨﻮان ﻗﻮی ﺑﮫ ﺗﺮﺗﯿﺐ ﺗﻮﮐﺴﯽ ژﻧﯿﻦ ﺗﻮﮐﺴﯿﻦ و دﯾﺠﯽ و دﯾﺠﯽ PCTN
ﺗﻮﺳﻂ اﯾﻦ ﻣﻮاد  1B1PTAOﺳﯽ ھﺎ ﺳﺒﺐ ﺗﺴﮭﯿﻞ ﻣﮭﺎر  ال دی ٣ﺷﻨﺎﺳﺎﯾﯽ ﺷﺪﻧﺪ. ﻋﻼوه ﺑﺮاﯾﻦ وﺟﻮد ﮔﺮوه ﻗﻨﺪی روی ﮐﺮﺑﻦ 
 ٢١ﮐﺮﺑﻦ  رویوﺟﻮد ﮔﺮوه ھﯿﺪروﮐﺴﯿﻞ  ﭼﮫﮔﺮدﯾﺪ. اﮔﺮ ﻣﯽ 3B1PTAOو  PCTNﺎﻟﯽ ﮐﮫ ﺳﺒﺐ ﮐﺎھﺶ ﻣﮭﺎر ﺷﺪ، درﺣ ﻣﯽ
ﺗﻮﺳﻂ اﯾﻦ ﮔﺮوه ﺷﯿﻤﯿﺎﯾﯽ ﮐﺎھﺶ  3B1PTAOو  1B1PTAOداد، ﻣﮭﺎر ﻋﻤﻠﮑﺮد  را اﻓﺰاﯾﺶ ﻣﯽ PCTNﺳﯽ ھﺎ، ﻣﮭﺎر  ال دی
 3B1PTAOو واﺑﺎژﻧﯿﻦ ﺑﮫ ﻋﻨﻮان ﺳﻮﺑﺴﺘﺮای  ھﯿﺪرو واﺑﺎﺋﯿﻦ ﯾﺎﻓﺖ. در اﯾﻨﺠﺎ، ﺑﺮای اوﻟﯿﻦ ﺑﺎر ﮐﻮﻧﻮاﻻﺗﻮﮐﺴﯿﻦ، واﺑﺎﺋﯿﻦ، دی ﻣﯽ
ﻋﻨﻮان ﺳﻄﺤﯽ ﺑﺮای ﺑﺮوز ﺗﺪاﺧﻼت داروﯾﯽ  ،ﺟﺬب داروھﺎ در ﮐﺒﺪ ھﺴﺘﻨﺪ ﻧﯿﺰ ﭘﺮوﺗﺌﯿﻦ ھﺎﯾﯽ ﮐﮫ ﻣﺴﺆولﺷﻨﺎﺳﺎﯾﯽ ﺷﺪﻧﺪ و 
 ﻣﻌﺮﻓﯽ ﮔﺮدﯾﺪﻧﺪ. 
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 اﻧﺪاز آﯾﻨﺪه ﮔﯿﺮی و ﭼﺸﻢ ﻧﺘﯿﺠﮫ
ﮐﻨﺶ ﮔﺮوھﯽ از ﻣﻮاد ﺷﺒﮫ دﯾﺠﯿﺘﺎﻟﯿﺲ ﺑﺎ ﻧﺎﻗﻠﯿﻦ اﻓﻼﮐﺲ  ، ﺟﮭﺖ ﻣﻄﺎﻟﻌﮫ ﺑﺮھﻢoviv niو  ortiv niھﺎی  ﻧﺎﻣﮫ از ﻣﺪل در اﯾﻦ ﭘﺎﯾﺎن
ﮐﻨﺶ ﺑﺎ ﻧﺎﻗﻠﯿﻦ داروﯾﯽ داﺷﺘﻨﺪ، ﺑﮫ ﻋﻨﻮان ﺟﺎﯾﮕﺰﯾﻦ  ﺳﯽ ھﺎﯾﯽ ﮐﮫ ﺣﺪاﻗﻞ ﺑﺮھﻢ ال ، دیﻓﺼﻞ ھﻔﺖو اﯾﻨﻔﻼﮐﺲ اﺳﺘﻔﺎده ﮔﺮدﯾﺪ. در 
ﮐﮫ ﮐﻤﺘﺮﯾﻦ ﺑﺮھﻢ ﮐﻨﺶ را ﺑﺎ ﻧﺎﻗﻠﯿﻦ ﺗﻮﮐﺴﯽ ژﻧﯿﻦ  ﻣﻨﺎﺳﺐ ﺑﺎ ﮐﻤﺘﺮﯾﻦ ﺗﺪاﺧﻼت داروﯾﯽ ﻣﻄﺮح ﮔﺮدﯾﺪﻧﺪ. ﺑﺮاﺳﺎس ﻣﻄﺎﻟﻌﮫ ﻣﺎ، ﺟﯽ
ﺗﺪاﺧﻼت ﺷﺎﻧﺲ ﺑﺎﻻی  ﺗﻮﮐﺴﯿﻦ ﮐﮫ دارای ﺗﻮاﻧﺪ ﺟﺎﯾﮕﺰﯾﻦ ﻣﻨﺎﺳﺒﯽ ﺑﺮای دﯾﮕﻮﮐﺴﯿﻦ و دﯾﺠﯽ اﯾﻔﻼﮐﺲ و اﯾﻨﻔﻼﮐﺲ داﺷﺖ، ﻣﯽ
دوﺳﺘﯽ  ﺑﮫ ﭼﺮﺑﯽ وزﯾﮑﻮﻟﯽ ھﺎی ﺳﻠﻮﻟﯽ و داروﯾﯽ و ﻣﺴﻤﻮﻣﯿﺖ ھﺴﺘﻨﺪ، ﺑﺎﺷﺪ. ﺷﺎﯾﺎن ذﮐﺮ اﺳﺖ ﮐﮫ از آﻧﺠﺎ ﮐﮫ ﻋﻤﻠﮑﺮد ﺗﺴﺖ
و ﺷﻨﺎﺳﺎﯾﯽ ﺳﻮﺑﺴﺘﺮاھﺎی  داروﯾﯽ ﺑﺮای ﻣﻄﺎﻟﻌﮫ ﻋﻤﻠﮑﺮد ﻧﺎﻗﻠﯿﻦ ortiv niاﺳﺖ، ﺑﮫ ﮐﺎرﮔﯿﺮی ﯾﮏ ﻧﻮع ﺗﺴﺖ  ﺳﻮﺑﺴﺘﺮاھﺎ واﺑﺴﺘﮫ
 . آﻧﮭﺎ ﮐﺎﻓﯽ ﻧﯿﺴﺖ
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List of abbreviations and glossary
 
A 
A
ABCB1 
Ala
AMP 
ANOVA 
AP1 
Asn
Asp
ATP
AV
Adenosine, a nucleobase found in DNA and RNA
Alanine, a hydrophobic amino acid
ATP-binding cassette B1/ gene name for P-gp
Alanine, a hydrophobic amino acid
Adenosine monophosphate
Analysis of variance
Activating protein 1
Asparagine, a polar amino acid
Aspartic acid, a charged amino acid
Adenosine triphosphate
Atrioventricular           
BCRP
BSA
BSEP
Breast cancer resistance protein
Bovine serum albumin                                                                                     
Bile salt export pump
C
Caco-2
CHO
ciPTEC        
Cytosine, a nucleobase found in DNA and RNA
Human epithelial colorectal adenocarcinoma
Chinese hamster ovary
Conditionally immortalized proximal tubule epithelial cell
DDI
DIG
DLC
DMEM                           
DMSO                 
Drug-drug interaction
Digitalis Investigators Group
Digitalis-like compounds
Dulbecco’s Modifi ed Eagle’s Medium
Dimethyl sulfoxide
E1S
E217βG
EDTA
EGFR
ERK                          
eYFP
Estrone 3-sulfateβ-estradiol 17-β-D-glucuronide
Ethylenediaminetetraacetic acid
Epidermal growth factor receptor
Extracellular signal-regulated kinase                                                      
Enhanced yellow fl uorescent protein
F
FCS                            
FDA
Phenylalanine, a hydrophobic amino acid
Fetal calf  serum
Food and drug administration
G
Gln      
Guanine, a nucleobase found in DNA and RNA                                  
Glutamine, a polar amino acid
HBSS
HEK
HEPES
HESI  
Hanks balanced salt solution
Human embryonic kidney cell line
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, a buffering 
agent 
Heated electrospray ionization
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
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R28
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R33
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R35
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I
IC50
d
IGEPAL CA-630     
Ile
IP3
Isoleucine, a hydrophobic amino acid
The concentration at which 50% of maximum rate of the enzyme 
is inhibited
Octylphenoxypolyethoxyethanol, a nonionic, non-
denaturing detergent
Isoleucine, a hydrophobic amino acid
Inositol 1, 4, 5-triphosphate
JNK Jun NH2-terminal kinase
Km Michaelis-Menten constant, the substrate concentration at which 
an enzyme reaction rate reaches at 50% of its maximum
L
LC-MS
Leu
LLC-PK1
LogPγ-lactoneδ-lactone        
Leucine, a hydrophobic amino acid
Liquid chromatography-mass spectrometry
Leucine, a hydrophobic amino acid
Epithelial-like pig kidney cell
Octanol: water partition coeffi cientγ-butyrolactone, four-carbon lactone ringδ-valerolactone, fi ve-carbon lactone ring
MAP
MDCK
MDR
MRP
Mus musculus    
Mitogen-activated protein
Madin-Darby canine kidney
Multiple drug resistance
Multidrug resistance-associated protein
House mouse
NBD
NF
NMQ
NTCP
NSAIDs
Nucleotide-binding domain
Nuclear factor
N-methyl-quinidine
Na+-dependent taurocholate co-transporting polypeptide            
Nonsteroidal anti-infl ammatory drugs
OATP Organic anion transporting polypeptide
PAGE
PCR
PEG
P-gp
Phe
Pro
PROVED
PSA                                      
Polyacrylamide gel electrophoresis
Polymerase chain reaction
Polyethylene glycol                                                                                            
P-glycoprotein, multidrug resistance protein 1
Phenylalanine, a hydrophobic amino acid
Proline, a non-essential amino acid
Prospective Randomized Study of Ventricular Function and 
Effi cacy of Digoxin
Polar surface area
QZ59-RRR
QZ59-SSS
cyclic-tris-(R)-valineselenazole
cyclic-tris-(S)-valineselenazole
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R3
R4
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RADIANCE
Rifampicin
Randomized Assessment of Digoxin on Inhibitors of the 
Angiotensin Converting Enzyme         
Rifampin, A bactericidal antibiotic that inhibits bacterial RNA 
synthesis 
RIPA Radio-Immunoprecipitation Assay buffer
SA
SD
SDS
SEM
SF21     
SIM
SLC
Sinoatrial
Standard deviation
Sodium dodecyl sulfate
Standard error of the mean
The cell line from Spodoptera frugiperda, a moth species and 
agricultural pest of corn
Single ion monitoring
Solute carrier transporters                                                                       
T
T
TCA
Thr
TM
TMD
TS
Threonine, a polar amino acid
Thymine,  a nucleobase found in DNA
Taurocholic acid
Threonine, a polar amino acid
Transmembrane
Transmembrane domain
Tris-HEPES                
V
Val
Vmax
VSV-G
Volume
Valine, a nonpolar amino acid
The maximum reaction rate of an enzyme
Vesicular stomatitis virus
W Weight
Xenopus laevis African clawed frog
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Dear Nazhat, it was delightful to have someone in the lab to speak to in my own 
language. I enjoyed all our talks, coffee drinking, and parties together. I wish you a 
wonderful time with Hamid and your cute sons.
Dear Alokta, it was lovley to have you on 7th fl oor of RIMLS to chat after long-term 
experiments. I will never forget your warm messages even after moving to UK. I wish 
you and Michael a wonderful life together.
I would like to use this opportunity to thank Prof. dr. John van Opstal and his lovely 
wife for all their kind favors and support that they always gave to us. Without your 
warm greetings, it was not possible to get through our fi rst cold days of winter in the 
Netherlands.
Dear Marly and Mark, we had lovely times together in Nijmegen. We will always 
remember the Dutch delights that you brought to our life. Enjoy and good luck with 
cute Finn!
Dear Faranak and Ali thanks for all the gatherings and BBQ arrangements and have 
lots of fun with Aida.
Dear Elahe and Bahram, thanks for your thoughtful messages and encouraging 
emails. I wish you both a lot of success with your projects. 
Here, I would like to thank all my friends Saeed, Hamed, Hossein, Alireza, Hamid 
and Marzie, Mohamad Reza, who made Nijmegen a home for us. I would also like 
to thank my friends in Tehran, specially Mojhgan and Marjan who with their warm 
greetings, persistent and encouraging emails did not let me to feel lonely.
Dan wil ik graag Anneke bedanken voor alle hulp met Nederlandse leren. Sammen 
hebben we veel gespreken en geode avonden gehad. Anneke, Je gaf me zelfvertrouwen 
om Nederlands te praten en ik nooit vergeet het.
رد ﺎﺠﻨﯾا زا ﮫﻤھ ﯽﻧﺎﺘﺳود نﻮﭼ یﺎﻗآ یﻮﺳﻮﻣ و نﺎﺷﺮﺴﻤھ، یﺮﺸﺑ و بﻮﻘﻌﯾ و هداﻮﻧﺎﺧ یﺎھ نﺎﺸﻣﺮﺘﺤﻣ  ﮫﮐ نﺎﺷرﻮﻀﺣ رد 
لﻮط ﻦﯾا نارود ﺚﻋﺎﺑ ﯽﻣﺮﮕﻟد و ﺖﯾﺎﻤﺣ ﻦﻣ و حور ﷲ دﻮﺑ، مﺮﮑﺸﺘﻣ.  
 
زا رﺪﭘ و ردﺎﻣ مﺮﺴﻤھ یاﺮﺑ ﺖﺒﺤﻣ ، ﺖﯾﺎﻤﺣ و نﺎﺸﯿﻣﺮﮕﻟد مراﺬﮕﺳﺎﭙﺳ و نﺎﺸﯾاﺮﺑ یوزرآ ﯽﺘﻣﻼﺳ، یدﺎﺷ و یﺪﻨﻠﺑﺮﺳ مراد .  
رﺪﭘ و ردﺎﻣ ﻢﻨﯿﻧزﺎﻧ، ﯽھﺎﮕﯾﺎﺟ ﮫﮐ نﻮﻨﮐا رد نآ راﺮﻗ مراد ﺮﺑ ﺖﺷد رﺎﺜﯾا و ﺖﻘﺸﻣ ﺎﻤﺷ ﮫﮐ ﻮﻠﻤﻣ زا ﻞﮔ یﺎھ ﻖﺸﻋ و ﺖﺒﺤﻣ 
ﺖﺳا، رد ﺖﺸﭘ هﻮﮐ ﺖﯾﺎﻤﺣ و ﯽﻧﺎﺒﯿﺘﺸﭘ نﺎﺗ و رد راﻮﺟ یﺎﯾرد ﮏﺷا یﺎھ ﯽﮕﻨﺘﻟد نﺎﻣ ﺎﻨﺑ هﺪﺷ ﺖﺳا، نآ ار ﺶﯿﺑ زا ﮫﻤھ ﮫﺑ ﺎﻤﺷ 
ﻢﻧﻮﯾﺪﻣ. نﺎﮕﺘﺷﺮﻓ ﯽﻨﯿﻣز ما، یاﺮﺑ ﯽﺘﺨﺳ یﺎھ ﮫﮐ ﻢﯾاﺮﺑ ﻞﻤﺤﺘﻣ ﺪﯾﺪﺷ و یاﺮﺑ ﺎﮭﻨﺗ ﻦﺘﺷاﺬﮔ ﺎﻤﺷ مرﺎﺴﻣﺮﺷ و یاﺮﺑ ﯽﯾﺎﯿﻧد ﮫﮐ ﮫﺑ 
ﻦﻣ ﮫﯾﺪھ هدﺮﮐ ﺪﯾا، مراﺰﮕﺳﺎﭙﺳ و ﯽﺘﻣﻼﺳ و ﯽﻧﺎﻣدﺎﺷ ﯽﮕﺸﯿﻤھ نﺎﺗ ار ﺪﻨﻣوزرآم.   
زا ﺮھاﻮﺧ و نارداﺮﺑ مﺮﺴﻤھ، ،ﮫﻤطﺎﻓ رذﻮﺑا و یﺪﮭﻣ ﮫﮐ هراﻮﻤھ یﺎﯾﻮﺟ لاﻮﺣا ﻦﻣ هدﻮﺑ ،ﺪﻧا و زا ﭻﯿھ ﮫﻧﻮﮔ ﯽﺘﺒﺤﻣ ﻎﯾرد  
ﺪﻧدﺮﮑﻧ ﻢﻧﻮﻨﻤﻣ نﺎﺸﯾاﺮﺑو ﯽﺘﻣﻼﺳ و ﯽﺘﺨﺒﺷﻮﺧ ار رد رﺎﻨﮐ ناﺮﺴﻤھ ﯽﻣاﺮﮔ و ناﺪﻧزﺮﻓ نﺎﺷﺪﻨﺒﻟد ﺪﻨﻣوزرآم  
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 ھﻤﮫ ﺑﺮای ،ای ﺑﻮده ﺗﺎﮐﻨﻮن ﮐﻮدﮐﯽ از ﻣﻦ ھﺎی ﺣﺴﺮت و ھﺎ ﻏﻢ ،آرزوھﺎ ،ھﺎ ﺷﺎدی ﺷﺮﯾﮏ ﺗﻨﮭﺎ ﺗﻮ ،ﻧﺎزﻧﯿﻨﻢ ﺧﻮاھﺮ ،ﺑﮭﻨﺎز
 ھﻤﺮاھﯽ ﺑﺮای و ﺷﺮﻣﺴﺎرم ،ﺷﺪی ﻣﺘﺤﻤﻞ ﻣﻦ ﻧﺒﻮد در ﮐﮫ ھﺎی ﺳﺨﺘﯽ ﺑﺮای ،ﻧﺒﻮدم و ﺑﻮدم ﻣﯽ ﮐﻨﺎرت در ﺑﺎﯾﺪ ﮐﮫ ﻟﺤﻈﺎﺗﯽ
  .مآرزوﻣﻨﺪ را ﺗﻮ ﺧﻮﺷﺒﺨﺘﯽ و ﺷﺎدﻣﺎﻧﯽ و ﻣﻤﻨﻮﻧﻢ ﺑﻮدﻧﺖ ﺧﻮاھﺮ و... ،ھﺎﯾﺖ ﻣﮭﺮﺑﺎﻧﯽ ،ھﺎﯾﺖ ﺷﻨﯿﺪن ،ھﺎﯾﺖ
 اﯾﻦ طﻮل در ﮐﮫ ای ﺑﻮده ﻣﻦ ﮐﻮﭼﻮﻟﻮی ﺑﺮادر ﺗﻮھﻤﯿﺸﮫ، ام ﺑﻮده ﺗﻮ ﺷﮑﻮﻓﺎﯾﯽ و رﺷﺪ ،ﮐﺸﯿﺪن ﻗﺪ  ﺷﺎھﺪ ﻣﻦ اﯾﻨﮑﮫ ﺑﺎ ،ﺑﮭﺮادﮔﻠﻢ
 ،ﮔﺬاﺷﺘﻢ ﺑﮭﻨﺎز و ﺗﻮ دوش ﺑﺮ رﻓﺘﻨﻢ ﺑﺎ ﮐﮫ ﺑﺎری ﮐﺸﯿﺪن ﺑﺮای ،ام ﺑﻮده ھﺎﯾﺖ ﻓﺮﯾﻨﯽ آ ﺷﺎدی و ھﺎ ﺷﯿﻄﻨﺖ دﻟﺘﻨﮓ ھﻤﯿﺸﮫ دوران
  .اﺳﺖ ﻣﻦ ھﻤﯿﺸﮕﯽ آرزوی ﺗﻮ ﺷﺎدﻣﺎﻧﯽ و ﺳﻼﻣﺘﯽ ،ﻋﺰﯾﺰﺗﺮﯾﻨﻢ .ام ﺷﺮﻣﻨﺪه
 I dna yenruoj DhP ym gnirud noinapmoc tseb eht erew uoy ,hallohooR ,gnilraD yM
 dedeen I nehw ereht syawla erew uoY .esle enoyna naht erom tnemeveihca siht uoy ewo
 ot dnah a dedeen I nehw ,yllanoitidnocnu sevol ohw ,yltneitap snetsil ohw enoemos
 ,seY :syas meop etirovaf ruo sa no og s’teL .ylmraw troppus ot guh a dna ylmlac ehtoos
 fo kniht ton od I ,raelc ton si yaw siht fo dne eht hguohtla ,evol fo gninnigeb eht si siht
.lufituaeb si evol siht esuaceb dne eht
